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Biopharmaceuticals, including proteins and peptides, are becoming 
increasingly important as therapeutic agents. However, the clinical use of 
protein and peptide therapeutics is still restricted due to undesirable properties 
such as their ability to self-assemble and aggregate. These properties not only 
influence production processes and storage but can also have adverse 
immunogenic effects within humans. To enhance their use, it is of great 
importance to understand and be able to manipulate their aggregation 
behaviour. In vivo, protein- and peptide-based drugs suffer from different 
problems, such as short lifetimes and low stability. Lipidation of peptides is 
widely established as a means of increasing stability in vivo. However, 
relatively little is known about the effect of lipidation on peptide self-assembly 
and other aggregation phenomena in vitro. 
The aim of this study is to develop a better understanding of the mechanism of 
aggregation and amyloid fibrillation of the therapeutic peptide GLP-1 and 
chemically modified forms of GLP-1. GLP-1, a metabolic hormone, has the 
ability to decrease blood sugar levels in a glucose-dependent manner by 
enhancing the secretion of insulin. Previous measurements of GLP-1 
aggregation revealed that, at certain pH values, unusual behaviour is observed 
that has established that the standard nucleation-polymerization mechanism is 
insufficient to fully describe the reaction under these conditions.  
To study the aggregation mechanism of GLP-1 and chemically modified forms 
of the peptide, aggregation kinetics were measured over a wide range of 
different conditions. In addition, many biophysical techniques, such as AFM, 
SEM, far-UV CD, FT-IR, !max, ANS, ex situ ThT and DLS, were employed to 
probe the structure, size and properties of species in solution during 
aggregation. 
The influence of amidation at the C-terminus of GLP-1 on physical stability 
was assessed and significant differences to GLP-1 were found. The study of 
this relatively small modification generates a better understanding of the 
interdependence of net charge, solubility and secondary structure on the 
aggregation kinetics. The results of these studies also provide further evidence 
that peptides belonging to the GLP-1 family can form off-pathway oligomeric 
species that have a significant impact on the aggregation kinetics. Two lipidated 
analogues of C-terminally amidated GLP-1 (Am-GLP-1) were also studied and 
the results analysed in detail and compared to those obtained for GLP-1 and 
Am-GLP-1. Both lipidated peptides show a strong, nearly switch-like, pH 
dependence. Surprisingly, it was also shown that the amidation of the C-
terminus had a bigger influence on the secondary structure of the peptides in 
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Chapter 1: Introduction 
  1 
In recent years, biopharmaceuticals specifically peptide therapeutics, have 
become increasingly important and are now responsible for a considerable 
share of the pharmaceutic market.1,2 However, despite many advantages over 
other types of therapeutic agents such as high bioactivity and specificity, 
peptides also pose considerable challenges.3 One of these is associated with 
their physical stability as many peptides have a tendency to aggregate and 
precipitate. This has a major impact on their usability and safety: predictable 
shelf lives are crucial, and it is known that peptide aggregates formed in drug 
solutions can induce adverse immune responses and lead to a loss of safety and 
efficacy.4  
One example of physical instability is polypeptide chain self-assembly into 
highly regular structures such as amyloid fibrils. The formation of amyloid 
fibrils is one of the most common processes influencing almost all phases of 
biological drug development. The importance of understanding these processes 
becomes clear by the broad range of different protein pharmaceuticals known 
to form different types of aggregates as shown in Table 1.1. 
  
1 INTRODUCTION 
Chapter 1: Introduction 
2   
peptide or protein length 
(residues) 
conditions type of 
aggregates 
GLP-1 (7-37) 31 pH 7.5-8.2 fibril5 
GLP-1 (7-36)-NH2 30 pH 7.4 fibril6 
glucagon 29 pH 2.0 fibril7–9  
glucagon 29 pH 8.5-9.7 fibril10,11 
salmon calcitonin 32 neutral pH fibril12–15 
amylin 37 under different 
conditions 
fibril16–20 
insulin 51 (31 chain A, 
20 chain B)  
pH 2.0  fibril21–23 
  pH 1.1-3.2 fibril24–27 




51 (31 chain A, 
20 chain B) 
 
pH 1.75-2.0 
conc. < 5 mg	ml-1 




insulin analogues 51 (31 chain A, 

















PYY (3-36) & 
lipidated derivatives 




Proleukin  +SDS formation of 
micellar-like 
structures 
   containing 
approx. 27 
molecules35 
Met-G-CSF  pH 6.9, 37 °C precipitation36 
    
Table 1.1. Some examples of peptide and protein pharmaceuticals known to form 
different types of aggregates. 
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To learn more about the formation of amyloid fibrils and the mechanisms by 
which peptide and protein aggregation occurs, as well as the factors that 
influence the reaction, numerous and extensive research programmes have 
been undertaken. This has led to significant progress, especially in the field of 
peptides and proteins where aggregation in vivo is associated with disease 
states, particularly neurodegenerative diseases.37 Typical examples of 
neurodegenerative diseases associated with amyloid aggregates are 
Alzheimer’s Disease (Amyloid-β)38, Parkinson’s disease (α-synuclein)39,40 and 
Huntington’s disease (Huntington fragments)41.	A considerable amount of the 
research on aggregation and self-assembly of disease-related peptides and 
proteins can be applied to the aggregation of peptide-based therapeutic agents 
currently developed by the pharmaceutical industry. In general, however, the 
aggregation pathways of peptides and polypeptide-based drugs coming through 
the drug pipelines have not been characterised in any depth. 	
The topic of this Thesis is the study of the physical stability of glucagon-like 
peptide 1 (GLP-1) and chemically modified forms of GLP-1. To understand the 
aggregation mechanism and the physical stability of peptide and protein 
pharmaceuticals, it is essential to understand the influence of mutations and 
other types of chemical modifications. In this Chapter, a short introduction is 
provided on the physical stability and aggregation of peptides, kinetics of 
peptide aggregation, different factors influencing peptide aggregation, the 
lipidation of peptides and more details about the peptide used throughout this 
study, GLP-1 and its lipidated analogues. 
The research on amyloids and amyloid fibrils has a long and eventful history. 
Most likely, the first observation was by Nicolao Fontano, who described an 
autopsy of a young man with an abscess in his liver and a large spleen filled 
with white stone.42 In 1854, Rudolf Virchow described the structures as 
amyloids because he observed the peculiar reaction of the corpora amylacea of 
the nervous system with iodine.43 He adopted the term from Matthias 
Schleiden, a botanist, who coined the term less than two decades earlier to 
describe a normal amylaceous constituent of plants.42 The iodine reaction for 
1.1 A Brief History of Amyloids  
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starch was already reported by J.J. Colin and H.F. Gaultier de Clauburg, and 
independently Stromeyer in 1814.44 The term amyloid replaced with time the 
originally more common terms ‘lardaceous’ or ‘waxy’ changes.  
In 1859, Carl Friedreich and August Kekulé proved that the waxy spleen they 
observed consisted neither of amylon nor cellulose but from albumoid 
compounds based on the high nitrogen content.42 Why the term amyloidosis 
still prevailed is not clear, but it is assumed that Virchows standing as a 
pathologist and the common use of iodine to stain the samples, had an 
influence.  
Aniline based dyes used to recognise amyloid were first described in parallel 
by André-Victor Cornil, Richard Heschl and Rudolph Jürgen in 1875.42 These 
initially used metachromatic stains were eventually replaced by another aniline 
based stain, Congo Red. Generally used for staining textiles, Congo Red was 
found to bind avidly to amyloid by Bennhold in 1922.45 
 
 
Figure 1.1. Negatively stained amyloid fibrils. 
Amyloid fibrils imaged using an electron microscope by Shirahama & Cohen 
in 1965.
46
 Note various combinations and coplanar disposition of filaments 
and loose random twisting of fibrils (x 250,000).  
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In the 20th Century, more and more details about the structure of amyloids were 
discovered. William Astbury took the first diffraction images of amyloid and 
discovered a fibrous state for many proteins, for example keratin	in 1931-33 
and pepsin in 1934.47–50 With the help of electron microscopy, Cohen and 
Calkins first recognised in 1959 that amyloid demonstrates a non-branching 
fibrillar structure with a width of 6-13 nm.51 The first twisting protofilaments 
were reported only six years later by Shirahana and Cohen,52 Figure 1.1.   
In 1967, Geddes, Parker, Atkins and Beighton also published a paper on X-ray 
diffraction patterns of naturally occurring cross-β fibrous proteins.53 Just one 
year later, Eanes and Glenner published their work about filamentous protein 
components of amyloid-laden tissue studied by X-ray diffraction procedures. 
They concluded from the X-ray diffraction patterns that the material forms a 
“cross-β” structure. They observed an intense ring at 4.75 Å, an overlaying 
diffuse halo at 4.3 Å and a broad and less intense ring at 9.8 Å.54 These features 
were interpreted as a “pleated sheet” structure consisting of amyloid 
polypeptide chains regularly folded on themselves, where adjacent chain 
segments were laterally and antiparallel arranged.54 The data also suggested 
that the axes of the chain segments run orthogonal to the filament axis.54  
In the last 50 years, the progress in our understanding of the structure of 
amyloid aggregates has been remarkable and has mainly been driven by further 
X-ray and electron diffraction experiments as well as the rapid evolution of 
solid-state nuclear magnetic resonance (ssNMR) and cryo-electron microscopy 
(cryo-EM). For a detailed review on about half a century of amyloid research 
see Ke et al., 2020.55 
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With the report of cross-β fibrils,53,54 a milestone in the general understanding 
of amyloid fibrils was reached. Nowadays, a commonly accepted biophysical 
definition of amyloid fibrils is that they show a cross-β fibre diffraction pattern 
when measured by X-ray diffraction.56 The origin of these patterns is caused 
by the unique way the peptides or proteins are assembled. Elongated peptide or 
protein strands (β-strands) stack on top of each other forming β-sheets.56 The 
β-strands within the β-sheets are held together by hydrogen bonds formed 
between their amide groups, 56–59 resulting in the measured distance of 4.8 Å of 
the β-strands within the β-sheets, Figure 1.2. The interaction of pairs of β-sheets 
to form a protofilament is supported by the interdigitating or butting of amino-
acid side chains extending on both sides of the β-sheets. Because of the 
interaction of the side chains between the b-sheets, protofilaments are 
sometimes also called steric zippers.56–59 The length of the side chains 
determines the distance of the two interacting β-sheets and is typically between 
5 and 16 Å, Figure 1.2. The interfaces between the β-sheets are, with few 
exceptions, devoid of water.58  
The self-assembly of these aggregates is energetically favourable and stable for 
several reasons. Water plays a significant role, specifically it orients near non-
polar surfaces, which adversely affects its 3D hydrogen-bonding network.60 
This leads to a decrease in configurational entropy. Reducing the hydrophobic 
surface interacting with water leads to increased configurational entropy of 
water molecules.60 Therefore, the hydrophobic effect is experienced as an 
attractive force between two non-polar objects if they are brought sufficiently 
close together.60  
The arrangement of the β-strands in the β-sheets can either be in- or out-of-
register. The former means that the β-strands are orthogonal to the β-sheet 
direction and out-of-register that the β-strands are out of square, Figure 1.3A.59  
 
1.2 Molecular Structure of Protein or Peptide Amyloid 
Fibrils 
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Figure 1.2. The cross-β-sheet motif. 
A defining characteristic of amyloid fibrils is the typical X-ray fibre cross-β 
diffraction caused by their cross-β-sheet motif. The typical spacing of the β-
strands causes a meridional reflection at about 4.8 Å and the distance between 
the stacked β-sheets causes a protein dependent equatorial reflection between 
6-12 Å. In the Figure the distance of 10 Å is chosen as an example. Figure 
adapted from R. Riek & D. S. Eisenberg, 2016.
58
 
If the β-strands are in-register in a β-sheet, energetically favourable side chain 
ladders can be formed. Typical ladders are formed of asparagine or tyrosine, 
Figure 1.3B.59  
From theoretical considerations, it becomes clear that there are many possible 
β-strand arrangements. Assuming that the interacting β-strands are homo-
steric, four distinctly different amyloid structures are adoptable by a single 
sequence. It is the case because each β-strand can be orientated, N- to C-
terminus, and has a distinct front and back side. These two variables lead to 
two arrangements in which the β-strands are parallel and two in which the 
orientation of the β-strands alternates (antiparallel). In addition, these 
arrangements can be found with separated face and back sides (antifacial) or 
alternating between face and back side (equifacial), Figure 1.4.59  
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Figure 1.3. In- and out-of-register β-sheets and energetically favourable ladders. 
A) In-register sheets are defined by strands orthogonal to its translational 
repeat direction (white vertical arrows) in comparison to out-of-register sheets. 
If the angle is not orthogonal, the sheet is out-of-register. B) In-register β-
sheets are capable of forming energetically favourable ladders, for example, 
asparagine (Asn) or tyrosine (Tyr) ladders. Figure adapted from D. S. 
Eisenberg & M. R. Sawaya, 2017.
59
 
These four different β-sheets can be arranged in ten different classes of homo-
steric zipper amyloid spines, Figure 1.4. These different possible β-strand 
arrangements are biological significant as it means that a single sequence can 
theoretically self-assemble in many ways, which is known and observed as 
amyloid polymorphism.59 This may be the molecular basis of prion strains.61,62 
The number of different steric zipper amyloid spines increases even further if 
segmental polymorphs, combinational polymorphs, intra-/intermolecular 
polymorphs and single-chain registration polymorphs are considered. For 
excellent reviews on the different structures of amyloid fibrils that have been 
observed, peptide fibrilization in general and the influence of peptide 
aggregation on current and future nanotechnology see D. S. Eisenberg & M.R 
Sawaya, 2016, I. Hamley, 2007 and Wei et al., 2017.59,63,64 
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Figure 1.4. Symmetry classes of homo-steric zipper amyloid spines. 
β-strands showing  the C- to N-terminal direction, up/down edge and 
front/back face are illustrated as fictitious Max Perutz bank notes. They can 
be arranged in four different β-sheet conformations. These four different β-
sheets can form ten different homo-steric zipper amyloid spines based on 
symmetry considerations, also called classes. Single-bladed arrows signify 21 
symmetry axes, a 180° rotation about the arrow. Shifts of one-half or a whole 
repeat distance between β-strands of a β-sheet are possible. Figure adapted 
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An example of the atomic structure of a fibrillar aggregate of a peptide hormone 
is shown in Figure 1.5. The structure of glucagon at pH 2 was resolved by 
Gelenter et al. using ssNMR and 13C and 15N-labeled glucagon. 
The observed length of the β-strand is formed by the complete length of the 29 
residues of glucagon.65 Such a long β-strand is remarkable as most commonly 
observed β-strands in known amyloid fibril structures and β-barrel membrane 
proteins only show β-strands containing fewer than thirteen amino acids.66,67  
Glucagon aggregated at pH 2 also showed not only one but two different β-
strand conformations. Conformer I and Conformer II can be differentiated from 
each other by their different wet and dry interfaces. Conformer I adopts a steric 
zipper structure with its odd-numbered residues, whereas Conformer II uses 
even-numbered residues. These two different conformers form the basic unit of 
glucagon fibrils at low pH which is a dimer of dimers.65 The symmetry class 
can be described as antiparallel, antisymmetric and equifacial like class 8 in 
Figure 1.4. The structure of two molecular conformations integrated within a 
single ultrastructural fibril morphology is unique among the amyloid fibril 
structures known today, as well as containing the longest known β-strand 
among all peptides and proteins.65 
The fibrillar structure of glucagon is a good example of typical side chain 
interactions. The steric zipper of glucagon formed at pH 2 is stabilised by a 
series of different side chain interactions. These favourable interactions include 
one tetrameric ‘aromatic box’ (F6-W25), several polar interactions (Q3-N28, 
T7-G24, S11-Q20, D15-S16), cation-, interactions (Y13-R18) and steric 
complementarity (M27-G4). The cation-, interaction mitigates an 
unfavourable electrostatic repulsion caused by the Arg18 side chains at the 
homodimer interface.65  
1.3 Atomic Structure of Glucagon Fibrils 
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Figure 1.5. Atomic structure of a glucagon fibril at low pH. 
Atomic-resolution structure of glucagon fibrils at pH 2 determined using 
ssNMR. A) Side and top view of the fibril. The conformation of the β-strands 
in the β-sheet alternate between Conformer I (red) and Conformer II (blue). It 
is similar to equifacial antisymmetric (class 8). However, one β-sheet is shifted 
by one position so that the β-strands are face-to-face. B) Side-chain packing 
in the dimer-of-dimer subunit steric zipper. The fibril axis is pointing out of 
the page. The light blue shaded region represents the solvent. Detailed image 
of the two conformers with hydrophobic side chains coloured white, polar 
residues green, and positively charged residues red. Figure adapted from 
Gelenter et al., 2019.65  
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Alterations in pH, temperature, mechanical conditions, or the peptide 
concentration can easily influence the interaction of amino-acid side chains. 
This leads to the assumption that the glucagon sequence can form a diverse set 
of 3D structures.65 This is supported by the fact that at a pharmaceutical 
concentration of ∼287	µM	(∼1 mg mL-1) glucagon not only exists as straight 
fibrils but also in a twisted morphology. The system shows a peptide 
concentration dependence as the twisted species become more predominant 
below 72 µM (0.25 mg mL-1). Additional fibrils morphologies can be formed 
by glucagon under different pH, temperature, and mechanical conditions.9,68  
Higher-order structures comprised of amyloid-like fibrils have been observed 
for a number of proteins. Insulin and β-lactoglobulin have been shown to form 
spherulites, spherical structures consisting of radiating fibrils from a central 
core.69 In addition, a number of peptides that self-assemble into fibrillar 
structures have also been shown to form hydrogels.63,70,71 The formation of 
hydrogels can also be influenced by lipidation. The gut-derived peptide 
hormone PYY3-36 was shown to form hydrogels if lipidated but not in its 
unlipidated form.34 The measured peptide concentration of the formed 
hydrogels was in the range of 3.5-5.5 mM.34 For an excellent book chapter 
about colloidal gels from proteins and peptides see Djabourov et al., 2013.72  
Amorphous aggregates, also known as disordered aggregates, are unstructured 
and contain no ordered intermolecular interactions.73 They are often granular 
in appearance and can vary in size and solubility. When insoluble they form 
precipitates, which presents a major challenge for biotechnology. 
Aggregation is a complex phenomenon and can occur from many different 
states. In many cases, aggregation occurs from an unfolded or largely 
unstructured state, i.e., in the case of many peptides and intrinsically disordered 
proteins.74–77 For amyloid fibril formation, the monomeric peptides first self-
1.4 Aggregation to Form other Types of Structures 
1.5 Kinetics of Fibrils Formation  
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associate to form oligomeric structures which go on to form a critical nucleus, 
Figure 1.6. Elongation of the nucleus is rapid relative to its formation giving 
rise to the sigmoidal aggregation kinetics often observed, Figure 1.6. The lag 
time caused by the primary nucleation process which can be shortened or 
eliminated by the addition of seeds.78,79 
 
Figure 1.6. General mechanism of amyloid formation  
Simplification of the mechanism of aggregation of amyloid fibrils following 
sigmoidal kinetics. Shown are the primary nucleation, elongation and 
saturation phases.  
1.5.1 Different Aggregation Mechanisms 
As shown in Figure 1.6, the kinetics of aggregation/fibril formation can often 
be described by a sigmoidal curve, with a lag phase, growth phase and a final 
plateau, at which point the system either completely depletes the pool of 
monomer, or the system reaches equilibrium between peptide monomers, 
oligomers and fibrils. Since the middle of the last century, significant research 
has been conducted in order to understand the aggregation process of 
polypeptide chains in detail.80 In 1961, Oosawa and Kasai introduced a 
nucleated-polymerisation mechanism and a theory on the helical aggregation 
of macromolecules in which each amino-acid residue binds to three 
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neighbouring residues instead of one, as it would in a simple linear polymer.81 
Two decades later, Ferrone & co-workers added a double nucleation 
mechanism in which the fibrils autocatalyze aggregation by the nucleation of 
additional polymers at the surface of existing ones.82 Recently, Cohen & co-
workers described an analytical solution for the formation and growth of fibrils 
including not only primary nucleation and growth elongation but fragmentation 
of filaments and surface-catalysed secondary nucleation,83 Figure 1.7A. Their 
approach has been successful in describing and predicting the aggregation 
behaviour of the Aβ42 peptide.84,85 In their model, nucleation is a high-order 
reaction and oligomeric species that are formed prior to the final fibrillar 
structure are all on-pathway. In this case, lag times depend strongly on the 
peptide/protein concentration and lag times decrease with increasing peptide 
concentration.  
1.5.2 Off-Pathway Oligomers or Off-Pathway Species 
In the last ten years, there have been a number of observations on peptide and 
protein aggregation which can’t be explained by these mechanisms alone. For 
example, it was shown that an amyloidogenic fragment of native human islet 
amyloid polypeptide (hIAPP)86 and GLP-1(7-37)5, under certain conditions, 
have aggregation kinetics that show no dependence on peptide concentration. 
Such unusual results are not consistent with a pure on-pathway oligomer 
mechanism and have been explained, in part, by the presence of off-pathway 
oligomeric species populated during the aggregation reaction. Rhoades & co-
workers also introduced an off-pathway oligomer model for peptide 
aggregation in 2000 in which the monomeric peptide concentration is buffered 
by the existence of off-pathway micelles87, Figure 1.7C. They proposed that 
above a minimum peptide or protein concentration, the minimum micelle 
concentration (CMC), off-pathway micelles are formed, Figure 1.7C. In this 
case, the formation of the micelles maintains the monomer concentration at the 
CMC. The formation of micelles is one property peptides have in common with 
surfactants and detergents. Supporting this, it was also shown that Aβ peptides 
lower the surface tension of water with increasing peptide concentration similar 
to the behaviour of surfactants.88 
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Figure 1.7. Different mechanisms involving on- and off-pathway oligomeric species.  
A) Simple on-pathway model and additional secondary nucleation where M is 
monomer, on are on-pathway oligomers, and off are off-pathway oligomers. 
Primary nucleation with the primary nucleation rate kn leads to on-pathway 
nuclei consisting out of nc monomers. They are assumed to be stable and no 
dissociation happens. Fibrils are formed by elongation or through 
fragmentation and by monomer-dependent secondary nucleation. The rate 
constants for elongation, dissociation, fragmentation and secondary nucleation 
are k+, kd, k- and ksn, respectively. In a nucleation-elongation model, a higher 
monomer concentration M leads to faster aggregation. B) Simple off-pathway 
model with the rate constants kon and koff as association and dissociation rate 
constants, respectively. C) On- and off-pathway species mechanism following 
a critical peptide concentration (CMC) model. At the CMC the system is 
saturated and excess monomers associate as off-pathway aggregates. D) On- 
and off-pathway species model without a CMC. The two pathways are 
independent of each other. E) On- and off-pathway species model in which 
there is an interaction between the different species. This can lead to 
aggregation reactions in which there is an increase in lag time and t1/2 with 
increasing peptide concentration. This could be caused by a change in the 
fluidity of the solution with increasing peptide concentration, or the binding 
of off-pathway species to binding sites of on-pathway aggregates. 
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In 2008 it was shown by Powers and Powers89 that aggregation mechanisms in 
which a parallel off-pathway process occurs additional to the on-pathway 
process can not only lead to constant tlag and t1/2 but also to increasing t1/2 values 
with increasing peptide/protein concentration. In their model, the increase of 
t1/2 with increasing peptide/protein concentration can be explained by the effect 
of the off-pathway species which buffer the available monomer concentration 
during the aggregation process, Figure 1.7D. Subsequently the rate of fibril 
formation is restricted but the amount of peptide/protein available for the 
formation of fibrils is not.  
However, tlag itself cannot increase with increasing peptide/protein 
concentration, as shown mathematically in Section 4.8. The observation of 
increasing tlag with increasing peptide concentration can only be explained by 
more complex models, for example, one in which there is an active interaction 
of the off-pathway species with on-pathway species (Figure 1.7D), in 
comparison to simple on-pathway models or other on- and off-pathway 
models.90 
It is well established that the physical stability of peptides is affected by many 
factors including temperature, excipients, freeze-thaw, processing, peptide 
sequence, peptide concentration, pH and chemical modifications.73,91–95 A brief 
summary of the different factors affecting the physical stability of peptides 
follows. 
1.6.1 Amino-acid Sequence 
How the amino-acid sequence of a peptide affects its intrinsic propensity to 
aggregate, to form either amorphous or amyloid-like fibrils, is now very well 
understood, such that there are numerous prediction programmes available.73,96 
Factors such as hydrophobicity, charge state, β-sheet forming propensity along 
with other properties are all known to contribute.73,96–98 A consecutive series of 
five or more residues which all have a high intrinsic propensity form what is 
1.6 Factors Affecting the Physical Stability 
(Aggregation) of Peptides 
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known as an aggregation-prone region, APR.96,99–102 In some cases, these 
methods have been used to predict the effect of an amino-acid substitution on 
aggregation propensity, for example, the effect of pathogenic mutations on the 
aggregation of Aβ in vitro and in vivo.96 A typical example of a prediction of 
structural aggregation using the TANGO method is shown in Figure 1.8. 
A number of approaches have been developed to predict aggregation propensity 
some of which are primarily based on our knowledge of the intrinsic propensity 
of amino acids to aggregate and form fibrils. As our understanding of the 
factors that affect aggregation in terms of amino-acid sequence has improved, 
methods have also been developed that not only take into account APRs in 
peptide sequence but also other factors such as the presence of gatekeeper 
residues that help prevent aggregation,103–105 and the flexibility and solvent 
accessibility of the peptide chain.106 Other algorithms also take into account the 
propensity of amino acids to form other forms of stable structure such as α-
helices, as aggregation is always in competition with the formation of other 
conformational states.107 
 
Figure 1.8. Prediction of structural aggregation.  
Aggregation propensity of GLP-1 predicted by the Tango algorithm at pH 7.5. 
Any segment with an aggregation tendency above 5% over five or more 
residues in length is a potential aggregating segment. The data are shown as 
percentage of β-strand (orange line), β-turns (red line), α-helical (green line), 
aggregation (dark blue line) and helical aggregation (bright blue line). 
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Since high-resolution structures of amyloid fibrils have become available from 
X-ray crystallographic and NMR studies,58 structure-based methods for 
predicting APRs have also been developed.73,96 In these cases, APRs which are 
compatible with the formation of the cross β-structure seen in the core of 
amyloid fibrils are identified by threading peptide and protein sequences 
through templates of different amyloid structures scoring each resultant 
structure in terms of packing density,108 pairing energies for side chains that 
pack against each other in the structure109–111 and other metrics.112,113 In another 
case, a combination of the two approaches has been used and a position-specific 
scoring matrix developed taking into account both intrinsic propensities and 
also structure.114 
 
Name Description of method  
Zygreggator APRs and gatekeepers, protein flexibility and solvent 
accessibility106 
TANGO statistical thermodynamics approach. Identifies APRs but takes 
into account competition β-aggregated state and other 
conformations107 
SALSA uses β-propensity for each amino acid and a sliding average to 
identify APRs102 






structure-based method uses amyloid fibril structure as a 
template112 
Pre-AMYL structure-based method uses amyloid fibril structure as a 
template113 
PASTA pairing energies calculated for pairs of residues within an 
amyloid structure. Sequences are scored by energies to identify 
APRs109,110,117 
BETASCAN β-strand pairing energies using amyloid core structure
111  
Table 1.2. Methods for predicting aggregation-prone regions and aggregation 
propensity in peptides. 
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For peptides which do not form stable tertiary or quaternary structures, these 
approaches work well, and predictions are generally reasonably accurate. In 
addition, while many algorithms which are not structure-based predict both the 
propensity for a peptide to form either an amorphous or highly structured 
aggregate, the structure-based methods are largely accurate only for predicting 
the formation of amyloid-like fibrillar structures. 
Given these prediction methods, summarized in Table 1.2, it is relatively 
straightforward to identify APRs in largely unstructured peptides and to 
rationally design amino-acid substitutions to reduce aggregation propensity. Of 
course, such changes may also affect activity. At the moment, there are no 
programs available to predict the effects of incorporating non-natural amino 
acids nor the effects of chemical modification of a peptide on its aggregation 
propensity.  
1.6.2 Peptide Concentration  
One of the most important factors influencing the physical stability of peptides 
is peptide concentration. This is long-established through numerous kinetic 
studies on the formation of amyloid fibrils,118–122 amorphous aggregates123,124 
and adsorption on surfaces.125 With respect to the formation of amyloid-like 
fibrils, extensive kinetic studies have been performed over wide ranges of 
peptide concentrations and, in the majority of cases, the kinetics have been 
shown to be consistent with a nucleation – polymerization mechanism, Figure 
1.7A.126 In this case, the monomeric starting material is converted into 
oligomers, and ultimately a species that can act as a nucleus for rapid fibril 
growth. Addition of usually monomers to a nucleus or growing fibrils occurs 
rapidly to form protofibrils and mature fibrils.  
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Figure 1.9. Definition of key kinetic parameters obtained from sigmoidal 
aggregation kinetics. 
The curve shows the key kinetic parameters that can be obtained from a fit of 
the aggregation data to a simple sigmoidal function: t1/2, the time at which the 
ThT fluorescence is 50% of its final value (red dashed line), the apparent 
growth rate which corresponds to the gradient of the steepest part of the rapid 
growth phase (blue line), and tlag, the lag time at which point sufficient nuclei 
are present in solution for elongation and growth of fibrils to become rapid.  
The essential features of such systems are that the kinetics show a lag phase, a 
rapid elongation or growth phase and a plateau. During the lag phase, a number 
of oligomeric species, including nucleating species, and short amyloid fibrils 
form until a point is reached at which the growth of fibrils is rapid, Figure 1.9. 
The formation of fibrils then slows as a plateau is reached which represents 
either the point where monomers are completely depleted or an equilibrium 
point at which mature fibrils are in equilibrium with starting monomers and 
other species. The sigmoidal kinetic traces can be fitted to obtain key kinetic 
parameters such as lag time, t1/2 and the apparent growth rate, Figure 1.9. How 
these kinetic parameters depend upon peptide concentration has been 
established for many systems including Aβ127, α-synuclein128, tau129, glucagon-
like peptide-1 (GLP-1)5 and other peptides. The majority of peptides and 
conditions show kinetics typical of nucleation – polymerization mechanisms, 
and in these cases, generally both t1/2 and tlag decrease with increasing peptide 
concentration. The growth rate has been shown to decrease or increase, or be 
independent of peptide concentration, depending upon the peptide/conditions 
and rate-limiting step. Cases where there is an increase in growth rate with 
Chapter 1: Introduction 
  21 
peptide concentration point towards association of monomer to the fibril being 
rate limiting to the growth. In contrast, if the growth rate is independent of 
peptide concentration this can indicate that some other step, such as a 
conformational change of the monomeric unit, is rate limiting. The growth rate 
is also dependent upon secondary nucleation steps, if they exist, such as 
fragmentation of the fibrils to form small fibrils with a net increase in reactive 
fibril ends from which growth can occur, or secondary nucleation sites on the 
surface of a fibril, Figure 1.7A.119 
The fact that t1/2 and tlag decrease with increasing peptide concentration 
highlights the issues of physical stability of peptides, which may not be a 
significant issue at low peptide concentrations, but which can become a serious 
problem at high concentrations such as those frequently used in therapeutics. 
 
Figure 1.10. Dependence of GLP-1 aggregation kinetics on peptide concentration at 
two different pH values. 
Data adapted and normalised from Zapadka et al.5 GLP-1 incubated at six 
different concentrations (dark blue circles 25 µM, bright blue circles 50 µM, 
bright green circles 75 µM, dark green circles 100 µM, orange circles 125 
µM, red circles 150 µM) and at 37 °C. A) Aggregation kinetics of GLP-1 in 
Tris buffer at pH 8.2 with decreasing t1/2 and tlag with increasing peptide 
concentration. Most likely following a simple nucleation – polymerization 
mechanism with only on-pathway oligomeric intermediate states. B) 
Aggregation kinetics of GLP-1 in phosphate buffer at pH 7.5 where t1/2 and 






pH 8.2 pH 7.5 
 
Time (h) Time (h) 
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In stark contrast to the systems and kinetics described above, there are an 
increasing number of peptides and conditions under which very different 
kinetics have been observed. In these cases, increasing concentrations of 
peptide leads to no change or an increase in t1/2 and tlag.5,89,130 This unusual 
kinetic behaviour has been attributed to the formation of a different form of 
oligomeric species where the oligomers formed are off-pathway, and either 
cannot directly be converted into on-pathway oligomers or nucleating species, 
or the interconversion is extremely slow, or where the off-pathway oligomers 
even actively suppress the on-pathway aggregation, Figure 1.7C,D & E. One 
such system is GLP-1, which is a particularly interesting system as, in this case, 
there is a switch in the kinetic behaviour with pH.5 At pH > 8.0, GLP-1 follows 
the more common nucleation – polymerization kinetics with t1/2 and tlag 
decreasing with increasing peptide concentration, Figures 1.10A and 1.11A & 
C; however, at pH 7.5, the kinetics reverse such that both lag time and t1/2 
increase with increasing peptide concentration indicating off-pathway 
oligomers have formed,5 Figures 1.10B and 1.11B & D.  
At an intermediate pH, 8.0, there is little dependence on peptide concentration 
as there is a delicate balance between on- and off-pathway species.5 Although 
off-pathway oligomers have been observed now for a number of peptides and 
proteins,5,89,130 these systems have not been studied in the detail that peptides 
and proteins showing simpler nucleation – polymerization kinetics have been 
and therefore not much is known about the nature of off-pathway oligomers, 
for example, their size, structure and cellular toxicity. 
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Figure 1.11. Influence of peptide concentration on GLP-1 aggregation parameters 
t1/2 and tlag at different pH values. 
Data adapted and normalised from Zapadka et al.
5
 GLP-1 incubated at 25, 
50, 75, 100, 125 and 150 µM and at 37 °C. A) Dependence of t1/2 on peptide 
concentration for the aggregation of GLP-1 into amyloid fibrils at pH 8.2 
under conditions where the peptide follows a simple nucleation–
polymerization mechanism with on-pathway oligomers only. B) Dependence 
of t1/2 on peptide concentration for the aggregation of GLP-1 into amyloid 
fibrils at pH 7.5. C) Dependence of tlag on peptide concentration for the 
aggregation of GLP-1 into amyloid fibrils at pH 8.2 under conditions where 
the peptide follows a simple nucleation-polymerization mechanism with on-
pathway oligomers only. D) Dependence of tlag on peptide concentration for 
the aggregation of GLP-1 into amyloid fibrils at pH 7.5 under conditions 
where on- and off-pathway oligomers are populated. 
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1.6.3 pH and Net Charge 
Electrostatic interactions are known to play major roles in the self-association 
of peptides to form all types of aggregates.131–136 Essentially, for systems 
carrying an overall net charge, unfavourable electrostatic repulsion needs to be 
overcome in order for self-association/aggregation to take place. Generally, it 
has been shown for many systems, the higher the net charge the slower the 
aggregation and the lower the net charge the higher the propensity to 
aggregate.131–136 As such, solution conditions such as pH, ionic strength, nature 
of cations and anions in solution and the presence of polyelectrolytes can all 
have a dramatic effect on both the rate and extent of aggregation. One of the 
best characterized systems in terms of the effects of net charge, ionic strength, 
and counter ions on aggregation is the 37-residue positively charged peptide 
IAPP which has no acidic groups.137 A comprehensive and rigorous study has 
shown that there are multiple effects on aggregation depending upon the pH.137 
At pH 8.0 there is a strong dependence on ionic strength due to Debye screening 
and increasing ionic strength accelerates aggregation by up to a factor of ten. 
In this case, specific ion effects were also observed, the nature of the cation 
being relatively unimportant but the rate depending crucially on the identity of 
the anion. For example, at pH 8.0 and a total ionic strength of 30 m, the t1/2 
measured in sulphate and fluoride differed by a factor of four. The effects were 
observed both on the lag phase and the apparent growth phase. At pH 5.5, where 
IAPP has a higher overall net charge, the aggregation kinetics were 
considerably slower than at pH 8.0, but there were similar effects of ionic 
strength.137 For lysozyme and acylphosphatase, studies have established that 
polyelectrolytes can also have significant effects. In these cases, a number of 
different polyelectrolytes were found to bind to and stabilize mature fibrils.138 
Although it is easy to establish some general rules of thumb with regards to the 
effects of pH, net charge, ionic strength, ions and polyelectrolytes, these rules 
should be viewed with caution. There are an increasing number of examples 
where these rules are not followed due to the complexity of aggregation 
reactions. For example, around the isoelectric point of peptides and proteins, 
where net charges are essentially zero, then monodisperse and quasi-
amorphous aggregates have been observed instead of amyloid-like fibrils.69 
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Thus, aggregation kinetics can be very different from those of amyloid-like 
fibril formation which is often seen at pH values away from the isoelectric 
point. In addition, other changes in mechanism have been found at different 
values of pH and net charge.  
For example, as already discussed in Section 1.6.2, the aggregation kinetics of 
GLP-1 into amyloid-like fibrils is highly sensitive to pH.5 In this case, the 
presence of off-pathway species slows the rate of aggregation considerably, 
particularly at high peptide concentrations. Thus, although the net charge on 
the protein at pH 7.5 is lower than at pH > 8.0, the rate of aggregation is 
considerably slower, contrary to what would be expected.5 
In previous studies, GLP-1 aggregation showed only minor changes with ionic 
strength. It was shown that 50, 75, 100, 125 and 150 µM GLP-1 in 25 mM 
citrate buffer at pH 3.5 show no change in aggregation kinetics at 0, 50 or 150 
mM NaCl (ionic strength of the samples 18, 68 and 168 mM, respectively).139 
1.6.4 Chemical Degradation 
Chemical degradation pathways in biological pharmaceuticals have been 
reviewed many times.140 A number of chemical degradation pathways have 
been characterized including: deamidation and isomerization,141 
oxidation,140,142 hydrolysis, disulfide bond breakage and formation, 
succinimidation,143 deglycosylation, Maillard reaction, racemization and β-
elimination and many of these have been shown to increase the aggregation of 
biologics.143 This is in effect because chemical degradation/modification often 
changes the physical properties of a peptide/protein such as hydrophobicity, 
secondary structure (relevant for relatively unstructured peptides) and/or 
tertiary structure, and the thermodynamic and/or kinetic barriers to unfold 
(relevant only for highly structured proteins and not discussed further here).143 
1.6.5 Surfaces and Interfaces 
Surface-induced aggregation, often called ‘surface adsorption’, is a physical 
degradation process whereby there is accumulation and adhesion of peptide 
molecules to a surface. During this process, peptide molecules change their 
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physical state, i.e., they are no longer in solution.144–147 There are different 
mechanisms of surface adsorption of biomolecules and some of the major 
factors driving adsorption include intra-molecular forces, hydrophobicity,148–
153 and ionic or electrostatic interactions.147,154 
Extensive research has been conducted on the surface adsorption of human 
insulin.150,155–159 It is well known that insulin aggregates to form fibres in the 
presence of hydrophobic surfaces149,150,157,158 and especially in a peristaltic 
pump system.159 In this case, the potential formation of aggregation-prone 
intermediates is very problematic as this may catalyse the aggregation of other 
molecules in bulk solution. Other studies have established that the aggregation 
of Aβ1–40 into fibrils is also influenced by surfaces.160–164 Surface adsorption 
has been studied for other systems such as GLP-1,154 GLP-2,165 acylated 
glucagon-like peptide-2,165,166 glucagon,167 poly(ethylene glycol) (PEG)-
glucagon168 and α-synuclein.151,169 
It has been demonstrated that any interface (between solid, liquid or air) will 
affect the ability of water molecules to form a dynamic hydrogen-bonding 
network as in bulk water, and therefore air–water and ice–water interfaces are 
described in the literature as hydrophobic interfaces, because these interfaces 
do not allow hydrogen bonding.146 Adsorption of peptides through their 
hydrophobic side chains to such hydrophobic interfaces can thus ‘hide’ the 
hydrophobic surface from the aqueous bulk. Some research shows that, for 
example, Aβ1–40161,170 and insulin both aggregate at air–water interfaces.171 
Many studies have confirmed that the rate of peptide and protein adsorption is 
normally governed by diffusion and is thus a function of concentration.143 The 
amount of surface-adsorbed species slowly increases over time, usually due to 
further peptide aggregation at the site.160 Of course, there may also be slow 
structural rearrangements of the adsorbed peptide.160 The adsorbed layer often 
changes its properties over time; this is associated with a change from a 
reversible to an irreversible process.147 The final morphologies of the 
aggregates formed can be sensitive to the surface chemistry.154,156,160 For 
example, charged surfaces promote protofibril formation, while hydrophobic 
surfaces promote formation of spherical amorphous clusters.160 
It is well known that after sufficient time most biomolecules will adsorb to solid 
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surfaces so strongly that they will not (or only very slowly) desorb from the 
attached surface back into solution.172 However, it is possible to some degree 
to control this process by adding surface active agents which can lead to 
desorption. The degree of adsorption depends on multiple factors, including 
concentration, pH, excipients and temperature.146,147 
1.6.6 Excipients 
Excipients of many types have been employed to try and reduce aggregation in 
numerous systems including salts, surfactants, osmolytes, preservatives, 
chelators and antioxidants, specific ligands, sugars and carbohydrates. Below 
is a brief description of some of the excipients that have been used and their 
effects on aggregation. 
Buffering agents 
As already discussed, pH strongly influences peptide stability and the potential 
for biomolecular aggregation. The most commonly used buffers in 
pharmaceutical development are acetate, citrate, histidine, phosphate, Tris and 
glycine.93,143 A complete description of the effects of buffer on peptide 
aggregation is beyond the scope of this chapter; however, there is an excellent 
review by Zbacnik and co-workers.173 
Salts 
Standard physiological salts have been used as tonicity modifiers in peptide 
formulations.93,143 Tonicity measures the effective osmotic pressure gradient of 
two solutions separated by a semipermeable cell membrane. It differs from 
osmotic pressure by taking only solutes into account, which cannot cross the 
membrane.174 Salts have complex effects on the physical stability of 
biomolecules affecting both conformational and colloidal stability. Their 
effects frequently vary according to the surface charge on the peptide or 
protein, and the overall effect of a salt on physical stability is a balance of 
different and multiple mechanisms by which salt interacts with water and 
biomolecules. Salts can influence physical stability by altering the properties 
of the peptide–solvent system (Hofmeister effects) and by screening electro-
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static interactions (Debye–Hückel effects). Many different studies on the 
dependence of amyloid formation on ionic strength over the past ten years have 
shown that ions can influence both the kinetics of aggregation and the structure 
of fibrils formed. This was, for example, shown for islet amyloid polypeptide 
(37-residue),137 human glucagon (29-residue),175 and Aβ peptide.134,136,176 
Surfactants  
Surface-active agents are amphiphilic molecules that tend to orient such that 
the exposure of the hydrophobic part of the molecule to the aqueous solution is 
minimized. Non-ionic surfactants such as Tween20 and Tween80 are often 
added to peptide solutions during pharmaceutical development to prevent 
aggregation or adsorption during purification, filtration, shaking and 
transportation.3,93,177–179 However, the chemical stability of Tween20 and 
Tween80 in pharmaceutical formulations is very important. Unfortunately, 
both surfactants are known to undergo oxidation and cleavage at their ethylene 
oxide subunits, as well as hydrolysis of the fatty acid ester bond.180–183 Thus, 
their use can be complicated as these chemical processes can potentially 
promote precipitation in some peptide formulations. The use of Tween80 is 
also far from straightforward as it has been reported that it can have a dual 
effect on physical stability. For example, Tween80 in the formulation of the 
protein IL-2 mutein inhibited shaking-induced aggregation, but also had a 
dramatic effect on the oxidation and aggregation of the protein during storage 
of the liquid formulation.184,185 To counteract this issue, methionine and 
tryptophan are used in formulation development to prevent Tween from 
oxidative degradation.186 There are two excellent reviews on the interaction 
between surfactants and peptides, see Otzen187 and Khan and co-workers.178 
Amino acids 
A number of free amino acids have been used to stabilize proteins and reduce 
aggregation. Arginine, histidine, lysine, glycine and aspartic acid have been 
found to reduce aggregation for a number of biomolecules.93 
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Osmolytes 
Osmolytes such as sucrose, trehalose, sorbitol and glycine are commonly used 
in formulation development.93 Sucrose has been shown to inhibit IL-1ra dimer 
formation.143 However, their use is not always beneficial and it has been 
reported that some osmolytes accelerate the rate of aggregation, for example, 
of glucagon.188  
Antioxidants and chelators 
Peptide oxidation is a major cause of chemical instability and also sometimes 
linked to physical stability. Amino acids such as methionine, cysteine, 
histidine, tyrosine and tryptophan in peptides are susceptible to oxidation under 
some conditions encountered during pharmaceutical development. Therefore, 
a number of antioxidants are used as excipients including ascorbic acid.93 It has 
also been reported that sodium thiosulfate, methionine, catalase or platinum, 
and the chelating agents EDTA and DTPA are also effective in reducing the 
oxidation of biologics.93,189–191  
Preservatives 
Preservatives are used as antimicrobial agents and are very common in liquid 
formulations.93,192 Their role is to prevent bacterial growth during storage.93 
The most commonly used preservatives in pharmaceutical development are m-
cresol, phenol and benzyl alcohol. However, it has been reported that 
preservatives can sometimes cause protein aggregation. For example, benzyl 
alcohol induces aggregation of recombinant human interleukin-1 receptor,193 
and m-cresol induces aggregation of cytochrome c.194 Moreover, destabilizing 
effects of phenol and m-cresol were reported for insulin lispro and insulin 
aspart.195 Little is known about their effects on the physical stability of peptides.  
Polymers and Proteins 
A number of polymers have been shown to stabilize drug products including 
polyethylene glycols (PEG). The process of both non-covalent and covalent 
attachment or amalgamation of PEG polymer chains is described as 
PEGylation. Other polymers that are used as excipients include dextrans, 
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heparin, gelatins type A, poly-L-glutamic acid, poly-L-lysine, poly-Asp and 
poly-Gly.93,143 For example, it has been reported that different PEGs stabilize 
the proteins lysozyme and bovine serum albumin.143 Human serum albumin is 
also commonly used as an excipient to inhibit protein/peptide adsorption onto 
surfaces during product development.143 However, adding protein-based 
excipients adds more complexity to pharmaceutical formulations.93  
Recently, some excellent reviews on biologics formulation196,197 and 
excipients, including protein–excipients interactions93,197,198 have been 
published.  
1.6.7 Impurities 
The results of in vitro aggregation studies are often controversial and difficult 
to reproduce by others. One of the reasons for this problem is the variable 
amounts of intrinsic impurities in peptide and protein preparations that can 
affect aggregation rates. For example, the aggregation kinetics of synthetic Aβ 
has been reported to vary not only batch-to-batch but also with storage and 
solubilization conditions.199 In line with these findings, kinetics studies 
revealed that the impurities left in the synthetic peptides of glucagon decreased 
fibrillation rates dramatically compared to that of pharmaceutical-grade 
glucagon.68,175,200 
1.6.8 External Factors 
Numerous other external factors including temperature, pressure, agitation and 
lyophilization/freeze drying can affect the aggregation of peptides, in many 
cases, in ways difficult to predict. 
Pressure 
High hydrostatic pressure (HHP) has been used in a number of studies.201 It is 
now well established that HHP pushes the conformational equilibria towards 
ensembles of structures that occupy smaller volumes, it acting on cavities that 
are excluded from solvent that can be found in the hydrophobic cores of 
natively folded proteins and aggregates including fibrils.201 HHP has been used 
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to dissociate multimers in oligomeric structures and, in some cases, dissociate 
aggregates.201,202 The degree to which HHP acts to dissociate aggregated forms 
of peptides depends upon the structures that are formed and also their inherent 
thermodynamic stability. For example, if fibrils have cavities within them 
(cavity defects as they are called) then often low pressures are sufficient to 
dissociate the aggregated form; for example, early aggregates and protofibrils 
are generally more readily dissociated by HHP than mature fibrils.203 For a 
peptide from transthyretin that can form fibrils, TTR105–115, 220 MPa 
dissociates aggregates and protofibrils while mature fibrils remain stable up to 
1.3 GPa.203 For α-synuclein, pathogenic variant fibrils are less resistant to HHP 
than those of the wild-type protein, hence more toxic oligomers are present.201 
The dissociation of aggregates and fibrils by HHP is reversible and can be 
enhanced by the addition of cosolvents such as glycerol, methanol and 
dimethylsulfoxide.203 
Temperature 
Aggregation kinetics frequently show non-Arrhenius behaviour even over short 
temperature ranges.204 A consequence of this is that it is challenging to 
extrapolate the results of aggregation kinetics commonly measured at higher 
temperatures to lower temperatures. In addition, cold denaturation of amyloid 
fibrils has been observed,205,206 and low temperatures have been combined with 
high pressures to dissociate aggregates and fibrils.203 Experiments at increased 
temperatures between 50 and 100 °C with globular proteins has shown heat-
induced gelation can occur for some systems.207 
Agitation 
Agitation, in the form of a magnetic stirring bar or by use of a shaker table, is 
routinely used in studies of peptide and protein aggregation. It has been 
employed in order to accelerate otherwise slow aggregation kinetics and also 
used to improve the reproducibility of experimental results.208 Despite the 
frequent use of agitation little is known about the shear forces that are produced 
and the effects on different steps in the aggregation reaction. In addition, as 
stirring/shaking is often different in different studies, it is challenging to 
Chapter 1: Introduction 
32   
undertake a comparative analysis on systems studied in different research 
groups.209 
Lyophilization/freeze drying 
The stabilization of peptides in a solid form is a very common approach to 
increase both their chemical and physical stability.210 Lyophilization and freeze 
drying are frequently used to prepare peptides in a solid state. However, for a 
number of systems studies have shown these processes can result in 
conformational changes leading to increased aggregation after 
reconstitution.211 These conformational changes can be caused by different 
effects such as stress induced by formation of ice-water interfaces, freezing 
induced pH-changes of specific buffers, changes in concentration of solutes and 
phase separations.146,212  
Parameters that can be controlled to minimise the effect of freeze-drying are 
the choice of the buffer,213 the duration of the freezing process214 or additives, 
which minimise the interaction of the peptide with the water-ice interface, for 
example, surfactants.146    
1.6.9 Chemical Modifications 
Chemical modifications of different types are increasingly used to optimize the 
chemical/physical and biological properties of therapeutic peptides. This 
includes the incorporation of non-natural amino acids,215 engineering of 
disulfide bonds216–220 and lipidation or acylation of the peptide.221,222 
Lipidation/acylation of peptides is becoming increasingly important in the field 
of therapeutic peptides.223,224 Inspired by endogenous lipidation processes, it 
has been shown to improve many properties of a peptide, particularly its ability 
to bind to human serum albumin increasing the half-life of the peptide in vivo 
dramatically and also enhancing its ability to permeate body tissues.223,224 
Current therapeutics which use this approach include Liraglutide225 (a lipidated 
form of GLP-1), and insulin detemir, a lipidated conjugate of insulin.226 
Although considerable research has been undertaken on how this class of 
chemical modification affects the activity of the peptide in vitro and in vivo, 
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rather little is known about how these modifications affect the physical stability 
of the system. One recent biophysical study on Liraglutide by Wang and co-
workers showed that this lipidated peptide can form oligomers in solution.227 
In this case, a pH-sensitive equilibrium between octamers and dodecamers was 
observed in the vicinity of pH 7.227 The importance and impact of oligomers, 
synthetic processes and lyophilisation on the aggregation of Liraglutide was 
also shown by Bothe et al.91 Different oligomeric states showed different 
aggregation kinetics as well as different potencies. They were also able to show 
that Liraglutide can maintain its oligomerisation state in dried lyophilised 
powders, acting as a memory effect from its synthetic process and purification.  
In another case, acylation of the anti-microbial peptide novicidin resulted in an 
increased tendency to form α-helical structure when a C12-acyl group was 
attached. The peptide concentration dependence of this conformational change 
was attributed to the increased tendency of the peptide to form micelles as 
shown by NMR.228 Although not peptides with any therapeutic potential, the 
Prive group has published extensively on the properties of lipopeptide 
detergents (LPDs) which have been developed for structural studies of 
membrane proteins.229 LPDs, which consist of an α-helical peptide with alkyl 
chains at either end of the helix, have been shown to self-assemble into 
cylindrical micelles that have a densely packed hydrophobic core.229 
In contrast to the chemical modifications used by the pharmaceutical industry 
to optimize the properties of therapeutic peptides, where little is known about 
the effect of the modifications on physical stability, a great deal has been 
reported for peptides whose aggregation is associated with disease states. In 
these cases, the modifications investigated are largely post-translational 
modifications that occur in vivo and which, in many cases, are thought to affect 
the disease state. For example, the effects of many post-translational 
modifications on the aggregation of Aβ peptides have been studied. An N-
terminal truncation and pyroglutamate modification at residue 3 of Aβ peptide 
has been shown to have a higher propensity for oligomerization and 
aggregation than full-length Aβ.230,231 In addition, phosphorylation of Aβ has 
been shown to increase oligomer formation,232,233 while citrullination of Aβ 
decreases the rate of fibril formation but may increase the amount of toxic 
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oligomers.234 Similarly, nitration of tyrosine 10 (Y10) of Aβ has also been 
shown to increase the amount of oligomers of Aβ in solution.235 Backbone 
modification of Aβ at Gly29 also shows decreased fibril formation and 
increased oligomer formation.236 Similarly, differences in the sequence in the 
form of mutations influence the aggregation pathway and, therefore, the 
progression of Alzheimer diseases. Common mutations of Aβ are A21G 
Flemish, E22K Italian, E22Q Dutch, E22G artic, and D23N Iowa. More details 
from a Chemist’s perspective about Aβ, its mutations and its role in 
Alzheimer’s Disease and fibrillation can be found in an excellent review by I. 
W. Hamley.38  
The aggregation and fibril formation of α-synuclein is associated with another 
neurodegenerative disease, Parkinson’s Disease. α-synuclein is a 14 kDa 
intrinsically disordered protein.237 It is known to consist of three main domains: 
An amphipathic N-terminal involved in membrane binding,238 an aggregation-
prone hydrophobic central region,239 and an acidic unstructured C-terminal 
region.238 Different autosomal dominantly inherited point mutations 
(Ala53Thr, Ala30Pro, and Glu46Lys) have been described.240–242 They all can 
cause Parkinsonism and, as shown for Glu46Lys, also result in clinical and 
pathological features characteristic of Lewy body dementia.242 There is also a 
large body of data that establishes that numerous post-translational 
modifications in vivo affect the propensity of the protein to aggregate and thus 
potentially the disease state. For example, N-acetylation has been shown to 
decrease fibrillation,243,244 post-translational modifications due to oxidative 
stress such as HNE conjugation, nitration and oxidation have been shown to 
reduce fibril formation but increase oligomer formation,245,246 and oxidation of 
Met5 also decreases fibril formation but increases the concentration of 
oligomers.247 
The intracellular protein tau, associated with Alzheimer’s disease, is also 
known to undergo a large number of post-translational modifications in vivo 
including phosphorylation, ubiquitination, nitration, truncation, prolyl 
isomerization, glycosylation and glycation. Many of these are thought to affect 
neurofibrillar tangle formation, the aggregated form of tau in cells.248 A few, 
but not many, of these post-translational modifications on tau aggregation have 
Chapter 1: Introduction 
  35 
been studied in detail. For example, cysteine guanylation of tau has been shown 
to inhibit fibril formation with a corresponding increase in the population of 
oligomers.248 
The effects of a large number of other modifications on the physical stability 
of specific peptides or proteins have also been reported, including different 
glycosylations249 and fatty acid conjugation.250 
The focus of this Thesis is the physical stability of GLP-1, GLP-1 with 
amidated C-terminus and two lipidated forms of GLP-1 with amidated C-
termini. The idea of using lipidation to influence the properties of peptides in 
vivo is directly motivated by examples observed in Nature, so called 
endogenous lipidation.  
1.7.1 Endogenous Lipidation  
Lipidation of polypeptides can be found naturally in mammalian cells, for 
example, palmitoylation or myristoylation. S-palmitoylation, in particular, is a 
reversible covalent post-translational attachment of palmitic acid to the amino 
acid cysteine. It is the most common acylation of polypeptides in eukaryotic 
cells and can be found in many proteins including G-proteins, ion channels, 
receptors, cytoskeletal proteins and kinases.222,251 The modification affects, 
amongst other things, the regulation of protein subcellular localisation, 
stability, trafficking, translocation to lipid rafts, aggregation and the interaction 
with effectors.222 Palmitoylation is reversible and dynamically regulated by 
enzymes.222 
Several naturally occurring acylations of different proteins are presented in 
Table 1.3. The spectrum of lipids is broad, ranging from caprylic acid, through 
geranylgeranyl groups to cholesterol. The attachment can be catalysed by 
enzymes, can be non-enzymatic, autocatalytic or the mechanism is still 
unknown. In the case of GAP-43, a heterogeneity in the naturally attached fatty 
acid was found with both C16 or C18 fatty acids observed, showing that either 
palmitoyl transferase can attach different fatty acids as substrates or there exist 
1.7 Lipidation of Peptides 
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other transferases which are, as yet, unknown.222,251  


















Palmitoleic acid Serine Porcupine Wnt3a 
Steeric acid Cysteine Unknown GAP-43 

























Table 1.3. Examples of endogenous protein lipidation.222  
1.7.2 Influence of Lipidation in Therapeutics 
Artificial lipidation can be used in a similar manner to that of Nature to improve 
the therapeutic effect of polypeptides.221 Connected by covalent bonding, a 
lipid group (cholesterol, palmitic acid or farnesyl) can have a significant 
influence on the efficiency of a drug.221 The lipid group can be attached to an 
alcohol, amino or acid group on a peptide/peptidomimetic inhibitor via amide, 
ether or carbamate linkages. Through its interaction with the membrane in cells, 
the lipid group has a strong influence on the location of the drug.  
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In Figure 1.12A, B and C, three different applications of lipidated peptides 
/proteins are shown. When anchored in a membrane, the lipidated 
peptide/protein can bind to soluble proteins or membrane-bound proteins. The 
former can be helpful in reducing the amount of a certain protein and the latter 
can take advantage of the higher molarity of membrane-binding peptides within 
the membrane.252  
Lipidation can also influence cell-permeability as it was shown for 
palmitoylated peptidyl inhibitors by Tarasova et al.,253 Figure 1.12D. However, 
the effect of lipidation is not restricted to its influence on the interaction with 
membranes. It also influences the binding affinity to plasma proteins as human 
albumin.254 A schematic representation of a lipidated peptide that binds to 
serum albumin is shown in Figure 1.12E. 
 
Figure 1.12. Different applications of lipidated peptides/proteins in vivo. 
A) A lipidated inhibitor binds to a membrane. B) Soluble protein (blue moon-
shaped molecule) immobilised by binding to the lipidated therapeutic. C) 
Membrane bound protein (green molecule) immobilised by binding to the 
lipidated therapeutic. D) Increased cell permeability due to lipidation. E) 
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The peptide used in these studies is glucagon-like peptide 1 (GLP-1 (7-37)). It 
is an incretin hormone and different modified variants are currently already in 
use as drugs to treat type two diabetes mellitus.224,255,256 Previously, Zapadka et 
al. have investigated and reported how the peptide concentration dependence 
of the aggregation kinetics of GLP-1 (7-37) varies from pH 7.5 to 8.2.5 The 
main finding was that there was a striking change in kinetic behaviour over this 
very short pH range, which was attributed to the population of off-pathway 
oligomeric species at pH values close to the pI of GLP-1. Values of t1/2 and the 
lag time were found to decrease with increasing peptide concentration at pH 
8.2 as expected for a nucleated-polymerisation mechanism. However, at pH 
7.7, little effect of peptide concentration on these kinetic parameters was 
observed and at pH 7.5, they were found to increase with increasing peptide 
concentration.5 
 
Figure 1.13. Products during the process of proglucagon.  
The numbering of GLP-1 (7-37) and (7-36) refers to the major proglucagon 
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1.8 Glucagon-Like Peptide 1 (GLP-1) 
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GLP-1 is important in mammalian metabolism and plays a main role in 
preventing hyperglycemia. GLP-1 was described for the first time in 1986 as a 
specific fragment of proglucagon. Proglucagon itself was described by K. Lund 
and J Habener, who were able to deduce the structure of proglucagon of angler 
fish.257 Bell and co-workers published the full human proglucagon structure in 
1983.258  
In addition to glucagon itself, proglucagon contains two glucagon-like 
structures. Framed by consensus cleavage sites for the prohormone convertase, 
the fragments for the two glucagon-like structures are proglucagon 72-108 and 
126-158.258 However, neither directly affected pancreatic insulin secretion, and 
only become active on truncation. This led to the conclusion that the sequence 
is processed in the pancreas as well as the gut. Holst and co-workers found that 
in the pancreas, the major proglucagon fragment (MPGF) is formed and 
secreted, whereas GLP-1 and GLP-2 were both formed and released in the 
gut.259,260 The highly immunoreactive GLP-1 turned out to be a truncated form 
of the predicted GLP-1. Instead of proglucagon 72-107, the active sequence 
starts with residue 78, Figure 1.13.261  
The naturally occurring and active human GLP-1 peptides are nowadays often 
referred to as GLP-1 (7-36) amide or GLP-1 (7-37) because of the original 
assumption that GLP-1 would consist of 37 amino acids. In vivo, the C-terminal 
Gly of GLP-1 7-37 can be amidated, Figure 1.13.261,262 
1.8.1 Biological Activity of GLP-1 
GLP-1 is, as mentioned, a highly immunoreactive incretin.263 It can influence 
the blood sugar level in two different ways, first by stimulating glucose-induced 
insulin release and second by inhibiting glucagon secretion.264 Both effects can 
limit hepatic glucose production, which is closely correlated to fasting 
hyperglycemia of type 2 diabetes. GLP-1 is also known to be a physiological 
and potent inhibitor of gastrointestinal secretion, both gastric and pancreatic, 
as well as motility.265 Glucagon-like peptide 1 (GLP-1) is an intestinal hormone 
signalling nutritional abundance, with an unusual therapeutic potential. An 
overview over the physiology of GLP-1 secretion and its influence on different 
organs and tissue is given in Figure 1.14. 
Chapter 1: Introduction 
40   
 
Figure 1.14. Physiology of GLP-1 secretion and action on GLP-1 receptors in 
different organs and tissues.  
Figure adapted from D. Drucker & M. Nauck, 2006.
266
 
1.8.2 GLP-1 as a Therapeutic Agent and its Challenges 
The biggest challenge in the development of GLP-1 as a therapeutic was that it 
lasts for extremely short times in blood plasma. The measured half-life of GLP-
1 in humans is around 2 min after injection. One major factor of its fast 
degradation is the enzyme dipeptidyl peptidase 4 (DPP-4).267 Ahren and co-
workers showed in 2004 that the use of DPP-4 inhibitors can prolong the half-
life of GLP-1.268 Another approach to minimise degradation uses the 
dependence of DPP-4 on the presence of a penultimate Pro or Ala at the N-
terminus. It was shown that GLP-1 analogues, with Ser, Val or a-aminobutyric 
acid substituted at the relevant positions, stayed biologically active and were 
more resistant against degradation.269 Unfortunately, the degradation through 
DPP-4 is only one factor in its degradation processes, and the half-life increased 
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only slightly up to 4-5 min.269 The remaining degradation is caused by 
extraction of GLP-1 in the kidneys270 although degradation by other enzymes 
may also play a role. It all meant that to overcome the challenge of a short half-
life, more complex modifications were needed.  
1.8.3 Modifications and Analogues of GLP-1  
Strategies to overcome the short half-life of GLP-1 were developed using two 
different approaches. The first one uses a non-human peptide, isolated from the 
saliva of a reptile, the Gila Monster (Heloderma suspectum).271 The 39-amino 
acid long peptide Exendin-4 has 53% homology to human GLP-1. Being a full 
and potent agonist of the mammalian GLP-1 receptor, Exendin-4 has the 
advantage that it is not sensitive to DPP-4 as well as the fact that it is barely 
extracted in the kidneys. Its half-life is about 30 min after injection and this can 
be increased further by subcutaneous injection, and adequate concentrations 
can be achieved for up to five hours.272 This was sufficient for the development 
of a therapeutic based on two daily injections. Subsequently, a synthetic replica 
was produced and marketed under the name Exenatide. It was the first GLP-1 
receptor agonist on the market in 2005.272 A slightly modified version is 
Lixisenatide which is designed for once-daily use. Despite its improved 
usability, it is identical to Exenatide in terms of its pharmacokinetics.273 
 
 
Figure 1.15. Sequence and structure of Liraglutide and its lipidation.  
Blue highlighted residues are known to be important for binding to the 
receptor. Residues by Tango predicted to be important for amyloid formation 
are highlighted by orange circles.  
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The second approach was based on modification of human GLP-1 with lipids. 
The potency of different lipidated GLP-1 analogues was determined using a 
functional assay with cloned human GLP-1 receptors which were expressed in 
baby hamster kidney cells.255 In general, lipidation at the carboxyl terminus (C-
terminus) with long chain fatty acids did not affect the potency of the GLP-1. 
From earlier studies it was already known that the amino acids at position 7, 
10, 12, 13, 15 in the N-terminal region and 28, 29 in the C-terminal region are 
important for binding and activation of the receptor as shown in Figure 1.15.274 
For the lipidation itself, Knudsen et al. used the amino acid lysine as the 
attachment site. 
The first successful approach, known as Liraglutide, was released in 2009/10. 
It is a lipidated form of GLP-1. The attachment of palmitic acid via a glutamic 
acid linker at residue 26 (Lys) results in the ability to bind non-covalently to 
serum albumin. The latter increases its half-life in blood plasma by reducing 
the renal filtration as well as by improved protection from DPP-4 degradation. 
With a half-life of about 12 hours, Liraglutide is suited for a once-daily 
injection. It has also been approved to treat obesity.275  
 
 
Figure 1.16. GLP-1 and GLP-1 receptor agonists used as pharmaceuticals.  
The sequence of GLP-1 (7-37) (blue circles) in comparison to different 
GLP-1 receptor agonists. Red circles highlight modifications of the original 
sequence of GLP-1 (7-37).  
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To reach the aim of improved usability, several once-weekly use agonists have 
also been developed. This was achieved by coupling the peptide to larger 
molecules, for example human albumin or an IgG4 Fc domain, by covalent 
(Albiglutide276–278, Dulaglutide278) or non-covalent (Semaglutide279) binding, 
Figure 1.16. The attachment to a larger molecule leads to slower clearance and 
improved half-life.  
The future of GLP-1 receptor agonist (GLP-1RA) treatment stays an exciting 
topic, more so as patents of the first marked products will run out in the early 
2020s. 
A commonly used lipid for lipidation of GLP-1 are fatty acids, a carboxylic 
acid with a long aliphatic chain. Typical examples of saturated fatty acids are 
shown in Table 1.4. In this Thesis, all modifications of GLP-1 are based on 
palmitic acid. Palmitic acid is the most common saturated fatty acid found in 
animals, plants and microorganisms and is a significant component of palm oil, 
as the name suggests. The lipid is attached to the peptide, via a glutamic acid 
spacer to increase the distance to the peptide, Figure 1.15. 
The lipidation of GLP-1 with palmitic acid and a glutamic spacer was based on 
detailed studies evaluating the influence of the position as well as different 
spacers and fatty acids with different lengths. Residues known to be important 
for binding to the receptor were excluded as lipidation sites.274 Different fatty 
acids, spacers and positions were screened by Knudsen et al. (2000).255 The 
combination of good biological activity and physical stability lead ultimately 
to the choice of glutamic acid and palmitic acid. 
 
Table 1.4. Examples of saturated fatty acids.  
Carbon atoms Sytematic name Common name Melting point (°C)
12:0 n-dodecanoic Lauric 44
14:0 n-tetradecanoic Myristic 54
16:0 n-hexadecanoic Palmitic 63
18:0 n-octadecanoic Stearic 70
20:0 n-eicosanoic Arachidic 77
1.9 Fatty Acids Used for Lipidation  
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In previous studies, the aggregation of GLP-1 into amyloid fibrils was 
investigated in some detail at pH values between pH 7.5- 8.2.5 Dr Karolina 
Zapadka extended these studies in previously unpublished work to characterise 
the physical stability of GLP-1 at low pH (3.0 and 3.5). Standard ThT assays 
were used to measure the aggregation kinetics to obtain the lag time, t1/2 and 
apparent growth rate as a function of peptide concentration, Figures 1.17 - 1.21. 
At both pH 3.0 and 3.5, GLP-1 aggregates into b-sheet rich fibrils that bind 
ThT and which show sigmoidal kinetic traces typical of a nucleated 
polymerisation reaction. The timescales of aggregation at pH 3.0 and 3.5 are 
similar to those at pH 7.5-8.2, lag times varying from 5-50 hours depending 
upon peptide concentration, Figure 1.18A & B. Figure 1.18C & D show the 
results at pH 7.5 and 8.2, which are consistent with previously reported 
aggregation kinetics of GLP-1.  
The dependence of lag time and t1/2 on the initial concentration of monomeric 
peptide is shown in Figures 1.18, 1.19 and 1.20, and this provides important 
information on the mechanism of fibril formation. At pH 3.0, t1/2 and lag time 
decrease with increasing peptide concentration, the slope of the plot of log 
peptide concentration vs log lag time, g, is -1.0 ± 0.2, Figure 1.20A. This 
suggests that, at this pH, only on-pathway oligomers play a major role and that 
the filamentous growth reactions are limited by primary and surface-catalysed 
secondary nucleation processes rather than by simple breakage.280 These results 
are similar to those obtained at pH 8.2, Figure 1.17D.5  In contrast, at pH 3.5, 
both the lag time and t1/2 increase with increasing peptide concentration similar 
to the results at pH 7.5, Figures 1.17B, 1.18B and 1.19B. These results suggest, 
under these conditions, off-pathway oligomeric species are present and 
significantly affect the aggregation kinetics.  
Additionally, at pH 3.5 and 7.5, there is an increase in ThT fluorescence in the 
initial baseline of the aggregation assays, Figure 1.17B & C. This indicates 
either that small fibrils are being formed or that other species such as on- or 
1.10 Aggregation of GLP-1 under Acidic, Neutral and 
Basic Conditions 
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off-pathway oligomers capable of binding and increasing the ThT signal are 
populated. However, the formation of early fibrils is unlikely as secondary 
nucleation mechanisms should result in an immediate rapid growth phase 
instead of the observed approx. relatively slow linear increase seen during the 
lag phase. Therefore, it is probable that the off-pathway oligomers have some 
capacity to bind to ThT and increase its fluorescence. 
 
Figure 1.17. Aggregation kinetics of GLP-1 as a function of peptide concentration at 
different pHs. 
Data collected by Dr Karolina Zapadka. GLP-1 aggregation kinetics in 25 
mM citrate buffer at pH 3.0 (A), 25 mM citrate buffer at pH 3.5 (B), 25 mM 
phosphate buffer at pH 7.5 (C), and 25 mM Tris buffer at pH 8.2 (D). Panels 
A-D show typical traces for the fibrillation of GLP-1 followed by ThT 
fluorescence at different peptide concentrations: 25 µM (yellow), 50 µM 
(red), 75 µM (green), 100 µM (blue), 125 µM (purple), and 150 µM (pink). 
Each peptide concentration was performed in triplicate.  
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Figure 1.18. Dependence of the GLP-1 aggregation lag time on the peptide 
concentration. 
Data collected by Dr Karolina Zapadka. Dependence of the lag time on the 
concentration of GLP-1 in 25 mM citrate buffer at pH 3.0 (A), 25 mM citrate 
buffer at pH 3.5 (B), 25 mM phosphate buffer at pH 7.5 (C), and 25 mM Tris 
buffer at pH 8.2 (D). All samples incubated at 37 °C. The error bars shown 
in A-D correspond to the standard deviations of the kinetic parameters 
determined from one experiment where each peptide concentration was run 
in triplicate. See Table 1.5 for further details. 
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Figure 1.19. Dependence of the GLP-1 aggregation half-time on the peptide 
concentration. 
Data collected by Dr Karolina Zapadka. Dependence of the half-time on the 
concentration of GLP-1 in 25 mM citrate buffer at pH 3.0 (A), 25 mM citrate 
buffer at pH 3.5 (B), 25 mM phosphate buffer at pH 7.5 (C), and 25 mM Tris 
buffer at pH 8.2 (D). All samples incubated at 37 °C. The error bars shown 
in A-D correspond to the standard deviations of the kinetic parameters 
determined from one experiment where each peptide concentration was run 
in triplicate. See Table 1.5 for further details. 
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Figure 1.20. Dependence of the GLP-1 aggregation half-time on the peptide 
concentration on a log-log scale. 
Data collected by Dr Karolina Zapadka. Dependence of the half-time on the 
concentration of GLP-1 in log-log scale in 25 mM citrate buffer at pH 3.0 
(A), 25 mM citrate buffer at pH 3.5 (B), 25 mM phosphate buffer at pH 7.5 
(C), and 25 mM Tris buffer at pH 8.2 (D). All samples incubated at 37 °C. 
The error bars shown in A-D correspond to the standard deviations of the 
kinetic parameters determined from one experiment where each peptide 
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Figure 1.21. Apparent growth rate of GLP-1 as a function of peptide concentration 
at different pHs. 
Dependence of the apparent growth rate on the concentration of GLP-1 in 25 
mM citrate buffer at pH 3.0 (A), 25 mM citrate buffer at pH 3.5 (B), 25 mM 
phosphate buffer at pH 7.5 (C), and 25 mM Tris buffer at pH 8.2 (D). All 
samples incubated at 37 °C. The error bars shown in A-D correspond to the 
standard deviations of the kinetic parameters determined from one 
experiment where each peptide concentration was run in triplicate. See Table 
1.5 for further details. 
Chapter 1: Introduction 
50   
  
Table 1.5. Summary of the averages and standard deviations of the kinetic 
parameters obtained from multiple repeats of the ThT assays for GLP-1 
at different pH values. 
Data collected by Dr Karolina Zapadka. 
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To study the change of the secondary structure during the aggregation process, 
time-course measurements of GLP-1 were conducted in the Jackson Group. 
The measurements of far-UV CD spectra at different time points from 0 up to 
144 h show for all four pH conditions (pH 3.0, 3.5, 7.5 and 8.2) an overall 
change from a structure containing α-helical, turn, disordered and β-sheet 
structure to a structure containing mainly β-sheet structure.  
In citrate buffer at pH 3.0, the most dominant change of the secondary structure 
can be observed between 4-6 h, and therefore approx. the same time as the lag 
time of 5 h, Figure 1.22A & Table 1.5. The time-course measurements at pH 
3.5 show an earlier change in the secondary structure. Here, the main change is 
observed after less than half of the measured lag time of 31 h, Figure 1.22B and 
Table 1.5.  
Under neutral pH conditions (pH 7.5), the data shows again a close relation 
between the lag time and the significant change of the secondary structure, 
which both were determined to be around 23 h, Figure 1.22C & Table 1.5. 
However, a more gradual transformation in secondary structure can be seen at 
pH 8.2, with some significant changes happening between 7 and 8 h and a 
complete transformation of the secondary structure already after 9 h, Figure 
1.22D. Between 9 and 144 h, the secondary structure stays constant. The 
change in secondary structure occurs earlier in comparison to the measured lag 
time of the ThT assay, which was measured to be 15 h, Table 1.5. 
1.11 Changes in Secondary Structure During 
Aggregation  
Chapter 1: Introduction 
52   
 
Figure 1.22. Changes in secondary structure in GLP-1 during aggregation shown 
with far-UV CD. 
Measurements conducted by Dr Karolina Zapadka. Far-UV CD spectra of 
150 μM GLP-1 incubated at 37 °C measured at different time points. The far-
UV CD measurements were conducted at 25 °C. The x-axis and y-axis show 
the wavelength (nm) and the molar ellipticity (10
3
 ⋅	deg ⋅	 cm2 ⋅	dmol-1), 
respectively. The different colours represent different time points in hours. 
The measured lag times taken from previous ThT assays, Figure 1.17, are 
shown in black. Time points showing the first major changes of the secondary 
structure are shaded in blue. A) 25 mM phosphate, pH 3.0. B) 25 mM 
phosphate, pH 3.5. C) 25 mM phosphate, pH 7.5. D) 25 mM Tris, pH 8.2. 
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The study of amyloid fibrils was, from the beginning, influenced and inspired 
by the usage of dyes. The most widely used amyloid dye is the fluorescent dye 
thioflavin T (ThT). In 1959, its potential was demonstrated by Vassar and 
Culling.281 Three decades later, the first detailed characterisation of the ThT 
fluorescence spectra and binding properties was undertaken by Naiki et al.282 
Their work on the fluorometric determination of amyloid fibrils in vitro showed 
that ThT in the absence of amyloid fibrils has only a faint fluorescence at the 
excitation and emission maxima of 350 and 438 nm, respectively. In 
comparison, the ThT fluorescence in the presence of amyloid fibrils was 
significantly increased at the shifted excitation and emission maxima of 450 
and 482 nm, respectively. Understanding the specificity of ThT binding to 
amyloid fibrils has been studied extensively using a broad range of biophysical 
and biochemical analyses, protein/peptide engineering, fluorescence 
microscopy, and computational simulations.283  
It has been suggested that ThT behaves in solution as a “molecular rotor” 
because of the single shared carbon-carbon bond between the benzylamine and 
benzathiole ring, Figure 1.23A.284,285 If the rotation is possible, it enables the 
molecule to undergo a charge transfer which leads to the population of a non-
fluorescent twisted intramolecular charge transfer state (TICT state)284. This 
quenching leads to a low fluorescence emission for non-immobilised ThT 
molecules. The binding of the ThT molecule to a fibril and selective 
immobilisation of a subset of the ThT molecules suppresses the population of 
the TICT state, which leads to an increase in the ThT fluorescence in samples 
with amyloid fibrils compared to samples without.  
The characteristics of increased fluorescence caused by the binding of ThT to 
amyloid fibrils has brought the mechanism of its binding into the focus of a 
wide range of studies. The typical structure showing the fibril-ThT interaction 
has been described by a “channel” model.286–288 Channel-like motifs are formed 
by amino-acid side chains forming cross-strand ladders. In these channels, the 
1.12 Thioflavin T as a Fluorescent Marker of Amyloid 
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ThT molecules bind aligned parallel to the long axis of the fibre, Figure 
1.23B.289 It was shown that ThT molecules prefer certain types of channels, 
especially channels formed by hydrophobic or aromatic residues.290 In contrast, 
highly charged fibrils often show a poor affinity for ThT.291 Furthermore, the 
minimum length of a channel to bind a ThT molecule was determined 
experimentally and corresponds to the height of five or more β-strands,292 
whereas computational simulations suggested that, in the absence of repulsive 
forces ,already a groove formed by the side chains of four β-strands is sufficient 
to bind ThT.293 
It is assumed that the groove's minimum length is why ThT typically does not 
bind to β-sheet rich globular proteins as they usually contain highly twisted β-
sheet motifs consisting of four or less β-strands.289,294,295 However, from several 
significant studies on the specificity of ThT, it is known that there are some 
exceptions where ThT has been shown to bind to globular proteins. For 
example, it was shown that ThT binds to acetylcholinesterase.296 In contrast to 
fibrils, here, the binding site is primarily formed of α-helices. The interaction 
of ThT and the hydrophobic binding pockets is again mediated by aromatic side 
chains, including ,-stacking of Tyr and Trp.296 Similarly, ThT has been shown 
to bind to a hydrophobic pocket of human serum albumin with an observed 
binding constant comparable to that of other drug-like molecules.297 
Despite some binding to globular proteins, ThT binds relatively specifically to 
amyloid fibrils and shows low or no binding affinity to soluble proteins in 
folded, unfolded or partially folded states.298  
 
 
Figure 1.23. Structure of ThT and its binding model to fibril-like β-sheets. 
A) Structure of ThT consisting out of two planar segments whose mutual 
rotation defines its chirality and influences its fluorescent
 
properties. B) The 
binding of ThT molecules is proposed to occur along surface side-chain 
grooves. These so called “channels“ run parallel to the long axis of the β-
sheet. Figure adapted from M. Biancalana & S. Koide, 2010.
283
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However, the low or sometimes complete lack of binding to non-fibrillar 
aggregates does not mean that these species cannot influence the ThT 
fluorescence indirectly. For example, it cannot be excluded that these 
aggregates reduce the overall fibril yield or affect the kinetics of fibril 
formation. In some cases, oligomers have been shown to have only a poor 
interaction with ThT resulting in a low ThT fluorescence.299  
During ThT assays, it is always important to check if the ThT fluorescence is 
linearly related to the amount of fibrils in solution, i.e., peptide concentration. 
Another factor influencing ThT fluorescence is pH. Caution should be 
exercised when comparing measurements under acidic conditions and neutral 
pH values, as the protonation of the tertiary amine leads to a lower ThT 
fluorescence absorption and emission below pH 3.0.300 Another critical factor 
influenced by pH is hydroxylation. Most notable under elevated temperatures 
and basic conditions, it can also play a role at neutral pH and 37 °C. For 
example, at pH 7.3 and 15 h incubation at 50 °C, a ∼25%	decrease in the ThT 
absorbance has been attributed to hydroxylation.301  
It has also been suggested that ThT binds to at least two different binding sites 
in insulin amyloid fibrils which each have a  different influence on its 
fluorescence,302 which is a good reminder that a change in ThT fluorescence 
intensity in a fibrillar sample does not automatically mean a change in the total 
fibril concentration. Instead, it could simply be caused by an equilibration 
process between two ThT binding sites on a given fibril surface. 
ThT assays can be conducted in-situ or ex-situ as fixed-timepoint assays. The 
latter has the advantage that no ThT is present during the actual aggregation 
process as it can theoretically influence the process. However, during fixed-
timepoint assays, the extraction of samples, volume change, and agitation 
caused by sample extraction can also influence the aggregation process. A 
recent study showed that ThT present during the aggregation process alters the 
fibrillation kinetics of α-synuclein in comparison to an ex-situ assay.303 
However, the main differences were only seen for the fluorescence intensity. 
The primary kinetic parameters lag time and t1/2 were not significantly affected. 
One possible explanation for the difference in the fluorescence intensity is the 
higher accessibility of binding sites during an in-situ assay.304  
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Overall, in-situ ThT assays are a powerful tool to follow the kinetics of fibril 
formation. They enable detailed kinetic analyses of the aggregation process, 
however, the linear dependence of the ThT fluorescence on fibril concentration 
should be checked and additional factors such as the effect of ThT binding to 
excipients and globular proteins (if included in the assay) must be excluded. It 
is also always recommended to support conclusions from ThT assay data with 
orthogonal methods such as AFM, SEM, TEM, far-UV CD or FT-IR.  
Biomolecules often possess a molecular asymmetry which means that their 
mirror image is not identical. Such behaviour is known as chirality, and these 
molecules are said to be optically active. Circular dichroism exploits the fact 
that chiral molecules have a non-zero difference in response to left- and right-
circular polarized light.305 In the case of polypeptides, the main chromophores 
interacting in the far-UV region are the peptide bonds.306 If the latter is part of 
a regular folded structure as in an α-helix or β-sheet, it is influenced by the 
conformationally asymmetric structure.  
To measure the circular dichroism, an unpolarised light source gets polarised 
and subsequently circular polarised with a quarter-wave modulator.305,307 
Depending on the modulation the circularly polarised radiation can be 
comprised of one of two different circularly polarised vectors.305 Both vectors, 
the right-handed and left-handed, are of equal intensity. Samples with 
chromophores in optically symmetrical structures will typically absorb the two 
components in equal measures. In contrast, chromophores in an asymmetric 
environment will absorb the two different vectors to a different extent. The 
difference between the absorption of the left-handed and right-handed polarised 
light provides insights into the conformation of the measured samples. The 
method of far-UV CD profits from requiring only a low sample volume needed 
to gain structural data and the fact that the samples can be measured in solution. 
Figure 1.24 shows different components of typical far-UV spectra of a 
polypeptide adopting different conformations. Excellent reviews or book 
1.13 Measurement of the Secondary Structure of 
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articles of the CD technique and its applications to the study of proteins and 
other biomolecules have been written by L. A. Nafie (1995)305, Kelly et al. 
(2005)307 and S. R Martin & M. J. Schilstra (2008).308   
A standard method to analyse far-UV CD spectra is to compare the measured 
dataset with spectra of proteins whose crystal structures have been determined. 
This is accomplished with the software package CDPro and the web-based 




Figure 1.24. Far-UV CD spectra associated with different types of secondary 
structure of proteins. 
Spectra shown of α-helix (solid line), anti-parallel b-sheet (long dashed line), 
type I b-turn (dotted line), extended 31-helix or poly (Pro) II helix (cross 
dashed line), irregular structure (short dashed line). Figure adapted from 
Kelly et al., 2005.307  
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A different spectroscopic approach to gain information about the secondary 
structure of polypeptides is Fourier-transform infrared (FT-IR) spectroscopy. 
While CD uses circularly polarised light, FT-IR measures the wavelength and 
intensity of a sample's absorption of infrared radiation.310 The technique is 
thereby based on interferometry and Fourier transformation.311 The 
interferometer in the instrument has one fixed and one movable mirror. A beam 
splitter directs 50% of the light onto the static and 50 % onto the movable 
mirror. If the right path length difference is introduced, it results in interference 
as soon as the two beams are recombined. After the beam interacts with the 
sample, the measured light intensity can be set in relation to the position of the 
movable mirror.311 It results in an interferogram, which is the Fourier transform 
of the spectrum. Therefore, a second Fourier transform is performed by a 
computer to convert the data back to a spectrum.312 In contrast to other 
spectrophotometric approaches, for example, far-UV CD, FT-IR is not based 
on a monochromatic scan of the sample. FT-IR benefits from its polychromatic 
approach in terms of speed and sensitivity.311  
 
 
Figure 1.25. FT-IR spectra of poly-L-lysine as a function of pH and temperature. 
The homopolymer forms a β-sheet at pH 12 and 46 °C, α-helix at pH 12 and 
20 °C and random coil at pH 4 and 20 °C. Figure adapted from L. P. DeFlores 
et al., 2009.313 
1.14 Fourier-transform Infrared Spectroscopy of 
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In the infrared spectroscopy of polypeptides, the peptide bonds absorb mainly 
in nine different characteristic infrared active vibration modes. The two most 
prominent vibration modes for analysing the secondary structure of 
polypeptides are the amide I and amide II modes.312 At a frequency of approx. 
1690-1600 cm-1, the amide I mode absorbs mainly due to the C=O stretching 
vibrations. Additionally, minor contributions come from out-of-phase C-N 
stretching and the N-H inplane-bend. The amide II mode, in comparison, 
absorbs at a frequency of approx. 1575-1480 cm-1. Its absorption is mainly 
caused by N-H plane-bend and the C-N stretching vibration.312  
The modes shift depending on the structure of the sample. From previous 
studies, it is known that the amide I mode is composed from different 
absorption bands. A strong absorption band at 1610-1640 cm-1 and a weaker 
band at 1680-1690 cm-1 are typical for β-sheets. The absorption band for α-
helical and random coil structure have been determined to be at 1640-1650 and 
1650-1660 cm-1, respectively. In Figure 1.25, typical FT-IR spectra of poly-L-
lysine in the three different conformations, α-helical, β-sheet and random coil 
are shown. 
The principal component analysis (PCA) is a computational method to analyse 
a set of multi-dimensional data,314 for example, the time-dependent change of 
absorbance spectra. The analysis aims to extract the important information 
from data by finding inter-correlated quantitative dependent variables. The 
latter are orthogonal variables and called principal components (PCs).315 In the 
case of a matrix of time-dependent absorption spectra, a PCA can give an 
overview of the variables which contribute the most to the different 
characteristics of the spectra at different time points.  
A mathematical approach to deconvolute a data table in which each row 
describes an absorbance spectrum is singular value decomposition. After such 
a deconvolution, the data can be transformed back to the original data space,316 
such as the absorbance spectra space. It can help to understand the dominant 
1.15 Principal Component Analysis of Spectroscopic 
Data 
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spectra composing the measured data. For example, the contribution of the first 
and most dominant principal component to each spectrum can be calculated 
using only the eigenvalue of the first principal component while all other 
eigenvalues are set to zero. The resulting matrix, MPC1 contains then, for each 
time point, the contribution of the first principal component, Figure 1.26. 
 
 
Figure 1.26. Singular value decomposition and back transformation of the first 
principal component to the original data space.  
Decomposition of a real matrix M into a real unitary matrix U, a diagonal 
matrix $ with the eigenvalues %x of the data set and a unitary matrix V. 
Multiplication of the two unitary with a single eigenvalue, for example %1, 
leads to the contribution of the first principal component for each row 
summarised in matrix MPC1 (Sigma 1). 
The isoelectric point (pI) is the pH value at which the molecule carries no net 
charge. Therefore, the pI value is of particular interest in the context of peptide 
aggregation and was determined for all investigated peptides and lipidated 
peptides using imaged capillary isoelectric focusing (iCIEF). 
iCIEF is an enhanced version of capillary isoelectric focusing (CIEF).317,318 
Both share the approach to focus polypeptides isoelectrically in a capillary 
coated with fused silica (FS). The coating is needed to suppress the electro-
1.16 Measurement of the pI of Polypeptides 
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endosomatic flow (EOF). This is essential because EOF disturbs the focusing 
process.319 
At the beginning of the measurement, the capillary gets filled with a mixture 
containing carrier ampholytes covering the anticipated pH range (e.g., 3-8), the 
sample(s) and pI markers.320 Sometimes also blocking agents are included, 
which have a lower or higher pI compared to the samples measured. Typical 
examples are iminodiacetic acid (pI 2.2) and arginine (pI 10.7).319 When the pI 
and the amount of the blocker agents are chosen correctly, this can help focus 
the mixture correctly. The pH of the starting mixture is determined by the 
concentration and dissociation state of all substances present. The capillary is 
connected to an inlet and outlet vial filled with a low pH solution (H3PO4) and 
a high pH solution (NaOH). A positive voltage can be applied to the inlet, 
which becomes the anode. The outlet is grounded and acts, therefore, as the 
cathode.320  
As soon as the voltage is applied, highly mobile hydrogen ions move towards 
the cathode, and hydroxyl ions move in the opposite direction. With time a pH 
gradient is created, and amphoteric molecules protonate/deprotonate and focus 
in a small zone in which their net charge is minimised.319 To determine if the 
molecules are in focus, CIEF relies on the current as an indirect measurement. 
iCIEF profits in this case from the fact that focusing is directly detected. 
Another advantage of iCIEF compared to CIEF is that it needs no mobilisation 
step, which increases the accuracy of the measurement.317,319   
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Figure 1.27. Schematic of capillary isoelectric focusing (CIEF) and imaged CIEF 
(iCIEF). 
A) Depiction of the capillary composition before and after the focussing 
process during a CIEF run. Before the voltage is applied, the mixture of 
carrier ampholytes, blocking agents, the protein or peptide sample to be 
analysed, and pI markers are all homogeneously distributed over the whole 
capillary. The applied voltage leads with time to a pH gradient within the 
capillary. In a classical CIEF experiment, the neutralised and focussed 
molecules must be subsequently mobilised and moved past the point of 
detection, a spectrophotometric detector (UV-DAD) at 280 nm. Figure 
adapted from T. Kristl, H. Stutz, C. Wenz & G. Rozing, 2014.
320
 B) 
Schematic of iCIEF. Compared to CIEF, it enables the measurement of the 
UV signal over the whole range of the capillary. It leads to an improved focus 
because the focusing process can be observed not only based on the current 
drop to a minimum as for CIEF but in real-time during the whole process. 
The precision also gains from the fact that no mobilisation step is needed to 
move the sample past a POD. Figure adapted from G. Rozing, 2019 (Picture 
courtesy of H. Stutz, Salzburg University).
319
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The aim of the work presented in this Thesis was to look into the aggregation 
pathways of GLP-1 and chemically modified forms of GLP-1 and to 
characterise their physical stability. GLP-1 and its analogues were selected due 
to their importance as therapeutics as well as their size, chemical structure and 
propensity to form fibrils. The focus was on the influence of amidation of the 
C-terminus as well as two lipidated versions which were investigated to 
understand how lipidation influences the aggregation behaviour of the peptide. 
  
Objective 1 
Based on the work of Dr Karolina Zapadka, the first objective of the research 
was to study the aggregation of GLP-1 at different time points during 
aggregation in order to understand the size, structure and nature of species in 
solution throughout the aggregation reaction. Motivated by the pH-dependent 
concentration dependence of the aggregation kinetics of GLP-1, four different 
pH values were selected which showed different behaviour. Many different 
biophysical techniques were used in order to obtain a better understanding of 
the aggregation mechanisms.  
 
Objective 2 
Another focus of the Thesis was on the determination of the influence of C-
terminal amidation (Am-GLP-1) on the physical stability and aggregation 
kinetics of GLP-1. The effect of pH and peptide concentration was studied and 
compared in detail to the results obtained for GLP-1. The amidation of the C-
terminus changes the net charge of the peptide enabling the role of net charge 
in determining the solubility as well as the aggregation propensity to be 
established.  
  
1.17 Aims of the Thesis 
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Objective 3 
Two lipidated forms of Am-GLP-1 were studied to determine the influence of 
lipidation on the aggregation kinetics. Similar to Am-GLP-1, the impact of pH 
and peptide concentration on the aggregation kinetics/amyloid fibril formation 
was studied. The studies also provided information on how the lipidation 
influences the secondary structure of the peptide by a comparison of results 
with those obtained for GLP-1 and Am-GLP-1. 
 
Objective 4 
Analysing the collected data using different fitting approaches provided a better 
understanding of the underlying mechanisms of the aggregation process. ThT 
assay data were subjected to a sigmoidal fit and also fit to an analytical solution 
of a Master equation describing the formation and growth of fibrils by 
nucleation, elongation and fragmentation.  
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The 31-residue GLP-1 (7-37) and Am-GLP-1 (7-37) (HAEGTFTSDVSSYLE-
GQAAKEFIAWLVKGRG-OH and HAEGTFTSDVSSYLEGQAAKEFIAW-
LVKGRG-NH2) were purchased from Bachem (Purity: 98.5% and 96.7%). 
Both peptides have a molecular weight of approximately 3.36 kDa. IPP4 
(HAEGTFTSDVSSYLEGK(7-E-palmitoyl)-AAREFIAWLVRGRG-OH was 
purchased from Peptides International (Purity: 96.3%) and IPP5 HAEGTFT-
SDVSSYLEGQAAK (7-E-palmitoyl) EFIAWLVRGRG-NH2) was purchased 
from Bachem (Purity: >95.0%). All peptides were used without further 
purification. 
 
Figure 2.1. Amino-acid sequence of GLP-1 and three GLP-1 analogues. 
The lipidated peptides are both based on the C-terminally amidated form of 
GLP-1 (Am-GLP-1) with additional modifications indicated by the red rings.  
GLP-1
H E G T GF T S D V S S Y L E G Q A A K E F I A L V K G R -NH2
H E G T GF T S D V S S Y L E G Q A A K E F I A L V K G RA
H E G T GF T S D V S S Y L E G K A A R E F I A L V G RR -NH2
!-E-palmitoyl












2 METHODS AND MATERIALS 
2.1 Peptides  
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The buffers were purchased from Sigma-Aldrich (citric acid anhydrous and 
sodium citrate dihydrate) and Baker (sodium phosphate dibasic 7-hydrate and 
dibasic sodium phosphate monohydrate/Tris base and Tris HCl). All buffers 
were prepared by weighing of the appropriate acidic and basic forms of the 
buffers, which were subsequently dissolved in deionised water. The final buffer 
concentration was 25 mM and citrate buffer was used at pH 3.0, 3.5, 4.0, 4.5, 
5.0, 5.5 and 6.0, phosphate buffer at pH 6.5, 7.0 and 7.5 and Tris buffer at pH 
8.0, 8.5 and 9.0. The pKa of Tris buffer is temperature-dependent which means 
if the temperature is increased from 25 to 37 °C, the pH of the buffer changes 
from 8.0, 8.5 and 9.0 to 7.7, 8.2 and 8.7, respectively. In this Thesis, the samples 
in Tris buffer are referred to as samples at pH 7.7, 8.2 and 8.7 if not stated 
otherwise, as these are the pH values under aggregation conditions. No 
additional salt was added. The ionic strengths due to the buffer itself varied 
with pH and were in the range from 2 to 121 mM, Figure 2.2. The decision to 
conduct all measurements at the lowest possible ionic strength at each pH was 
based on a brief study by Dr Karolina Zapadka, which showed no significant 
differences in aggregation rate over this ionic strength range, Section 1.6.3.  
 
Figure 2.2. Ionic strength of citrate, phosphate and Tris buffers 
The calculated ionic strength of 25 mM citrate, phosphate and Tris buffer 
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After preparation, the buffers were filtered through a 0.2 µm PES filter unit 
(Thermo Scientific™ Nalgene™ Rapid Flow™ 90 mm) and the pH checked 
using a multiparameter pH meter (SevenExcellence, Multiparameter, Mettler 
Toledo, pH electrode: InLab® Micro-Pro-ISM). Buffers were stored at -20 °C.  
The sources of all other reagents are given in the relevant Methods sections. 
A NanoDrop 2000 spectrophotometer (Thermo Scientific) with a 1 mm 
pathlength was used to determine the concentration of GLP-1 or ThT in 
solution. After recording an appropriate buffer as a blank, an absorption 
spectrum of the sample was recorded in triplicate. Concentrations were 
determined using the measured absorbance at 280 nm and corrected for light 





The correlation of the absorbance with the concentration c is given by the Beer-
Lambert equation, Equation 2.2, where B! is the extinction coefficient at a 
specific wavelength and l the pathlength in cm.  
A& 	= 	 ϵ& ⋅ l	 ⋅ c	 (2.2) 
For all GLP-1 peptides a theoretical extinction coefficient of 6990 M-1cm-1 at 
280 nm was used, which was calculated using the Expasy ProtParam tool322. 
The molar extinction coefficient for ThT was 31600 M-1 cm-1 at 412 nm.323 
The sample size was 2.5 μL. The data were analysed with the program 
NanoDrop 2000/2000c, which calculates the absorbance using the logarithmic 
relation between the absorbance A at a certain wavelength, and the intensity of 
the sample Is and blank Ib 





2.3 UV-visible Absorption Spectroscopy – NanoDrop 
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The peptides were dissolved in 25 mM citrate, phosphate or Tris buffer up to a 
final stock concentration of 300 µM depending on the solubility of the peptide. 
Citrate was used to buffer from pH 3.0 to 6.0, phosphate from pH 6.5 to 7.5 
and Tris from 8.0 to 9.0. After the peptides were dissolved, the pH was checked 
using a pH meter (SevenExcellence, Multiparameter, Mettler Toledo, pH 
electrode: InLab® Micro-Pro-ISM) and the solutions were subsequently filtered 
using a 0.45 µm PVDF Millipore centrifuge filter prior to use (Biofuge pico, 
Heraeus, 2 min, 13000 rpm at room temperature). The peptide concentration 
was then determined spectrophotometrically using a NanoDrop 
spectrophotometer, Section 2.3. 
The peptides were weighed, and approx. 0.2 mg were dissolved in 50 µL of 
buffer to get a final concentration of approx. 1200 µM. 25 mM buffer was used 
for all pH values between pH 3.0 and 9.0. After the buffer was added to the 
peptide, the samples were left to dissolve for 30 min and were subsequently 
centrifuged for 5 minutes at 13000 rpm at room temperature (Biofuge pico, 
Heraeus) before the concentration of the supernatant was determined 
spectrophotometrically using a NanoDrop spectrometer. 
For the LC-MS measurements, lyophilised sample was dissolved in 33% 
deionised water, 33% acetic acid (glacial, purum) and 33% acetonitrile (HPLC 
grade). The sample size was 5 µL with a peptide concentration of 30 µM. The 
LC-MS was performed using an Agilent System, with an Agilent Polaris 
analytical C8-A, 4.6 x 100 mm, 5 µm Agilent Technologies column attached. 
The experiment was run at room temperature. The instrument was equipped 
with a 3100 Mass Detector (Waters, GB) and the peptides were run according 
2.4 Sample Preparation 
2.5 Solubility Measurements 
2.6 Liquid Chromatography-Mass Spectrometry (LC-
MS) 
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to the methods summarised in Table 2.1 depending on whether they were 
lipidated or not.  
 
 
Table 2.1. Parameters for the LC-MS experiments.  
 
For the DLS experiments, a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK) was used. Using a monochromatic laser light source and quasi-elastic light 
scattering it determines the mutual translational diffusion coefficient Dt of 
macromolecules in a sample. Assuming that all particles are spherical, 
homogeneous and with equivalent density (Mie scattering), the Zetasizer 
software calculates the intensity-weighted mean hydrodynamic distribution and 
of the number size distribution.  
Samples of 150 µM GLP-1, freshly prepared or fibrillar, were measured. The 
Flow rate 1.5 ml/min
UV detector 210 nm 
Run time 6 min 
Sample injection 5 µL
Mobile phase A 0.1 % trifluoroacetic acid (TFA) in water
Mobile phase B 0.1 % trifluoroacetic acid (TFA) in acetonitrile
Gradient of the run for non-lipidated peptides





Gradient of the run for lipidated peptides





2.7 Dynamic Light Scattering (DLS) 
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measurements were recorded at 25 °C in a Zen 2112 cuvette and with a 
scattering angle of 173 degrees. Before each measurement, the cuvette was 
rinsed three times with deionised water and subsequently with ethanol (95%). 
After the cuvette was dried using compressed air, it was filled with 
approximately 60 μL of the sample. The submenu measurement type was set 
on peptide, and in the submenu the appropriate dispersant was chosen. This was 
either 25 mM citrate, phosphate or Tris buffer. For each sample, three 
consecutive traces were recorded and averaged. 
The pI of the peptides was determined using iCIEF (proteinsimple - Maurice). 
All peptides were dissolved in Tris buffer at pH 8.5 with a final peptide 
concentration of 336 µM (approx. 1 mg mL-1). For each run, 40 µL of the 
sample was diluted with 160 µL of Master Mix, which contained distilled 
water, methyl cellulose, broad-range ampholytes, arginine and different pI 
markers. The composition of the Master Mix varied for different peptide 
samples.  
For two runs of Am-GLP-1, the Master Mix was mixed using 178 µL distilled 
water, 168 µL 1% methyl cellulose (proteinsimple), 19.2 µL pharmalytes® 3-
10 (Sigma), 9.6 µL 500 mM arginine (prepared from L-Arginine 
monohydrochloride, Merck), 4.8 µL pI marker I (Trp-Asp-Asp-Arg, pI 4.05), 
and 4.8 µL pI marker II (Trp-Tyr-Lys-Lys, pI 9.99).  
The Master Mix for the GLP-1 sample contained urea to prevent precipitation 
and was prepared for approximately eight samples. For the Master Mix with 
urea, 0.96 g of urea was weighed and dissolved in 500 µL distilled water, 
vortexed and subsequently heated for 5 minutes at 80 °C (heat block). 
Immediately afterwards 400 µL 1% methyl cellulose (proteinsimple) was 
added and the sample vortexed again. After the sample cooled down to room 
temperature, 80 µL pharmalytes® 3-10 (Sigma), 80 µL 500 mM arginine 
(prepared from L-arginine monohydrochloride, Merck), 20 µL pI marker I 
(Trp-Asp-Asp-Arg, pI 4.05), and 20 µL pI marker II (Trp-Tyr-Lys-Lys, pI 
9.99) were added.  
2.8 Imaged Capillary Isoelectric Focusing (iCIEF) 
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The Master Mix for IPP4 and IPP5 followed the same method as GLP-1 but 
the pharmalytes® were changed to 40 µL pharmalytes® 3-10 (Sigma) and 40 
µL pharmalytes® 5-8. Additionally, the second marker was changed to 20 µL 
pI marker II (pI 7.05). 
The cartridge was prepared by adding 2 mL of Catholyte solution (100 mM 
sodium hydroxide in 0.1% MC, proteinsimple) to the OH- electrolyte tank and 
2 mL of Anolyte solution (80 mM phosphoric acid in 0.1% MC, proteinsimple) 
to the H+ electrolyte tank. 2 mL 0.5% methyl cellulose (proteinsimple) and 500 
µL fluorescence calibration standard (proteinsimple) were used as batch 
reagents.  
All samples were measured with a pre-focusing time of 1 min at 1500 V and a 
focusing time of 10 min at 3000 V. Before the measurement a System 
Suitability (proteinsimple) sample was run to the check the performance of the 
instrument. The experimental data were processed and analysed using Compass 
Software for ICE (Protein Simple, USA). 
Thioflavin T (ThT) was purchased from Sigma. For kinetic experiments, a 
stock solution of 300 μM of each peptide was prepared, as described above. 
The samples were incubated in a 96-well half-area plate made of black 
polystyrene with a clear bottom and a non-binding surface (Corning 3881, 
USA). The appropriate volumes of peptide stock solution and buffer were 
mixed with 6 μL of 1 mM ThT stock in the wells in the plate such that the final 
peptide concentrations were 25, 50, 75, 100, and 150 μM and the ThT 
concentration was 50 μM and the final volume 120 μL. A sealing tape (Corning, 
ThermowellTM Sealing Tape for 96 Well Plates, 6570) was used to protect 
samples from evaporation. Fluorescence measurements were carried out using 
a Fluostar Optima Microplate Reader (BMG Labtech, Offenburg, Germany) at 
37 °C. Fluorescence was measured using an excitation filter at 440 nm and 
emission filter at 480 nm. Bottom reading of the plate every 30 min with 5 min 
of shaking prior to each measurement was performed. Each cycle was executed 
with the orbital shaker at 350 rpm, 5 flashes per well and fluorescence 
2.9 Thioflavin T Aggregation Assay  
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measurements were made at a gain of 800. All measurements were made in 
triplicate for each peptide concentration in a single 96-well plate and each 
experiment was repeated at least three times on different days with freshly 
prepared samples. 
2.9.1 Preparation of ThT Stock Solution  
For all ThT assays, a 5 mM ThT stock solution was prepared by dissolving dry 
ThT powder (Sigma-Aldrich, T3516-5G, Lot # MKCF7580, dye content 66 %) 
in deionized water. After the ThT was completely dissolved, the stock solution 
was filtered using a 0.22 μm PVDF syringe filter. The stock was stored at -20 
°C. Before use, the stock was diluted to 1 mM and the concentration was 
verified spectrophotometrically using a NanoDrop spectrometer and a molar 
extinction co-efficient (K) of 31600 M-1cm-1 at 412 nM.323	
2.9.2 ThT Assay Data Analysis: Fitting to a Sigma Function  
Each individual ThT dataset was fit to 
L = L# +
C





with y0 as the starting fluorescence, A is the amplitude of the transition, t1/2 the 
half-time, which is defined as the time at which the ThT fluorescence has 
reached 50% of its final baseline value, k the apparent growth rate and b the 
slope of the final baseline.324,325 Note, in many other studies data are normalized 
prior to fitting such that the inclusion of the additional term bt is not needed. 







2.9.3 ThT Assay Data Analysis: Fitting to a Fragmentation-
Dominated Model 
To gain further insight into the aggregation kinetics, the ThT data were also 
fitted to an equation based on principal moments. This simplified solution of a 
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Master equation takes primary nucleation, elongation and fragmentation into 
account.83,280 




where the fibril mass is MRF, the total protein concentration is M0 and C± = ± 
(δ/2κ). Here δ and κ represent the effective rate for nucleated polymerisation 
without secondary pathways and the rate of multiplication of the filament 
population, respectively. The effective rate for nucleated polymerisation 
without secondary pathways, d, is given by 
δ = 	!2M0ncknk+	 (2.7) 
It depends, therefore, on the total peptide concentration M0, the size of the 
nucleus nc, the primary nucleation rate constant kn and the elongation rate 
constant kp. δ is precisely the effective rate constant derived by Oosawa81,326 
for nucleated polymerisation without secondary pathways. The rate of 
multiplication of the filament population, k, is given by 
κ = 	^2M#k7k8 (2.8) 
It includes the fragmentation rate constant km. 
Circular dichroism measures the differential absorption of right-handed and 
left-handed polarised light by chiral molecules. The far-UV CD spectra of 
freshly prepared peptide samples (150 µM) in the appropriate buffer, as well as 
samples aggregated in a BMG Fluostar plate reader (150 µM) using the method 
described in Section 2.9 without ThT, were measured using a 0.1 mm 
pathlength cuvette in a Jasco J815 spectrophotometer (Jasco Spectroscopic Co. 
Ltd., Tokyo, Japan). The cuvette was filled with 75 µL of sample and the CD 
spectra and HT voltage were recorded from 180 to 260 nm at 25 °C. Data with 
a HT voltage higher than 500 V was discarded as the CD signal was too noisy 
to use. Therefore, only data from 190 to 260 nm were further analysed as in 
2.10 Far-UV Circular Dichroism (Far-UV CD) and 
CDPro 
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this range the HT voltage was always below 500 V. For each measurement, 
spectra were acquired three times with a scanning speed of 20 nm min-1.  
After baseline subtraction, the spectra were processed using Spectra Manager 
Version 2 software and smoothed using a mean movement method with a 
convolution width of 5. The method, also known as the simple moving average 
method, uses a rectangular function as a weighting function. The smoothed 
value y(i) for each discrete value x(i) of the input signal was determined using 
Equation 2.9. The rectangle width is defined as N = 2m + 1 and i = m+1, 








The data output was in ellipticity θ (mdeg). The mean molar ellipticity per 
residue [θ]MR was calculated using Equation 2.10. 




where l is the pathlength in cm, and CMR is the mean residue concentration, 
which was calculated from the concentration of peptide, C, in molar units and 
the number of residues N in the peptide using Equation 2.11. 
C<. = C	 ⋅ N (2.11) 
The data were further analysed using CDPro.327,328 The programme compares 
a far-UV CD spectrum to the far-UV CD spectra of different proteins whose 
crystal structures and therefore secondary structures are known. Three different 
reference sets were used (SP29, SP43 and SDP48). The reference sets tested 
included data of 29, 43 or 48 proteins within the range of 178-260 nm (SP29) 
and 190-240 nm (SP43 and SDP48). A detailed comparison of the different 
reference sets has been made by Sreerama and Woody.329 Their results indicate 
that far-UV CD data in the wavelength range of 190-240 nm can give reliable 
results when a larger reference set is used.329 Whitmore and Wallace309 give a 
complete list of the proteins in each reference set in their paper about the 
analysis of protein secondary structures and features of the DichroWeb, a web 
application of CDPro. The corresponding names of the datasets in DichroWeb 
are RDB1 (SP29), RDB4 (SP43) and RDB7 (SDP48). For GLP-1, the reference 
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dataset SP43 showed the most consistent results. Therefore, it was used to 
calculate secondary structure content using three different algorithms 
(SELCON3327,330, CDSSTR329,331,332 and CONTINLL333,334).  
The Fourier-transform IR spectra of different peptide samples were measured 
with a Perkin Elmer FT-IR spectrometer (Spectrum 400) equipped with an 
Attenuated Total Reflectance (ATR) crystal. For each sample, small volumes 
(8 x 0.75 µL) were repeatedly dried on the crystal surface using a gentle, filtered 
air stream. The resolution employed was 4 cm-1 and the signal was accumulated 
using 32 repetitions. The spectra were recorded from 2000 to 1000 cm-1 and 
analysed in the amide I region (1720 - 1580 cm-1) using the Perkin Elmer 
Spectrum Software. 
A Hitachi F-7000 fluorescence spectrophotometer plate reader was used for all 
extrinsic or intrinsic protein fluorescence time point measurements. Emission 
spectra were collected using top reading of the plate. 
2.12.1 Tryptophan Fluorescence 
The intrinsic fluorescence of 150 µM Am-GLP-1 at different pH values and at 
different time points was recorded. 100 µL aliquots were pipetted into wells of 
a 96-well half-area plate mode of black polystyrene, with flat wells and non-
binding surface (Corning 3993, US). Emission spectra were collected from 285 
to 500 nm using an excitation wavelength of 277 nm (scan speed: 1200 nm  
min-1, excitation bandpass: 2.5 nm, emission bandpass: 2.5 nm, voltage: 900 V, 
response: 2.0 s, data point collection: 1 nm). 
  
2.11 Fourier-transform Infrared Spectroscopy (FT-IR) 
2.12 Extrinsic and Intrinsic Protein Fluorescence 
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2.12.2 8-Anilinonaphthalene-1-sulfonic Acid (ANS) Binding 
Assay 
8-anilinonaphthalene-1-sulfonic acid (ANS) has been used to detect the 
presence of exposed hydrophobic patches in the aggregated species.335 ANS 
was purchased from Sigma-Aldrich (A1028-5G, Lot # MKCJ6296, purity ≥ 97 
%). Measurements were taken at the beginning of the ThT assay and one after 
144 h of aggregation. Typically, 50 µL of peptide sample was mixed with 2.5 
µL 1 mM ANS stock directly in a 96-well half-area plate made of white 
polystyrene and non-binding surface (Corning 3693, US). The final 
concentrations were 143 µM (peptide) and 48 µM (ANS). The emission spectra 
were acquired from 420 to 600 nm using an excitation wavelength of 350 nm 
(scan speed: 240 nm min-1, excitation bandpass: 1 nm, emission bandpass: 2.5 
nm, voltage: 800 V, response: 0.01 s, data point collection: 1 nm). 
Preparation of ANS Stock Solution 
A 1 mM ANS stock solution was prepared by dissolving dry ANS powder in 
deionized water. After the ANS was completely dissolved, the stock solution 
was filtered using a 0.22 μm PVDF syringe filter. The stock was stored at -20 
°C. The concentration was determined spectrophotometrically using a molar 
extinction coefficient at 350 nm of 5000 M-1 cm-1.335 
2.12.3 Ex-situ ThT Fluorescence Measurements 
Ex-situ ThT measurements were taken before the aggregation assay and after 
144 h of aggregation. Typically, 50 µL of peptide sample was mixed with 1 µL 
2.5 mM ThT stock to a final concentration of 147 µM GLP-1 and 49 µM ThT 
in wells of a 96-well half-area plate made of black polystyrene, with flat wells 
and non-binding surface (Corning 3993, US). Emission spectra were collected 
from 450 to 600 nm using an excitation wavelength of 440 nm (scan speed: 240 
nm min-1, excitation bandpass: 5 nm, emission bandpass: 5 nm, voltage: 800 V, 
response: 0.01 s, data point collection: 1 nm). 
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For the fibril separation experiment, 6 x 120 µL of GLP-1 or Am-GLP-1 at a 
concentration of 150 µM were prepared. The samples were aggregated at 37 °C 
with agitation for 144 h in a BMG Fluostar plate reader. After the incubation, 
the tryptophan fluorescence was measured using 3 x 100 µL of the aggregated 
peptide sample (Section 2.12.1). Subsequently, the samples were split in half, 
2.5 µL of 1 mM ANS stock or 1 µL of 2.5 mM ThT stock was added to 50 µL 
of peptide sample, and the fluorescence spectra recorded as described in 
Sections 2.12.2 and 2.12.3. 
In addition, 360 µL of aggregated peptide sample was placed into a 0.6 mL 
Eppendorf tube and centrifuged for 20 min at 17000 g and 25 °C. The 
supernatant was then carefully separated from the pellet using a pipette, Figure 
2.3.  The separated pellet was subsequently suspended in the appropriate buffer 
to reach a final volume of 360 µL. After a repetition of this process, the 
tryptophan, ANS and ThT fluorescence were measured as described in Section 
2.12.2 and 2.12.3. 
 
Figure 2.3. Separation of peptide aggregates from supernatant using centrifugation.  
The separation of the supernatant was repeated twice. 
2.13 Fibril separation 
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2.14.1 Atomic Force Microscopy (AFM) 
Peptide samples in solution were taken directly after the peptides were 
dissolved and filtered and at different time points during the aggregation assay 
or at the end. Typically, 5 µL of each sample was spread onto freshly cleaved 
mica. After the sample dried, it was rinsed with 2 x 300 µL deionised water and 
dried using a gentle nitrogen stream. The AFM images were acquired with a 
PicoPlus AFM instrument with a PicoSPM II controller from Molecular 
Imaging (Agilent Technologies, USA) in AC mode (Tapping mode), equipped 
with a MikoMasch NSC26/No Al cantilever, between 65 and 130 Hz 
frequency, force constant varying from 0.6 to 2.0 N m-1 (Innovative Solutions 
Bulgaria Ltd., Sofia, Bulgaria). All images were taken in air and at room 
temperature. The images were analysed with the open-source software 
Gwyddion.336 The stated width of the measured aggregates is equivalent to the 
full width half maximum (FWHM). Therefore, the profiles were fitted with a 
Gaussian and the standard deviation of the function multiplied by 2.35.337,338 	
2.14.2 Scanning Electron Microscopy (SEM) 
SEM does not have the highest possible magnification of available microscopy 
techniques, but it has the advantage that it enables scanning over a broad range 
of magnifications and therefore it is less likely to miss important details in the 
sample. For example, if the sample spot has a diameter of 4 mm, for three 10 x 
10 µm2 pictures with AFM only a few millionths of the whole sample surface 
is imaged. As for every other microscopy technique using dried samples, the 
images are, of course, influenced by the drying process. 
Typically, 5 µL of GLP-1 or Am-GLP-1 in buffer were spread onto microscope 
glass slides which were cleaned before use with acetone and isopropanol. The 
samples were either left to dry or the drop was gently blown away with a stream 
of nitrogen after it had been on the surface for 2 min. The slides were rinsed 
with 2 x 300 µL of deionized water and dried under a gentle stream of nitrogen 
before the samples were coated with a 10 nm thick platinum layer (Quorum 
2.14 Imaging 
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Technologies Q150T ES Turbo-Pumped Sputter/Carbon Coater). The samples 
were imaged using a Tescan Mira3 FEG-SEM. The In-Beam SE detector was 
used with SEM HV 5.0 kV and WD 4 m. 
The net charge was determined using the Henderson-Hasselbalch equation and 
the isoelectric point calculation.339 For residues of the amino acids with a 
negative charge the contribution can be calculated using Equation 2.12 and 








For positively charged residues the charge contribution can be calculated using 







The final charge is the sum over all negative charges plus the sum of all the 
positive charges which are, of course, both pH dependent. 
 







Arginine R 2.17 9.04  12.48 
Aspartic Acid D 1.88 9.60 3.65  
Glutamic Acid E 2.19 9.67 4.25  
Glycine G 2.34 9.60   
Histidine H 1.82 9.17  6.00 
Lysine K 2.18 8.95  10.53 
Table 2.2. pKa values of ionisable groups in proteins.  
pKa is the negative of the logarithm of the dissociation constant of the -COOH 




2.15 Net Charge and pI Determination 
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GLP-1 was reconstituted in 25 mM sodium phosphate buffer at pH 7.5 to a final 
peptide concentration of approximately 300 μM. The UPLC was performed 
using an Acquity UPLC Waters System, with a BEH C18 2.1 x 100 mm, 3.5 
μm (300 Å) column attached. The method used is shown in Table 2.3. 
 
Flow rate 0.3 ml/min  
Run time  40 min  
Mobile phase A 95% water, 5% acetonitrile (ACN), 0.03% trifluoroacetic (TFA) 
Mobile phase B 95% acetonitrile (ACN), 5% water, 0.03% trifluoroacetic (TFA) 
Gradient of the run 
Time (min) Mobile phase A (%) Mobile phase B (%) 
0 75 25 
30 10 90 
40 0 100 
Table 2.3. UPLC method.  
 
A singular value decomposition (SVD) of far-UV CD and FT-IR data was 
performed using Matlab. A SVD factorises an m⋅ n real matrix M (it is possible 
for a complex matrix as well but not relevant in this case) into an m⋅ m real 
unitary matrix U, an m⋅ n rectangular diagonal matrix with non-negative real 
numbers on the diagonal j, and an n⋅ n real unitary matrix V.  
k = l	j	m∗ (2.14) 
 
The diagonal entries ni = oii are the singular values of M and the columns of U 
and the columns V are called the left-singular vectors and the right-singular 
2.16 Ultra-Performance Liquid Chromatography (UPLC) 
2.17 Singular Value Decomposition (SVD)  
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vectors. The contribution of the different principal components of the analysed 
spectra was calculated by multiplying U⋅o⋅V*, with all values in o set to 0 
except of ni, as shown in Section 1.15.  
Analytical size-exclusion chromatography (SEC) was performed by Eva 
Brichtová using an ÄKTA FPLC system (GE Healthcare).341 A Superdex 200 
Increase 10/300 column (GE Healthcare) was used and samples were loaded 
using 100, 200 or 500 μL loops. Each sample was filtered through a 0.22 μm 
filter prior to loading. The system was run at a flow rate of 0.75 mL min-1 at 
room temperature and UV absorbance at 280 nm was measured using a 0.5 cm 
flow cell. For the calibration of the column, globular protein standards (GE 
Healthcare) were used under the same buffer conditions as in the experiments 
with samples of lipidated peptides (IPP4 and IPP5).  






Where Ve is the elution volume of a protein standard, V0 is the void volume of 
the column and Vc is the total volume of the column. The logarithm of the 
molecular weight of each protein standard, Table 2.4, was plotted against its 
Kav and from its linear regression the molecular weight of IPP4 and IPP5 was 
determined. The Stoke’s radius, RSt, was determined using a calibration plot of  
(-log(Kav))-1/2 against RSt and its linear regression, Figure 2.4. However, the 
commercially-available SEC calibration kits contain only globular proteins. 
Therefore, the values of molecular weights of oligomeric species are only 
estimates. 
  
2.18 Size-Exclusion Chromatography 
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Standard MW [Da] Stoke’s radius [Å] Velution [ml] 
Blue Dextran 2000 N/A (void volume) N/A 8.1 
Aldolase 158 000 48.1 12.2 
Ovalbumin 44 000 30.5 14.1 
Ferritin 440 000 61 9.7 
Conalbumin 75 000  13.6 
Thyroglobulin 669 000 85 8.8 
Ribonuclease A 13 700 16.4 17.7 
Carbonic Anhydrase 29 000  16.0 
Table 2.4. SEC calibration standards. 
Molecular weights (MW), Stoke’s radius,
342
 and elution volume on a 
Superdex
®
 200 Increase 10/300 column. The calibration standards were 
obtained from GE Healthcare and the samples were run in 25 mM sodium 
phosphate buffer, pH 7.5 at a flow rate of 0.75 mL min
-1






Figure 2.4. Calibration curve for SEC column 
Calibration curve for the Superdex 200 Increase 10/300 column. Calibrations 
conducted in 25 mM sodium phosphate at pH 7.5 using proteins standards, 
Table 2.4. Calibration for the molecular weight (A) and the Stoke’s radius (B) 
were performed at room temperature, with a flow rate of 0.75 mL min
-1
 and 
100 μM of each protein was injected using a 200 μL injection loop. Figures 
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Peptide therapeutics represent an increasingly important class of 
pharmaceutical drugs. However, despite efficacy and improvements in in vivo 
half-lives, there remain some key challenges in the development, formulation 
and use of these biologics. The physical stability of peptides is a common 
problem that, in some cases, results in major obstacles in the development 
pipeline of the potential drug. Poor physical stability can result in the formation 
of amorphous or highly structured aggregates that prevent use of the peptide or 
which may result in an adverse immunogenic response. The problems of 
physical stability are often exacerbated at the high concentrations of peptide 
used for subcutaneous injection. Excipients, that are commonly selected from 
screening experiments, are frequently used to minimise aggregation, however, 
they are sometimes ineffective. In order to rationally design peptide 
sequences/modification strategies that result in peptides with intrinsically 
higher degrees of physical stability, or rationally select excipients to combat 
aggregation, a much greater understanding of the mechanisms underpinning the 
aggregation of therapeutic peptides is required. 
The 31-residue (7-37) therapeutic peptide GLP-1 is known to suffer from low 
physical stability and forms a range of aggregates under different conditions, 
for example, linear, rigid, amyloid-like fibrils and other species.5 A detailed 
investigation of its aggregation behaviour at pH values between 7.5 and 8.2, 
3 PHYSICAL STABILITY OF GLP-1 
3.1  Introduction 
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established that in addition to the on-pathway oligomers that can go on to form 
fibrillar structures, GLP-1 can form off-pathway oligomeric species at pH 7.5, 
which dramatically affect the kinetics of aggregation slowing down the rate of 
fibrillation.5 In addition, it was shown that at all pH values investigated, freshly 
prepared solutions of GLP-1 contained small soluble oligomers as well as 
monomers. The presence of these small oligomers was particularly pronounced 
at pH 7.5 or 7.7 where the peptide has a higher propensity to form off-pathway 
oligomers and slow aggregation kinetics. In addition, the aggregation of GLP-
1 has been investigated at pH 3.0 and pH 3.5, Section 1.10, and it was 
established that amyloid fibril formation also takes place at these acidic pH 
values, and that, similar to what was previously observed at pH 7.5-8.2, even 
small changes in pH can result in a switch in the self-assembly mechanism from 
predominantly on-pathway oligomers being populated to conditions where off-
pathway species become populated. 
In this Chapter, the aggregation of GLP-1 over a wide range of pH values and 
peptide concentrations is studied in further detail.  In particular, the 
reproducibility of the aggregation assays was initially assessed. Once 
reproducibility had been established, time-course experiments, in which 
samples were taken at different times during the aggregation reaction and 
analysed using a range of biophysical approaches, were undertaken. Far-UV 
CD and FT-IR were used to provide information on the secondary structure at 
different times. The spectra from both techniques were subsequently analysed 
using a single-value decomposition method to discover more about how the 
structure evolved with time. AFM was used to image any species in the 
aggregating sample large enough to be detected using this method, providing 
information on higher-order structures.  
The time-course experiments led to a deeper understanding of the differences 
between samples which showed predominantly on-pathway behaviour in 
comparison to samples where off-pathway oligomers were populated. The 
observed differences in terms of the evolution of the secondary structure, the 
size of the aggregates, as well as evidence for aggregates with different 
structures, is discussed in detail.  
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RESULTS 
3.2.1 GLP-1 Lag Time Comparison of Data collected by KLZ 
and FJB 
In initial experiments performed at the start of the PhD, some of the GLP-1 
ThT aggregation assays that had been performed previously by Dr Karolina 
Zapadka (KLZ) were repeated. This was undertaken for a number of different 
reasons. First, to verify the results of experiments performed by KLZ, second 
to ensure good training in the assays, and third to check for any issues of 
reproducibility between different researchers. 
The peptide concentration dependence measurements of the aggregation of 
GLP-1 were repeated at pH 7.5 and 8.2. The data are shown in Figure 3.1A & 
B and Figure 3.2A & B and show the expected trend where tlag and t1/2 increase 
with increasing peptide concentration at pH 7.5, but decrease with increasing 
peptide concentration at pH 8.2, as had been reported previously. The variance 
between measurements recorded in triplicate was, however, slightly more 
significant compared to the data previously obtained Dr Karolina Zapadka, 
Figure 1.18E & G. No additional peptide concentration dependence 
measurements at pH 3.0 and 3.5 were undertaken in order to save peptide from 
the same batch for other experiments. 
 
3.2 Aggregation of GLP-1 at Neutral and Basic pH  
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Figure 3.1. ThT assay data following the aggregation of GLP-1 at different peptide 
concentrations.  
All samples were measured at 37 °C and at the following peptide 
concentrations: 25 µM (pink), 50 µM (orange), 75 µM (blue), 100 µM (dark 
blue), 125 µM (green), and 150 µM (dark green). A) GLP-1 aggregated in 25 
mM phosphate buffer at pH 7.5 B) GLP-1 aggregated in 25 mM Tris buffer at 
pH 8.2.  
 
Figure 3.2. Comparison of the kinetic parameters obtained from ThT aggregation 
assays performed by FJB and KLZ.  
Lag times of GLP-1 at different peptide concentrations. The error bars show 
the standard deviation. A) GLP-1 aggregated in 25 mM phosphate buffer at 
pH 7.5. The graph shows data previously obtained by Dr Karolina Zapadka 
(KLZ), and two sets of repeated triplicate measurements of GLP-1 performed 
by FJB, set I and set II). B) Lag times of GLP-1 aggregation in 25 mM Tris 
buffer at pH 8.2. The graph shows data previously obtained by Dr Karolina 
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3.2.2 Reproducibility of GLP-1 ThT Assays with Different GLP-
1 Batches 
One additional measurement was undertaken using a different batch (Bachem 
- B2) of GLP-1 which was previously used in the experiments published by 
Zapadka et al.5 A comparison of the lag times obtained from the aggregation 
kinetics at pH 7.5 for the different batches is shown in Figure 3.3A. The 
measured values are in good agreement with the data previously obtained by 
Dr Karolina Zapadka5 which shows that results of the ThT aggregation assays 
can be reproduced. N.B., both datasets also show the unusual increase of the 
lag time with increasing peptide concentration typical under these conditions. 
However, the differences in lag time between Batch 2 and Batch 3 are an 
important reminder that batch-to-batch variation must always be considered in 
the study of peptide aggregation, Figure 3.3B. In the rest of this Thesis, all 
samples of the different peptide analogues were taken from a single batch, 
which in the case of GLP-1 was Batch B3. 
 
Figure 3.3. Comparison of the aggregation lag times of different batches of GLP-1 
at pH 7.5. 
A) Lag times for GLP-1 aggregation in 25 mM phosphate buffer at pH 7.5. 
The graph shows repeated measurements recorded by FJB (grey diamonds) 
and previously obtained data from Dr Karolina Zapadka (black solid circles). 
B) Lag times for GLP-1 aggregation recorded by FJB. Peptides taken from 
two different batches (Batch B2 and B3) and aggregated in 25 mM phosphate 
buffer at pH 7.5. The error bars shown in A & B correspond to the standard 
deviations of the kinetic parameters determined from one experiment where 
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3.2.3 GLP-1 Aggregation Kinetics Around pH 7.5 in Tris and 
Phosphate Buffer 
To compare the influence of different buffers, GLP-1 aggregation was 
measured in phosphate buffer (PB) at pH 7.5, and Tris at pH 7.2 and 7.5, all at 
37 °C and at a buffer concentration of 25 mM. All measurements in 25 mM 
phosphate buffer, pH 7.5 show the same trend as previously reported, where 
the lag time increases with increasing peptide concentration. In Tris buffer at 
pH 7.5 (37 °C), the trend was not as pronounced and values of tlag varied less, 
Figure 3.4, however, there was still some evidence to suggest the formation of 
off-pathway oligomers under these conditions. Under slightly more acidic 
conditions, at pH 7.2, the lag time of GLP-1 aggregation increases again with 
increasing peptide concentration from approximately 30 to 60 h, Figure 3.4, 
and it is interesting to note that it is slower than at pH 7.5 
These results suggest that the identity of the buffer plays a rather small role in 
GLP-1 aggregation kinetics compared with the pH.  The small differences that 
were observed most likely can be explained by the different ionic strengths of 
the phosphate and Tris buffers at the same pH.  
 
Figure 3.4. Comparison of the lag time of GLP-1 aggregation in different buffers 
around pH 7.5 
Lag times of GLP-1 aggregation at different peptide concentrations. The graph 
shows data previously obtained by Dr Karolina Zapadka (black solid 
diamonds), as well as other measurements performed by FJB: two sets of 
repeated triplicate measurements in phosphate buffer, pH 7.5 (blue solid and 
open hexamers), triplicate measurements in Tris buffer at pH 7.5 (37 °C) 
(green solid triangle) and a triplicate measurement in Tris buffer at pH 7.2 (37 
°C) (orange solid triangle). The error bars show the standard deviation. 








h) FJB pH 7.5 I PBFJB pH 7.5 II PB
KLZ pH 7.5 PB
FJB pH 7.5 Tris (37°C)
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From previously conducted ThT assays on the aggregation of GLP-1, it was 
seen that GLP-1 aggregates not only under neutral and basic but also under 
acidic conditions. Additionally, the unusual pH and concentration dependence 
seen at pH 7.55 was also shown to exist at pH 3.5, Section 1.10. Understanding 
why such behaviour occurred under certain conditions but not all, for example, 
at pH 3.0 and 8.2, was one of the main motivations of this study. To provide 
information on how the solubility and net charge of GLP-1 vary with pH, the 
solubility and the pI of GLP-1 were determined experimentally, and the net 
charge was calculated at different pH values.  
After dissolving approx. 0.2 mg of GLP-1 in approx. 50 µL of buffer at 
different pH values to get a final concentration of approx. 1200 µM, samples 
were centrifuged to get rid of undissolved peptide, and the peptide 
concentration determined spectrophotometrically.  The results showed an 
apparent minimum in solubility around pH 4.5 and 5. As expected, the 
solubility correlates reasonably with the net charge and shows a minimum 
when the net charge is zero/very low.  However, the pH values of the minimum 
solubility are slightly more acidic in comparison to both the calculated pI value 
5.4 and the experimentally measured pI of 5.8 using iCIEF, Figure 3.5B & C. 
3.3 Solubility and Net Charge of GLP-1 
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Figure 3.5. Solubility measurement, net charge calculation and pI measurement for 
GLP-1 using capillary isoelectric focusing. 
A) Peptide concentration measured after dissolving approximately 0.2 mg 
GLP-1 into 50 µL buffer. The open circles indicate a concentration of at least 
1000 μM. The error bars show the standard deviation of three peptide 
concentration measurements. B) Calculated net charge of GLP-1 peptide using 
the sequence and the Henderson-Hasselbalch equation, Section 2.15. C) pI 
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In order to further investigate the mechanism by which GLP-1 aggregates to 
form amyloid fibrils at pH 3.0, 3.5, 7.5 and 8.2, a series of experiments were 
conducted aimed at characterising the size and structure of species in solution 
at different time points during the aggregation reaction. In particular, time 
points were chosen to focus on changes occurring in the lag phase of the 
aggregation kinetics. The size of the species formed was assessed using atomic 
force microscopy (AFM) and dynamic light scattering (DLS); the secondary 
structure assessed using far-UV CD and FT-IR. In addition, GLP-1 aggregation 
under acidic conditions was measured in both citrate and phosphate buffer as 
citrate has a strong absorbance in the FT-IR experiments in a similar region to 
the peptide and also leads to higher background noise in the far-UV CD spectra.  
3.4.1 Imaging of Peptide Aggregates  
To learn more about the size and structure of GLP-1 aggregates formed during 
the time course of the aggregation process AFM images were taken. A small 
sample was taken during a ThT assay at each time point marked with a red 
downwards facing triangle as shown in Figure 3.6A.  
A comparison of the results obtained at different times and pH values shows 
that a large number of different species are populated, before, during and after 
aggregation depending upon conditions. These species are classified into eight 
different types. Curly and tangled fibrillar structures formed immediately after 
the monomeric peptide was dissolved are called Type s. Oligomer-like 
structures also observed at the start of the aggregation reaction are referred to 
as Type o. The most common species observed was mainly straight fibrils, 
however, even these are heterogeneous and have varying heights and widths. 
Here, the differences in height are used to distinguish six different types of 
fibrils. Fibrils with heights ranging from 0.5 - 1.5 nm are classified as Type a, 
between 1.5 - 2.5 nm as Type b, between 2.5 - 3.5 nm as Type c, between 3.5 - 
5 nm as Type d, between 5 - 10 nm (Type e) and over 10 nm as Type f. The 
most commonly observed fibrils were Types c and e and these are likely to be 
3.4 Time-Course Experiments 
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assembled from multiples of thinner fibrils. Many, even thicker fibrillar 
structures were observed, however, as they were normally simple multiples of 
the previously defined fibril types, no additional types were introduced.  
N.B. The definition of the different types of fibrils does not mean that the fibrils 
of the same type are identical if formed under other conditions. It rather 
indicates that they share similar dimensions.   
At pH 3.0, GLP-1 was measured in citrate and phosphate buffer. In citrate 
buffer no aggregates could be observed directly after the preparation and 
filtration of the samples, Figure 3.6B. However, after only 4 hours, thin and 
curvy fibrils were observed, Figure 3.6C. Additionally, some entangled 
aggregates can be seen embedded into the thin mesh of fibrils. In total, at least 
four different fibrillar species with other profiles can be seen. The thinnest fibril 
(Type a) has a width of approx. 15 ± 2 nm and a height of 1.2 ± 0.1 nm. The 
width of the second smallest fibril (Type b) shows only a slight increase to 16.7 
± 0.2 nm. However, it nearly doubles in height to 2.0 ± 0.2 nm. The width of 
the third (Type c) and fourth type of fibril observed (Type d) are 18 ± 1 nm and 
22 ± 2 nm, respectively, and their heights are 2.8 ± 0.2 nm and 4.8 ± 0.2 nm, 
respectively, Figure 3.7C. After seven hours, the fibrils are less curvy, and the 
aggregates can be found in larger patches, Figure 3.6D. Analysis shows that 
after seven hours, fibrils of type c, d remain but a new fibrillar structure (Type 
e) appears. Interestingly, the fibrils of Type c observed after seven hours have 
a similar height of 2.9 ± 0.2 nm as fibrils of Type c formed after four hours but 
are approx. 5 nm smaller in width (13 ± 1 nm). This is also true of fibrils of 
Type d which, after 7 hours, also have smaller widths by approx. 7 nm. As soon 
as the plateau phase was reached in the ThT assay and at the end point, the mica 
sheet was entirely covered by a dense mesh of rigid fibrils, making it 
challenging to differentiate and analyse single fibrils in detail, Figure 3.6E & 
F.  
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Figure 3.6. AFM images of GLP-1 species formed at different time points during 
peptide aggregation in citrate buffer at pH 3.0. 
A) ThT assay run in triplicate of 150 μM GLP-1 in 25 mM citrate buffer at pH 
3.0 and 37 °C. Triangles indicate timepoints at which AFM samples were 
taken. B)-F) 3x3 µm AFM pictures with inverse colour scheme (nm). Inset 
scale bar is 0.5 µm. The first time point was taken within one hour after 
preparation and filtration (B), 4 (C), 7 (D), 24 (E) and 168 (F) h. 
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Figure 3.7. AFM images and analysis of the height and width of GLP-1 aggregates 
formed in citrate buffer at pH 3.0. 
Measurement of height and width of fibrils shown in Figures 3.6C & D and 
3.7A & B. The profiles were analysed using the AFM data analysis program 
Gwyddion. A) AFM image of GLP-1 aggregates (Type a) after 4 h of 
incubation, showing the positions on the fibrils where the profiles were 
measured. B) AFM image after 7 h of incubation showing thicker fibrils (Type 
e). Indicated are the positions where the profiles are measured. C) Complete 
plot of fibril profiles of different fibril types (Type a, b, c, d & e) taken after 
4 h and 7 h. See Table 3.1 and Table 3.2 for further details. 
GLP-1 aggregation in phosphate at pH 3.0 shows similar results to those 
obtained in citrate buffer: no fibrils or aggregates were observed at the earliest 
time point, Figure 3.8B. In the lag phase, after 2.5 and 7 hours, thin and partly 
curvy fibrils formed, Figure 3.8C & D.  In detail, two different types of fibrils 
(Type c and d) were measured after 2.5 hours with heights of 2.7 ± 0.3 nm 4.1 
± 0.3 nm, respectively and similar widths between 17-18 nm, Figure 3.9A & C. 
After 7 hours of incubation, fibrils of Type e formed, which were slightly lower 
in height (5.6 ± 0.5 nm) and thicker (28 ± 2 nm) than fibrils of Type e after 2.5 
hours, Figure 3.9B & C. After the steep growth phase, the surface of the mica 
sheet was again covered with a thick mesh of fibrils, Figure 3.8E & F. 
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Figure 3.8. AFM images of GLP-1 species formed at different time points during 
peptide aggregation in phosphate buffer at pH 3.0. 
A) ThT assay run in triplicate of 150 μM GLP-1 in 25 mM phosphate buffer 
at pH 3.0 and 37 °C. Triangles indicate timepoints at which AFM samples 
were taken. B)-F) 3x3 µm AFM pictures with inverse colour scheme (nm). 
Inset scale bar is 0.5 µm. The first time point was taken within one hour after 
preparation/filtration (B), as well as after 2.5 (C), 7 (D), 24 (E) and 168 (F) h. 
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Figure 3.9. Height and width of GLP-1 aggregates formed in phosphate buffer at 
pH 3.0. 
Measurement of height and width of fibrils shown in Figures 3.8C and 3.90A 
& B. The profiles were analysed using the AFM data analysis program 
Gwyddion. A) AFM image of sample after 2.5 h of incubation. Indicated are 
the places where the profiles of the thinnest fibrils (Type c) were measured. 
B) AFM image showing a sample after 7 h of incubation. Indicated are the 
six positions on fibrils of Type e where a profile was measured. C) Complete 
plot of fibril profiles of different fibril types (Type c, d & e) taken after 2.5 h 
and 7 h. See Table 3.1 and Table 3.2 for further details. 
The AFM imaging of GLP-1 at different time points during aggregation in 
citrate buffer at pH 3.5 showed curly and tangled fibril-like aggregates 
immediately after the sample preparation, Figure 3.10B. The height and width 
of these short fibril-like aggregates was measured as 2.2 ± 0.1 nm and 15 ± 1 
nm, respectively (Type s), Figure 3.11A. Some of these aggregates even formed 
closed ring-like structures. After 6 hours, the time point corresponding to the 
end of the growth phase, the sample formed fibrils with three different profiles, 
Figure 3.10C, Type a, b and e. The thinnest fibril (Type a) has a height of 1.5 
± 0.2 nm whilst Type b heights were 3.0 ± 0.2 nm, they both had similar widths 
of approx.14 nm.   Type a and b fibrils are probably the predecessor for some 
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longer, straight, and partly twisted fibrils (Type e), Figures 3.10C and 3.11E. It 
is interesting to note that the width of the latter decreases from approx. 23 nm 
to less than 18 nm during the lag phase. After 23 hours, Type a fibrils disappear 
and only mostly straight, longer and more rigid fibrils were detected, Figures 
3.10D-F and 3.11E. In Figure 3.12D, the tip of a thick fibril of Type f is 
analysed which appears to be assembled out of thinner fibrils of Type c and e. 
The findings for GLP-1 at pH 3.5 in phosphate buffer show similar aggregates 
as in citrate buffer. Again, short and curly fibril-like structures (Type s) are 
formed immediately after the preparation of the samples, Figure 3.12B. The 
formation of ring-like structure also seems independent of the buffer. It is worth 
highlighting that similar as for the citrate buffer at pH 3.5 also in phosphate 
buffer, the thinnest fibrils (Type b) measured at the second time point are lower 
and thinner in comparison to the earlier formed curly and tangled fibril-like 
aggregates. However, during the lag phase and at the beginning of the growth 
phase, the images show more amorphous structures, Figure 3.12C & D. At the 
beginning of the plateau and at the end of the aggregation assay, the fibrils are 
rigid and similar to those observed in citrate buffer, Figure 3.12E & F 
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Figure 3.10. AFM images of GLP-1 species formed at different time points during 
peptide aggregation in citrate buffer at pH 3.5. 
A) ThT assay run in triplicate using 150 μM GLP-1 in 25 mM citrate buffer 
at pH 3.5. Triangles indicate timepoints at which AFM samples were taken. 
B)-F) 3x3 µm AFM pictures with inverse colour scheme (nm). Inset scale 
bar is 0.5 µm. The first time point was taken within one hour after 
preparation/filtration (B), as well as after 6 (C), 23 (D), 30 (E) and 144 (F) h. 
Note, sample shown in F was diluted to ~50 µM before imaging. 
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Figure 3.11. AFM images and analysis of the height and width of GLP-1 aggregates 
formed in citrate buffer at pH 3.5. 
AFM images of GLP-1 aggregates formed in citrate at pH 3.5 illustrating the 
sections of the fibrils analysed. The profiles were analysed using the AFM 
data analysis program Gwyddion. A) Short curly fibrils (Type s) imaged 
before the incubation at t = 0 h. Indicated are the six positions on the fibrils 
where a height/width profile was measured. B) AFM image recorded after 6 
h indicating the nine places where profile measurements were taken on Type 
a fibrils. C) AFM image after 30 h of incubation indicating the six positions 
on the Type e fibrils where profiles were measured. D) AFM image after 143 
h showing Type d, e and f fibrils and the six positions on the fibrils where 
profiles were measured. E) Complete plot of fibril profiles of different fibril 
types (Type s, a, c, e & f) taken between 0 and 143 h. See Table 3.1 and Table 
3.2 for further details. 
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Figure 3.12. AFM images of GLP-1 species formed at different time points during 
peptide aggregation in phosphate buffer at pH 3.5. 
A) ThT assay run in triplicate using 150 μM GLP-1 in 25 mM phosphate 
buffer at pH 3.5 and at 37 °C. Triangles indicate timepoints at which AFM 
samples were taken. B)-F) 3x3 µm AFM pictures with inverse colour scheme 
(nm). Inset scale bar is 0.5 µm. The first time point was taken within one 
hour after preparation/filtration (B), as well as after 3 (C), 8 (D), 48 (E) and 
143 (F). Samples in (F) were diluted to ~50 µM before imaging. 
D 
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Figure 3.13. AFM images and analysis of the height and width of GLP-1 aggregates 
formed in phosphate buffer at pH 3.5. 
Measurement of height and width of fibrils shown in Figures 3.12B, D, E & 
F and 3.13A-D. The profiles were analysed using the AFM data analysis 
program Gwyddion. A) AFM image of short curly fibrils (Type s) imaged 
before incubation. The six positions used to calculate the height/width of the 
fibrils are shown.  B) AFM image of aggregates after 6 h of incubation (Type 
b). Shown are the six positions used to measure the height/width of the fibrils. 
C) AFM image of aggregates (Type c) after 48 h of incubation. The six 
positions used to measure the height/width of the fibrils are shown. An AFM 
artefact most likely causes the double peak. D) AFM image after 143 h 
incubation (Type c). The six positions used to measure the height/width of 
the fibrils are shown. E) Complete plot of fibril profiles of different fibril 
types (Type s, b, & c) taken between 0 and 143 h. See Table 3.1 and Table 
3.2 for further details. 
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It is interesting to note that the ThT assay used to assess the aggregation of the 
samples of GLP-1 in phosphate buffer at pH 3.5 for the AFM experiments 
shows some differences in lag time compared to previous measurements in 
phosphate buffer at pH 3.5. The differences are most likely caused by the 
disturbance of the aggregation process resulting from the opening and closing 
of the plate reader during the sampling, as well as inserting a pipette to remove 
sample. 
The aggregation of two samples of GLP-1 was also measured at pH 6.5, a pH 
close to the pI of GLP-1 (Figure 3.5C) and, in this case, no increase in ThT 
fluorescence even after the 140 h of incubation was observed, Figure 3.14A. 
AFM images were taken at the beginning and at the end of ThT assay to confirm 
that fibrils had not formed, Figure 3.14B & C.  
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Figure 3.14. AFM images of GLP-1 species formed at different time points during 
peptide aggregation in phosphate buffer at pH 6.5. 
A) ThT assay run in duplicate of 150 μM GLP-1 in 25 mM phosphate buffer 
at pH 6.5 and 37 °C. Triangles indicate timepoints at which AFM samples 
were taken. B and C) 3x3 µm AFM pictures with inverse colour scheme 
(nm). Inset scale bar is 0.5 µm. The AFM was taken within one hour after 
sample/preparation filtration (B) and after 144 (C) hours. 
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At pH 7.5, immediately after sample preparation, samples of GLP-1 contained 
small, thin and curly fibril-like structures (Type s), Figure 3.15B. These had 
heights of 1.2 ± 0.1 nm and widths of 12 ± 1 nm, and were smaller than their 
curly counterparts under acidic conditions, Figure 3.16A. At the end of the lag 
phase, the thin curvy structures convert to short and straight fibrils, Figure 
3.15C. They have profiles that are typical of fibrils of Type b, Figure 3.16B. 
The short and straight fibrils of Type b most likely grow and form the mature 
fibrils of Type c to f, which are present in the samples taken from the midpoint 
of the growth phase, at the start of the plateau phase and at the end of the 
aggregation assay, Figure 3.15D-F.  
At the start of the aggregation reaction, at pH 8.2, small oligomeric species 
(Type o) were observed with diameters of 33 ± 3 nm and heights of 1.9 ± 0.2 
nm, Figures 3.17B and 3.18A. After 5 hours, these species vanish and short 
fibrils (Type b) appear, Figures 3.17C and 3.18B. The distribution and pattern 
of the aggregates suggests that this species is the predecessor of the short fibrils 
and, therefore, an on-pathway species, Figure 3.18A & B. After an additional 
four hours, these short fibrils grew only moderately in terms of height whilst 
their widths decreased and a few longer fibrils appeared, Figure 3.17D. The 
fibrils observed in the growth phase and in the plateau appear region appeared 
rigid,  Figure 3.17E & F, and were similar to the fibrils observed at late time 
points for GLP-1 at pH 3.0, 3.5 and 7.5 
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Figure 3.15. AFM images of GLP-1 species formed at different time points during 
peptide aggregation in phosphate buffer at pH 7.5. 
A) ThT assay run in triplicate using150 μM GLP-1 in 25 mM phosphate 
buffer at pH 7.5 and 37 °C. Triangles indicate timepoints at which AFM 
samples were taken. B)-F) 3x3 µm AFM pictures with inverse colour scheme 
(nm). Inset scale bar is 0.5 µm. The first time point was taken within one 
hour after preparation/filtration (B), as well as after 11 (C), 23 (D), 35 (E) 
and 145 (F) h. 
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Figure 3.16. AFM images and analysis of the height and width of GLP-1 aggregates 
incubated in phosphate buffer at pH 7.5. 
Measurement of height and width of fibrils shown in Figures 3.15B-F and 
3.16A, B & D. The profiles were analysed using the AFM data analysis 
program Gwyddion. A) AFM image of aggregates of GLP-1 before 
incubation (Type s). The six positions where profiles were measured are 
shown. B) AFM image after 11 h of incubation (Fibril b). The six positions 
where profiles were measured are shown. (C) Plot of the height/width 
profiles of fibrils measured using data shown in panel (B). The height/width 
of the fibrils was measured above the blue shaded plateau. D) AFM image of 
aggregates formed after 143 h incubation. The six positions where profiles 
were measured are shown. E) Complete plot of fibril profiles of different 
fibril types (Type s, b, c, d, e & f) taken between 0 and 145 h. See Table 3.1 
and Table 3.2 for further details. 
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Figure 3.17. AFM images of GLP-1 species formed at different time points during 
peptide aggregation in Tris buffer at pH 8.2. 
A) ThT assay run in triplicate of 150 μM GLP-1 in 25 mM Tris buffer at pH 
8.2. Triangles indicate timepoints at which AFM samples were taken. B)-F) 
3x3 µm AFM pictures with inverse colour scheme (nm). Inset scale bar is 0.5 
µm. The first time point was taken within one hour after preparation/filtration 
(B), as well as after 5 (C), 9 (D), 21 (E) and 94 (F) h. 
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Figure 3.18. AFM images and analysis of height and width of GLP-1 aggregates 
incubated in Tris buffer at pH 8.2. 
Measurement of height and width or diameter of small oligomers and fibrils 
shown in Figures 3.17B, C, D & F and 3.18A-D. The profiles were analysed 
using the AFM data analysis program Gwyddion. A) AFM image of GLP-1 
aggregates (Type o) before the incubation. The six positions where profiles 
were measured are shown. B) AFM image after five h of incubation showing 
fibrils of Type b. The six positions where profiles were measured are shown. 
C) AFM image of intermediate fibrils imaged after nine h of incubation 
(Type c). The six positions where profiles were measured are shown. D) 
AFM image of thick fibrils (Type c) observed after 94 h incubation. The six 
positions where profiles were measured are shown. E) Complete plot of fibril 
profiles of different fibril types (Type o, b, & c) taken between 0 and 94 h. 
See Table 3.1 and Table 3.2 for further details. 
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type Height (nm) 
Height SD 
(nm) Width (nm) 
Width SD 
(nm) 
Citrate buffer pH 3.0 
4 a 1.2 0.1 14.9 1.6 
4 b 1.9 0.2 16.7 1.2 
4 c 2.8 0.2 17.9 1.2 
4 d 4.8 0.2 21.8 1.6 
7 c 2.9 0.2 12.9 0.7 
7 d 4.3 0.1 14.0 0.7 
7 e 7.6 0.5 19.4 1.8 
Phosphate buffer pH 3.0 
2.5 c 2.7 0.3 17.3 2.1 
2.5 d 4.1 0.3 17.9 2.0 
7 e 5.6 0.5 27.5 2.1 
Citrate buffer pH 3.5 
0 s 2.2 0.1 15.4 1.3 
6 a 1.5 0.2 13.7 1.3 
6 c 3.0 0.2 14.6 0.5 
6 e 5.6 0.7 23.4 1.5 
23 c 2.5 0.3 12.9 1.6 
23 e 5.9 1.0 17.0 0.8 
30 e 6.0 0.6 17.6 0.6 
143 d 3.6 0.0 12.4 0.2 
143 e 8.1 0.8 17.7 0.2 
143 f 10.8 0.8 24.3 2.9 
Phosphate buffer pH 3.5 
0 s 2.8 0.4 14.3 3.3 
8 b 1.6 0.3 16.6 1.2 
48 c 3.0 0.4 21.1 0.7 
143 c 3.4 0.1 13.6 0.5 
Phosphate buffer pH 7.5 
0 s 1.2 0.1 12.1 1.2 
0 s 1.7 0.1 11.1 0.9 
11 b 1.6 0.1 16.2 1.1 
11 b 1.6 0.4 26.2 1.0 
23 c 3.0 0.2 16.2 0.2 
23 e 6.6 0.4 29.9 1.1 
35 b 2.5 0.2 20.9 2.6 
35 d 4.1 0.5 22.5 0.5 
35 e 7.2 0.6 21.2 0.3 
35 f 15.0 1.1 27.0 1.1 
143 d 4.2 0.2 18.2 0.7 
143 e 7.3 0.3 21.1 0.6 
143 f 15.4 0.4 27.7 0.3 
Tris buffer pH 8.2 
0 o 1.9 0.2 33.0 2.5 
5 b 1.8 0.1 14.3 1.2 
9 b 1.7 0.2 12.0 0.4 
9 c 2.4 0.3 15.4 0.2 
94 c 3.1 0.2 35.1 4.0 
Table 3.1. Heights and widths of different fibril profiles. 
The values for the height and width were determined from the fibril profiles 
using a Gaussian fit. The width of the fibril is equivalent to the FWHM of the 
Gaussian. 
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(PB): Approx. round 
spots with a diameter 
of 15-100 nm and a 
height of 1-10 nm  
 Few impurities or 
contaminations 
Few impurities or 
contaminations, < 
2 nm width 
t < 1h  Citrate buffer (CB): 
No fibrils 
PB: No fibrils 
CB: Type s, curly, 
ring-like 
structures, height 
∼2.5 nm, width 
∼15 nm, length 50 
– 400 nm, 
clumping. 
PB: similar as in 
CB. 
Type s, 50-500 nm 
length, curly, 
clumping 
Values of height 
(∼1.5 nm) and 
width (∼12 nm) 
smaller than for 
Type s at pH 3.5. 
Oligomer-like 
structures 
∼33 nm diameter, 




CB: Mainly curved 
fibrils, Type a, b, c, 










fibrils, Type b 
Transition from 
oligomer-like 
structure to short 





CB: Mainly straight 
fibrils Type c, d, and 
e. Tightly packed, 
don’t stick, not 
twisted  
PB: Type e, 1-10 µm 
length, curvy, 
clumping 
CB: Long and 
curved fibrils, 
Type c and e 
Type c, and e 
0.25-3.0 µm 
length, straight, 
twisted: ∼0.27 µm 
per turn 
Mainly fibrils of 
Type b, ∼ 30-200 
nm length. Very 




t = 0 
plateau 
CB: t = 0 plateau: 
Type e, straight, not 
twisted, Dense mash. 
PB: t = 0 plateau: 
Type e, 2-3 µm 




straight, Type c, 
length ∼1 µm 
t = 0 plateau: 
Type c, d, e, and f.  
>9 µm length, 
straight, twisted, 
no clumping, stick 
to each other 
 
 
t = final 
plateau 
CB: Straight, Type e, 
Dense mesh. 
PB: Dense mesh, 
Type c or thicker, 
straight, clumping. 





Type c and 
multiples of it. 
Width 45-55 nm, 
hight 6-10 nm, 
length > 9 µm, 
straight 
Table 3.2. Description of GLP-1 aggregates imaged by AFM under different 
conditions. 
Different peptide aggregates are defined as oligomer-like aggregates (Type o), 
curly and tangled fibril-like aggregates (Type s) and fibrils with a height of 0.5 
- 1.5 nm (Type a), 1.5 - 2.5 nm (Type b), 2.5 - 3.5 nm (Type c), 3.5 - 5 nm 
(Type d), 5 - 10 nm (Type e) and >10 nm (Type f). 
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3.4.2 Disturbance of Aggregation Kinetics  
The aim of the time-course experiments was to follow the aggregation kinetics 
of GLP-1 under different pH and buffer conditions. However, taking samples 
during a ThT assay introduces some disruption to the system which might 
influence the kinetics of peptide aggregation. The samples for AFM imaging 
were taken using a pipette which induced a gentle mixing of the samples and 
every time point involved an opening and closing of the plate reader. To learn 
more about the influence of these factors, the ThT assay data in Section 3.4.1 
were analysed using a sigma function (Equation 2.5) and compared to the 
expected lag times of undisturbed samples, Figure 3.2A & B. The data shows 
that under neutral and basic conditions, the aggregation kinetics are in good 
agreement with the expected lag times of undisturbed samples, Figure 3.19. At 
pH 7.5 the lag time is most influenced by sample removal and significantly 
shorter, Figures 3.17A and 3.19.  
 
Figure 3.19. Assessment of the effect of sampling on GLP-1 aggregation kinetics.  
Comparison of lag times of GLP-1 aggregation measured under different 
conditions.  All measurements were conducted in 25 mM buffer, at 37 °C and 
in triplicate. Kinetics measured with disruption from sample acquisition for 
AFM experiments are shown as solid green circles (phosphate), solid red 
squares (citrate), and solid blue diamonds (Tris). Lag times calculated from 
a kinetic run which was completely undisrupted by sample removal and 
opening/closing at pH 3.0 are shown as a solid green triangle. Lag times for 
aggregation at pH 7.5 and 8.2, during which the plate reader was opened and 
closed but for which no sample was removed are shown as an open green 
circle (phosphate) and open blue triangle (Tris), respectively. Reference 
measurements (no sample removal and no opening/closing) are shown as a 
solid black circle (phosphate), triangle (Tris) and square (citrate). The error 
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Under acidic conditions, the lag times of GLP-1 aggregation in phosphate 
buffer at pH 3.0 and 3.5, are influenced by sample removal and show different 
aggregation kinetics compared to the reference data, Figures 3.8A and 3.19. 
Interestingly, the kinetics of GLP-1 aggregation in citrate buffer at pH 3.0 
shows nearly no influence of sample removal, whereas at pH 3.5 they are 
affected, Figure 3.19.   
3.4.3 Changes in Secondary Structure During Aggregation 
Far-UV CD and FT-IR time-course experiments were undertaken to elucidate 
the change in the secondary structure during the aggregation process. To enable 
the measurement of the FT-IR spectra under acidic conditions, phosphate 
buffer was used as citrate is known to absorb in the infrared in the same range 
as GLP-1. The samples for the far-UV CD and FT-IR measurements were taken 
at the same time and from the same plate as that used for the acquisition of 
samples for the AFM experiments.  
The change in secondary structure was probed by far-UV CD and FT-IR at two 
or four different pH values, respectively, and compared with the lag time 
measured from the ThT assays under the same conditions, Section 3.4.2.  At all 
the pH values studied, there is an overall change from secondary structures 
containing both a-helical and b-sheet structure to one that is largely b-sheet in 
nature at the end of the aggregation reaction as expected for the conversion of 
monomeric GLP-1 into amyloid fibrils. 
Figure 3.20 shows the results of far-UV CD measurements at different time 
points during the aggregation of GLP-1 at pH 3.0 and 3.5 in 25 mM phosphate 
buffer. These experiments show how the main change in secondary structure 
of GLP-1 occurs after the lag phase and during the growth phase.  
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Figure 3.20. Changes in secondary structure in GLP-1 during peptide aggregation 
at pH 3.0 and 3.5 in phosphate buffer shown by far-UV CD. 
Far-UV CD spectra of 150 µM GLP-1 measured at 25 °C.  The x-axis and y-
axis show the wavelength (nm) and the molar ellipticity (10
3
 ⋅ deg ⋅ cm2 ⋅ 
dmol
-1
), respectively. The different colours represent different time points in 
hours. The measured lag time is shown in red. Time points showing the first 
major changes of the secondary structure are shaded in blue. A) 25 mM 
phosphate buffer pH 3.0. B) 25 mM phosphate buffer pH 3.5.  
FT-IR spectra were recorded at different time points during aggregation at pH 
3.5, Figure 3.21A & B, and the data indicate an even later shift from α-helical 
to β-sheet structure between 8 and 23 h instead of 6 to 8 h, as seen in the far-
UV CD data, Figure 3.21B.  
At pH 7.5, FT-IR measurements show that the major change in secondary 
structure occurs after the lag time and during the growth phase, Figure 3.21C. 
These results are in good agreement with the previously conducted far-UV CD 
time-course measurements, Figure 1.22C. In contrast, at pH 8.2, major changes 
in secondary structure occur earlier and within the lag phase, Figure 3.21D. 
Again, this is in good agreement with the earlier far-UV CD time-course 
measurements conducted by Dr Karolina Zapadka, Figure 1.22D.  
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Figure 3.21. Changes in secondary structure in GLP-1 during peptide aggregation 
at different pHs shown by FT-IR. 
FT-IR spectra of 150 µM GLP-1 measured at different time-points. The x-
axis and y-axis show the wavenumber (cm
-1
) and the absorbance 
(normalised), respectively. The different colours represent different time 
points in hours. The measured lag time is shown in red. Time points showing 
the first major changes of the secondary structure are shaded in blue. A) 25 
mM phosphate pH 3.0. B) 25 mM phosphate pH 3.5. C) 25 mM phosphate, 
pH 7.5. D) 25 mM Tris, pH 8.2.  
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An SVD analysis of the far-UV CD and FT-IR data was performed in order to 
assess whether any species with secondary structure significantly different to 
either the monomer or fibril could be identified, and its spectrum elucidated. In 
all conditions, the SVD analysis demonstrates that the spectra obtained at 
different time points during the aggregation reaction can be deconvoluted 
mainly into two spectra. Typical examples of single-value deconvolution of the 
far-UV CD and FT-IR data are shown in Figures 3.22 and 3.23, respectively. 
In both cases, the data of GLP-1 at pH 3.0 at nine different time points are 
shown. The far-UV CD spectra in Figure 3.22A can be deconvoluted mainly 
into two spectra. The first, Figure 3.22B, represents the fibrillar end point, and 
the second represents the starting monomer, Figure 3.22C. 
For the FT-IR spectra, the data can be deconvoluted mainly into two spectra, 
however, in this case, it is not possible to assign these two spectra to the 
monomer or fibrillar end point. Here, the first spectrum represents an average 
of both states, Figure 3.23B, and the second spectrum describes the change 
needed to get from the monomer to the fibrillar end point, Figure 3.23C. The 
fact that the first component shows an average value is most likely because the 
difference of the spectra is relatively symmetric between both states. 
The cumulative percentages of SVD components of the far-UV CD and FT-IR 
spectra are shown in Figure 3.24. At pH 3.0 and 8.5, the SVD analysis of the 
far-UV CD data shows that the system is over 90% determined by two-states, 
whilst at pH 3.5 and 7.5, the values are slightly lower than this. This suggests 
that the system populates another state under these conditions, although not to 
a very high level, Figures 3.22 and 3.23D. The SVD analysis of the FT-IR data 
shows an even higher percentage for the sum of the first two SVD components 
but still lower values at pH 3.5 and 7.5 in comparison to the samples at pH 3.0 
and 8.5. However, even if the system can be described by only two sigma and 
their vectors, this does not mean that there are no oligomeric species present, 
just that, if they become significantly populated that their spectra must be 
similar to either that of monomer or fibril.  
In general, both datasets, far-UV CD and FT-IR, show high cumulative 
percentages already for the first sigma. The value of the first sigma of FT-IR 
is even higher in comparison to the first sigma of far-UV CD. This is most 
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likely because the FT-IR data also includes a contribution from the buffer. A 
subtraction of the buffer spectrum was not possible due to the drying process 
and unknown amounts of buffer on the observation plate in the instrument.
 
Figure 3.22. Singular value decomposition of the far-UV CD spectra of GLP-1 at 
pH 3.0 at different times during aggregation. 
Singular value decomposition of the far-UV CD spectra of 150 µM GLP-1 
in 25 mM phosphate buffer at pH 3.0, measured at nine different time points. 
A) Complete far-UV CD spectra. B) The first component of the analysed far-
UV CD spectra. The data were calculated by multiplying U⋅&⋅V*, with all 
values in & set to 0 except %1. The first component represents the far-UV CD 
spectra measured for aggregated GLP-1. C) The second component of the 
CD spectra is calculated as in B but with %2 as sole value instead of %1. The 
spectra represent the monomer/non-aggregated structure of GLP-1. D) 
Calculated third component based on %3. All components higher than the 
third show values close to 0 (data not shown). 
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Figure 3.23. Singular value decomposition of FT-IR spectra of GLP-1 at different 
time points during aggregation at pH 3.0. 
Singular value decomposition of FT-IR spectra of 150 µM GLP-1 in 25 mM 
phosphate buffer at pH 3.0, measured at nine different time points. A) 
Complete FT-IR spectra. B) The first component of the analysed FT-IR 
spectra. The data was calculated by multiplying U⋅&⋅V*, with all values in & 
set to 0 except %1. The first component represents an FT-IR spectra showing 
average spectra for non-aggregated and aggregated GLP-1 peptide structure. 
C) The second component of the FT-IR spectra is calculated as in B but with 
%2 as sole value instead of %1. The spectra represent the change between 
monomer/non-aggregated and aggregated structure of GLP-1. D) Calculated 
third component based on %3. All components higher than the third show 
values close to 0 (data not shown). 
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Figure 3.24. Cumulative percentage of single-value decomposition (SVD) 
components. 
A) Cumulative percentage of SVD components of far-UV CD spectra. 150 
µM GLP-1 in 25 mM buffer measured at 25°C. The measured samples were 
aggregated in phosphate buffer at pH 3.0, phosphate buffer at pH 3.5, 
phosphate buffer at pH 7.5 and Tris buffer at pH 8.5. B) Cumulative 
percentage of SVD components of FT-IR spectra. 150 µM GLP-1 in 25 mM 
buffer measured at 25 °C. The measured samples were aggregated in 
phosphate buffer at pH 3.0, phosphate buffer at pH 3.5, phosphate buffer at 
pH 7.5 and Tris buffer at pH 8.5. 
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3.4.4 Size of GLP-1 Aggregates in Solution 
To elucidate the size of the aggregates formed during GLP-1 aggregation, DLS 
measurements were performed at the same time points as the AFM, far-UV CD 
and FT-IR data. The conducted measurements at pH 3.0, 3.5 and 6.5 were used 
together with previous data obtained for GLP-1 at pH 7.5, 7.7 and 8.25 to 
establish how the size of species varies over time over a wide range of pH 
values. It is essential to mention that the data are presented as both intensity 
and number distributions. The intensity measurements have a stronger signal 
for larger particle sizes so tend to be dominated by these species, however, this 
measurement does not depend upon any model used. N.B., the Zetasizer 
software calculates the number distribution based on the intensity distribution 
using assumptions about the samples' shape, density, and optical properties.  
Throughout this section measurements given are for the diameter of species 
present. 	
Freshly prepared samples of GLP-1 at pH 3.0, show a peak corresponding to 
monomer and possibly small oligomers at 5-6 nm, in addition to a peak 
indicting species with a size of approx.1000-2000 nm caused by a small number 
of particles which scatter the light with high intensity. Still, the smaller 
molecular weight peak represents only 5-10% of the sample concentration and 
disappears completely after the first measurement, presumably as monomers 
and small oligomers are converted into larger aggregates and ultimately fibrils. 
In general, there are large differences between the single measurements at 
different time points, Figure 3.25A & B. This is most likely caused by ongoing 
aggregation reactions of the samples which are not at equilibrium or simply the 
settlement of the aggregates at the bottom of the cuvette during the 
measurement. To be consistent with the previous experiments, 150 µM GLP-1 
was used, and it should be noted that this is lower than the optimal 
concentration needed for DLS measurements and this may also contribute to 
the variation in signal between time points. 
At pH 3.5, the first peak of the earliest time points shows even smaller particles 
around 3-4 nm, which corresponds with approximately 5% of the total peptide 
concentration. Additionally, larger particles are also present. They have a 
diameter of about 50-200 nm, tenfold smaller than the larger aggregates 
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observed at pH 3.0. After 3, 6 and 8 h smaller aggregates can be observed, with 
diameters of approximately 10 - 100 nm, Figure 3.25C & D. 
At pH 6.5, two measurements were conducted. Immediately after the peptide 
was dissolved and filtered, the intensity data shows species and aggregates 
around 3-4 and 50-200 nm. After the ThT assay (144 h), during which no 
increase of ThT fluorescence was observed, the monomer/dimer peaks vanish 
and the number of larger aggregates between 30 and 700 nm increases. 
Additionally, a few aggregates with diameters larger than 2000 nm are present, 
Figure 3.25E. At time point zero the majority of the aggregates are between 3-
4 nm and after the ThT assay between 20-80 nm, Figure 3.25E. 
In general, it is assumed that the smaller molecular weight species between 2 – 
6 nm are most likely monomer or dimer, and this is only observed for the first 
measurement of the freshly dissolved peptide solution. This is similar to the 
findings for GLP-1 at pH 7.5, 7.7 and 8.2.5  These results suggest that the 
monomer/dimer rapidly converts into other species. 
At pH 3.5, the data at time points within the lag phase, show large numbers of 
oligomeric-like aggregates around 10 – 100 nm. Similarly sized oligomeric-
like aggregates (20 – 100 nm) were found at pH 6.5 at the end of the ThT assay. 
As the results of the AFM and ThT assays showed no evidence for fibrillar 
species, this suggests that the oligomeric-species observed at both pH 3.5 and 
6.5 are related and likely to be off-pathway, not converting directly into 
amyloid fibrils. At pH 6.5, both these species are highly stable and do not 
convert back into monomer, on-pathway species or fibrils. Alternatively, fibrils 
may not be stable under these conditions. 
Chapter 3: Physical Stability of GLP-1 
  121 
 
Figure 3.25. Results of DLS measurements to determine the size of GLP-1 species in 
solution at different time points during aggregation. 
DLS measurements of 150 µM GLP-1 A) Intensity vs. size of particles 
(diameter) in 25 mM phosphate buffer at pH 3.0. B) Number of particles vs. 
size of particles (diameter) in 25 mM phosphate buffer at pH 3.0. A & B) 
Time points taken after 0 h (dark red), 3 h (red), 6 h (dark orange), 8 h 
(orange), 21 h (dark green), 25 h (bright green), 30 h (bright blue), 122 h 
(blue) and 143 h (dark blue). C) Intensity vs. size of particles (diameter) in 
25 mM phosphate buffer at pH 3.5. D) Number of particles vs. size of 
particles (diameter) in 25 mM phosphate buffer at pH 3.5. C & D) Time 
points taken after 0 h (dark red), 3 h (red), 6 h (dark orange), 8 h (orange), 23 
h (dark green), 30 h (bright green), 48 h (bright blue) and 144 h (blue). 
E) Intensity vs. size of particles (diameter) in 25 mM citrate buffer at pH 6.5. 
F) Number of particles vs. size of particles (diameter) in 25 mM citrate buffer 
at pH 6.5. E & F) Time points taken after 0 h (red) and 141 h (black).  
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Problems associated with the physical stability of many potentially otherwise 
very efficacious therapeutic peptides has hindered or prevented their use in the 
clinic. Amongst other forms of physical instability, many peptides are known 
to form amyloid-like fibrils at their high formulation concentrations. In order 
to be able to better develop peptide-based drugs with improved physical 
stability profiles, a better understanding of the underlying mechanisms of 
aggregation and amyloid formation are required. The therapeutic peptide GLP-
1 has been shown to form amyloid fibrils and this has been studied in detail at 
pH 7.5-8.2.5 An unusual change in the aggregation kinetics between pH 7.5 and 
8.2 has been attributed to the population of off-pathway oligomers at pH 7.5, 
in addition to the on-pathway oligomers which convert into the amyloid fibrils. 
There is increasing evidence for, and awareness of, off-pathway 
species,5,89,130,343–349 however, few detailed studies of such species and their 
impact on aggregation kinetics have yet to be published. 
Following on from the work on GLP-1 at pH 7.5 - 8.2, here an investigation of 
the physical stability of GLP-1 at basic, neutral and acidic pH values is 
reported. The focus was on time-course measurements during which a number 
of biophysical techniques were employed that report on the structure and size 
of species in solution at various times during the aggregation reaction. The 
objectives of the study were two-fold, i) to understand in more detail the 
conditions in which off-pathway species become significantly populated in 
order for us to better understand the nature of these species, and ii) to gain 
further information on species present in solution at different time points under 
conditions which favour the population of on- and off-pathway oligomers, 
particularly focussing on processes that occur within the lag time.  
3.5.1 Physical Evidence for Off-Pathway Oligomeric Aggregates 
The unusual concentration dependence of GLP-1 aggregation kinetics at pH 
7.5 has been previously explained by the influence of off-pathway oligomeric 
aggregates.5 The experiments in this Chapter were conducted to understand 
3.5 Discussion 
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why such an unusual behaviour can be found not only at pH 7.5 but at pH 3.5 
suggesting that off-pathway oligomers are also populated under acidic 
conditions at pH 3.5, but interestingly not at pH 3.0. For both pH 3.5 and 7.5, 
the study also reveals further evidence for off-pathway species. For example, 
analysis of the far-UV CD and FT-IR data with SVD showed that an additional 
species with characteristics different to either the monomer and fibrils is more 
evident and populated at pH 3.5 and 7.5 in comparison to pH 3.0 and 8.2. In 
addition, and based on the results of the AFM experiments, results suggest that 
such a putative off-pathway oligomer may be the short and curly fibril-like 
aggregates observed at early time points at some pH values. These species 
appear to have hydrodynamic radii of about 20-80 nm as observed by DLS at 
pH 3.5 and 6.5.  
3.5.2 Characteristics of GLP-1 Aggregates and Fibrils Formed 
Under Acidic and Basic Conditions.  
As mentioned in the previous section, short and curly fibril-like species have 
been seen under both conditions known to show off-pathway behaviour. Under 
acidic conditions, the curly fibril-like aggregates are thicker in comparison to 
the thinnest types of fibrils observed in the same sample, consistent with the 
idea that these aggregates are off-pathway because they would have to undergo 
dissociation and a significant change in structure to transform them into the 
thinnest types of fibrils observed.  
While showing the same characteristics as the short curly fibrils formed under 
acidic conditions, the dimensions of the curly fibril-like aggregates imaged at 
neutral pH are thinner than the curly fibril-like aggregates imaged at pH 3.5. 
Their dimensions are similar to the height and width of the observed thin fibrils 
at pH 7.5. Although these aggregates are similar in width to other fibrils 
formed, they are still likely to be off-pathway, as again they would need to 
undergo a structural transformation in order to form the more rigid structure 
adopted by fibrils. 
The aggregation of GLP-1 under basic conditions (pH 8.2) follows kinetics 
typical of a nucleation-elongation mechanism. The AFM data suggests that the 
nucleation may occur in small on-pathway, oligomer-like aggregates with a 
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diameter slightly bigger than the width of the fibril formed from the nucleus.    
In general, during the lag phase and partly at the beginning of the growth phase, 
several different sized fibrils have been detected, for example, at pH 3.0. Their 
dimensions suggest that fibrils are multiples of the thinnest fibril type, Type a, 
which is possibly a protofibril. Fibrils of Type b are most likely formed from 
two Type a species. The number of protofibrils in fibrils of Type b, c and d is 
estimated to be 2, 4, and 8, respectively. However, it cannot be excluded that 
some fibrils are formed from different numbers of protofibrils. As fibrils of 
Type c and e appear under most or even all pH conditions, it is reasonable to 
speculate that all fibrillar species share the same overall assembly pattern.  
3.5.3 Challenges and Further Results from the Time-Course 
Measurements 
The time-course measurements lead to important insights regarding the nature 
of the aggregates formed by GLP-1 and the changes in secondary structure 
during the aggregation process. However, especially under acidic conditions, it 
is evident that the removal of samples for the AFM and other measurements 
has an influence on the aggregation. Additionally, it cannot be excluded that 
the phosphate buffer shows different behaviour than the citrate buffer. While 
the aggregates formed in citrate or phosphate buffer were similar, the measured 
lag times showed some differences. These all make it more challenging to draw 
conclusions from the data collected under acidic conditions.  
The data recorded under neutral and basic conditions is, in contrast, more 
reliable. At pH 7.5, the secondary structure stays in the α-helical conformation 
during the whole lag phase, suggesting that off-pathway oligomers formed may 
have α-helical structure. In the basic regime, the secondary structure changes 
early from α-helical to β-sheet, this transformation happens even before the lag 
time and before any significant ThT signal was observed. These results suggest 
that an intermediate, non-fibrillar species which has considerable β-sheet 
content but which cannot bind to ThT is populated. 
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3.5.4 The Relationship Between Aggregation Propensity and pI 
and Net Charge 
The aggregation kinetics show that the lag time for fibril formation at pH 3.0-
3.5 varies between 5 and 30 h and the half times vary from 10-40 h, depending 
upon pH and peptide concentration, Figures 1.17 and 1.18. These values are 
comparable to those measured at pH 7.5-8.2. The approx. net charge GLP-1 
carries under these conditions is +3 to +4 at low pH, compared to -1 to -2 under 
slightly basic conditions. Despite having higher net charge values under acidic 
conditions, collectively, the results of the aggregation assays conducted at 
different pH values show that there is some symmetry in the behaviour, i.e., 
aggregation propensity, lag time and peptide concentration dependence, around 
the pI value of GLP-1. The simplest explanation of this phenomenon is that off-
pathway oligomers which affect the kinetics are populated close to the pI, i.e., 
under conditions where the net charge on the peptide is close to zero. It is 
interesting to note that at pH 6.5, the pH closest to the pI, GLP-1 appears to 
populate off-pathway species that do not convert into fibrils as no fibrils were 
detected either by ThT fluorescence or in AFM imaging.  
3.5.5 Conclusions  
In summary, the extensive study of GLP-1 presented here has led to a more 
detailed understanding of the aggregation kinetics of GLP-1 under several 
conditions. Starting from the observation that the unusual peptide concentration 
dependence of the aggregation kinetics is not restricted to neutral and basic 
conditions but can also be found under acidic conditions, it can be concluded 
that off-pathway oligomer formation occurs at pH 3.5, 6.5 and 7.5. Time-course 
studies at these pH values reveal the possible structure of these oligomers. As 
there were no observed changes in secondary structure during the lag phase and 
before there is any significant ThT fluorescence under these conditions, this 
suggests that this type of oligomer has α-helical structure. The pH range over 
which there is evidence of off-pathway oligomer formation suggests that off-
pathway oligomers are populated under conditions close to the pI of the peptide 
and therefore that net charge plays a significant role in determining the species 
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formed (on versus off-pathway oligomers) and therefore the rate of 
aggregation.  
Chapter 4: The Influence of C-terminal Amidation on the Physical Stability of GLP-1 
  127 
The physical stability of therapeutic peptides and proteins is of great 
importance as their physical instability, i.e., their tendency to self-associate into 
aggregated states, is a significant problem for the pharmaceutical industry. In 
previous work, it was shown that the kinetics of aggregation of GLP-1 depends 
critically on pH and that a switch in aggregation mechanism takes place over a 
narrow pH range near pH 3 to 3.5 and pH 7.5 to 8. This has been attributed to 
a change in mechanism from one in which on-pathway oligomers dominate, to 
one in which off-pathway oligomeric species become populated and drastically 
affect the kinetic behaviour.  
In this Chapter, a detailed study on the effect of C-terminal amidation on the 
physical stability of GLP-1 is undertaken. The purpose of this study is to assess 
the influence of chemical modification, in this case the amidation of the C-
terminus of a therapeutic peptide, on its physical stability. In comparison to 
other modifications, amidation represents a rather small change to the peptide 
and is often used in combination with other modifications. It is also found in 
4 THE INFLUENCE OF C-
TERMINAL AMIDATION ON THE 
PHYSICAL STABILITY OF GLP-1 
4.1 Introduction 
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naturally occurring peptides and, for some neuropeptides, amidation is crucial 
for their full biological activity.350 
Here, the physical stability of GLP-1 and GLP-1 amidated at the C-terminus 
(Am-GLP-1) are compared and the differences and similarities in their physical 
stability highlighted. The focus is on their behaviour at different pH values and 
the peptide concentration dependence of their aggregation kinetics. Numerous 
biophysical measurements including ThT assay, far-UV CD, SEM, ANS and 
tryptophan fluorescence were used to gain insight into the mechanism of 
aggregation into amyloid fibrils and the nature of species populated during 
fibrillation under different conditions. 
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RESULTS 
The molecular weight and purity of GLP-1 and Am-GLP-1 were determined 
using LC-MS measurements. The UV absorbance at 210 nm from the liquid-
chromatography step shows a single narrow peak for both peptides, Figures 
4.1A and 4.2A, indicating the samples have high purity. The same peak as 
observed with UV absorbance was observed in the total ion current (TIC) data, 
Figures 4.1B and 4.2B. However, both peptides also show additional smaller 
peaks at longer elution times. These observed ions do not absorb in the UV and 
are most likely hydrophobic in nature, hence the longer retention time. At the 
current time, the identity of these smaller peaks is not known, however, it is 
currently under investigation as part of a new PhD project within the Jackson 
group. 
From the mass spectrometry data, it is possible to calculate the molecular 
weight of the peptide from the measured m/z of the protonated peptide ions. 
The data shows that GLP-1 is mainly present as a +3 molecular ion (1119.42 
m/z). Minor peaks can also be seen for the +4 molecular ion (839.72 m/z), and 
+2 molecular ion (1678.91 m/z). From these data, the determined molecular 
weight of GLP-1 is 3355.3 ± 0.5 Da which is in agreement with the theoretical 
value of 3355.66 Da as well as the molecular mass of 3355.71 Da measured 
using electrospray ionisation-mass spectrometry reported by Bachem, Figure 
4.1. 
The mass spectrum of Am-GLP-1 is similarly to GLP-1 mainly present as a +3 
molecular ion (1119.1 m/z), Figure 4.2. The other peaks represent the +5 
molecular ion (671.87 m/z), +4 molecular ion (839.55 m/z), and +2 molecular 
ion (1678.43 m/z). The molecular weight determined is 3354.68 ± 0.5 Da which 
agrees with the theoretical value of 3354.68 Da as well as the relative molecular 
mass of 3354.93 Da obtained using electrospray ionisation-mass spectrometry 
by Bachem. 
4.2 Molecular Weight and Purity of GLP-1 and Am-
GLP-1 
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Figure 4.1. LC-MS of GLP-1. 
A) UV absorbance signal at 210 nm. The peak at 0.79 min is caused by the 
injection of the sample. It is influenced by the different percentage of 
acetonitrile in the sample in comparison to the LC gradient as well as the 
presence of salt in the sample. The x-axis is given in minutes. B) Total ion 
current (TIC) chromatogram. The x-axis is given in minutes. C) Mass 
spectrum of peak eluting at 2.59 min.  
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Figure 4.2. LC-MS of Am-GLP-1. 
A) UV absorbance signal at 210 nm. The peak at 0.79 min is caused by the 
injection of the sample. It is influenced by the different percentage of 
acetonitrile in the sample in comparison to the LC gradient as well as the 
presence of salt in the sample. The x-axis is given in minutes. B) Total ion 
current (TIC) chromatogram. The x-axis is given in minutes. C) Mass 
spectrum of peak eluting at 2.57 min.  
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The solubility of Am-GLP-1 was measured and compared to that of GLP-1, 
and significant differences were observed. GLP-1 shows a minimum in 
solubility around pH 4.5 whilst for Am-GLP-1 it is around pH 7.5, Figure 4.3A. 
The observed minimum in solubility for Am-GLP-1 is much broader than the 
one observed for GLP-1 and stretches from pH 5.0 to 8.5 in comparison to pH 
4.0 to 5.5 for GLP-1, Figure 4.3A. These differences are likely to be due to the 
difference in net charge as amidation results in the removal of the negative 
charge at the carboxy terminus at pH values above the pKa (2.3) of the C-
terminal glycine carboxyl group. Figure 4.3B shows the net charge of GLP-1 
and Am-GLP-1 at different pH values calculated using the Henderson-
Hasselbalch equation and standard pKa and pKb values for N- and C-terminus 
and ionisable side chains. The details of the calculation are shown in Section 
2.15 and Table 2.2. Ignoring other influences, such as changes in conformation, 
amidation of the C-terminus leads to a steady net charge difference of 1 
between GLP-1 and Am-GLP-1 at most pH values until below pH 2.3 when the 
C-terminus of GLP-1 becomes protonated and the two peptides have the same 
net charge. It is also clear that the net charge curve for the two peptides cuts the 
zero net charge line at different positions and with different slopes, Figure 4.3B. 
It means that the data predicts the net charge of GLP-1 to be within a range 
between ± 0.5 from approx. pH 5.0 to 6.0 in comparison to the wider range of 
pH 6.0 to 9.0 in the case of Am-GLP-1. This correlates well with the solubility 
data for GLP-1 and Am-GLP-1 shown in Figure 4.3A.  
The pI values of GLP-1 and Am-GLP-1, calculated theoretically using standard 
pKa values, are 5.4 and 7.6, respectively and can be compared to the values 
determined experimentally using imaged capillary isoelectric focussing 
(iCIEF) shown in Figure 4.3C. For GLP-1, a pI of 5.9 was determined, which 
is in good agreement to the theoretical value of 5.4. In the case of Am-GLP-1, 
the difference between the calculated pI of 7.6 and the measured value of 6.8 
is slightly larger. This difference may be due to the fact that Am-GLP-1 has a 
4.3 The Influence of C-terminal Amidation on Peptide 
Solubility 
Chapter 4: The Influence of C-terminal Amidation on the Physical Stability of GLP-1 
  133 
very broad minimum of net charge around the pI in comparison to GLP-1. 
Small alterations of the net charge, for example caused by changes in 
conformation, may therefore have a bigger influence on the pI. 
 
Figure 4.3. Solubility, net charge of Am-GLP-1 and GLP-1. 
A) Peptide concentration measured after dissolving approximately 0.2 mg in 
50 µL of buffer: GLP-1 (black closed circles) or Am-GLP-1 (grey closed 
squares). The open circles indicate a concentration of at least 1000 μM. The 
error bars show the standard deviation of three peptide concentration 
measurements. B) Calculated net charge versus pH based on the peptide 
amino-acid sequence and standard pKa values. Note the rather flat intersection 
of the net-charge curve of Am-GLP-1 and the zero value. C) pI measurement 
for Am-GLP-1 and GLP-1 using imaged capillary isoelectric focussing. 
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The aggregation kinetics of the GLP-1 peptides were measured using a ThT 
assay. In Figure 4.4A & B, two three-dimensional aggregation landscapes are 
shown which are composed of ThT data measured over time at different pH 
values between pH 3.0 and 8.7 and where the peptide concentration was kept 
constant at 75 μM. These data allow one to quickly visualise the aggregation 
propensity of GLP-1 and Am-GLP-1 over a wide range of pH values giving a 
broad overview of the influence of pH on the aggregation behaviour of both 
peptides. There is a strong correlation between the net charge and solubility of 
the peptides and their propensity to aggregate. GLP-1 shows a minimum in 
aggregation around its pI and, as net charge and solubility increases between 
pH 5.5 and 7.5, this results in a shortening of the lag times. Am-GLP-1 also 
shows a similar relationship between net charge, solubility and aggregation 
propensity and has a minimum of aggregation between pH 6.0 and 8.2, which 
corresponds to the range in which the net charge on the peptide is between +0.5 
and -0.5.  
Starting from these observations, four different pH values were chosen at which 
the aggregation of Am-GLP-1 was investigated in further detail. In particular, 
the effect of peptide concentration on the aggregation kinetics was measured 
thereby enabling us to compare it with our previously published data on GLP-
1.5 
 
4.4 The Peptides Have a Lower Aggregation Propensity 
Close to Their pI Values 
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Figure 4.4. Aggregation landscapes for GLP-1 and Am-GLP-1. 
A) ThT assays of peptide aggregation for GLP-1 at 75 µM from pH 3.0 to 8.7 
at 37 °C. The buffers are citrate (pH 3.0 - 6.0), phosphate (pH 6.5 - 7.5) and 
Tris (pH 7.7 – 8.7, 37 °C) with a buffer concentration of 25 mM. For each pH 
the results of triplicate runs are shown. The x-axis shows the pH value, z-axis 
time (h) and the y-axis ThT fluorescence (a.u.) where the signal between 0-
500 is blue, 500-1000 (red), 1000-1500 (green) and 1500-2000 (purple). B) 
ThT fluorescence for Am-GLP-1 at 75 µM from pH 3.0 to 8.7 at 37 °C. For 
each pH the results of triplicate runs are shown. The axes are the same as in 
Figure 4.3C. 
To learn more about the influence of the amidation of the C-terminus on the 
physical stability of GLP-1, kinetic aggregation assays were performed for Am-
GLP-1 at different peptide concentrations. The aggregation kinetics were 
monitored using ThT fluorescence and all measurements were run in triplicate 
4.5 Aggregation Kinetics of Am-GLP-1: Peptide 
Concentration Dependence 
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and the experiments repeated at least two times on different days. The pH 
values were chosen taking into account the previous ThT fluorescence 
measurements on Am-GLP-1 (Figure 4.3), as well as the previous 
measurements conducted on GLP-1 at pH 3.0, 3.5, 7.5 and 8.2, Figures 3.1 and 
1.17.5,351 
Four pH values, 3.0, 4.0, 8.2 and 8.7, were chosen and measurements were 
performed at six different peptide concentrations between 25-150 μM, Figure 
4.5A-D. In many cases, it was possible to describe and fit the ThT fluorescence 
data to a sigmoidal curve with a flat lag phase, a steep growth phase and a 
plateau. The kinetic parameters t1/2 and tlag were determined from a standard 
sigmoidal fit of the data to Equations 2.4 and 2.5, respectively.  
Figure 4.5A shows the ThT aggregation data for Am-GLP-1 in 25 mM citrate 
buffer at pH 3.0 and both the lag time and t1/2 decrease with increasing peptide 
concentration (Figure 4.6A & C) typical of a nucleation-polymerisation 
mechanism with predominantly on-pathway oligomers. It is interesting to note 
that at low peptide concentrations the data fit well to a sigmoidal function, 
however, at higher peptide concentrations the data fit less well.  
Data for Am-GLP-1 aggregation in citrate buffer at pH 4.0 are shown in Figure 
4.5B. Under these conditions, the lag time and t1/2 are independent of the 
peptide concentration, in contrast to the results obtained at pH 3.0. It is possible 
to explain these results by the population of off-pathway oligomeric species 
under these conditions,87 as has been shown for GLP-1 at pH 7.5.5 At pH 4.0, 
the ThT data shows some deviation from the standard sigmoidal behaviour. 
First, at low peptide concentrations, the growth phase of Am-GLP-1 shows two 
distinct regions – an initial very steep slope which changes to a slope that is 
less steep before the plateau region is reached, Figure 4.5E. In addition, at 
higher peptide concentrations, a linear increase in the baseline within the lag 
phase was observed before it changes over to the typical sigmoidal growth 
phase, Figure 4.5F. At intermediate peptide concentrations the aggregation can 
alternate between the two types of behaviour leading to a higher variance 
between runs, Figure 4.5B, than seen at pH 3.0. 
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Figure 4.5. ThT aggregation assays of Am-GLP-1 at different peptide 
concentrations and pH values.  
All samples were measured at the following peptide concentrations: 25 µM 
(pink), 50 µM (orange), 75 µM (blue), 100 µM (dark blue), 125 µM (green), 
and 150 µM (dark green). The data were fitted with Equation 2.4, the best fits 
are shown by the solid lines. All experiments performed at 37 °C. A) Am-
GLP-1 in 25 mM citrate buffer at pH 3.0 B) Am-GLP-1 in 25 mM citrate 
buffer at pH 4.0. C) Am-GLP-1 in 25 mM Tris buffer at pH 8.2. D) Am-GLP-
1 in 25 mM Tris buffer at pH 8.7. E) 25 µM Am-GLP-1 at pH 4.0 in detail. F) 
150 µM Am-GLP-1 at pH 3.0 and 4.0 in detail. 
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Figure 4.6. Kinetic parameters from the aggregation kinetics of GLP-1 and Am-
GLP-1. 
The parameters were determined at six different peptide concentrations 
between 25 – 150 µM. The error bars show the standard deviation. A) and C) 
t1/2 and tlag of GLP-1 at pH 3.0 (red open triangles) and pH 3.5 (orange open 
circles) as well as Am-GLP-1 at pH 3.0 (red closed triangles) and pH 4.0 
(green closed hexagons). All samples in 25 mM citrate buffer. B) and D) t1/2 
and tlag of GLP-1 at pH 7.5 in phosphate buffer (green open triangles) and Tris 
at pH 8.2 (dark blue open squares) as well as Am-GLP-1 at pH 8.2 (dark blue 
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Figure 4.7. Apparent growth rate results. 
A) Apparent growth rate (k) of GLP-1 at pH 3.0 (red open triangles) and pH 
3.5 (orange open circles) as well as Am-GLP-1 at pH 3.0 (red closed triangles) 
and pH 4.0 (green closed hexagons). All samples in 25 mM citrate buffer. B) 
Apparent growth rate (k) of GLP-1 at pH 7.5 in phosphate buffer (green open 
triangles) and Tris at pH 8.2 (dark blue open squares) as well as Am-GLP-1 at 
pH 8.2 (dark blue closed squares) and pH 8.7 (blue closed diamonds). Error 
bars show the standard deviation between triplicate runs for Am-GLP-1.  The 
apparent growth rates are taken from the sigmoidal fit of the aggregation 
kinetics shown in Figure 4.5A-D. For GLP-1, the apparent growth rates were 
measured by Dr Karolina Zapadka.
5
 
The data for Am-GLP-1 at pH 8.2 and 8.7 are shown in Figure 4.5C and D, 
respectively. At pH 8.2, the kinetic data are typical of a nucleation-
polymerisation mechanism where lag time decreases with increasing peptide 
concentration up to a concentration of 100 µM. Above this concentration an 
increase in t1/2 and lag time with increasing peptide concentration is observed, 
Figure 4.6C & D. The shape of the ThT fluorescence data can be described by 
a sigmoidal curve with a slight linear increase in fluorescence in the final 
plateau region. The lag phase itself is completely flat and does not show any 
increase in fluorescence before the growth phase, Figure 4.5C. At the most 
basic pH measured, pH 8.7, the variation of the data between runs is 
pronounced, Figure 4.6C & D.  
The variation of the apparent growth rate with peptide concentration is 
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less than threefold and there is no real trend with peptide concentration, Figure 
4.7. Some higher variations in the apparent growth rates are seen for Am-GLP-
1 at pH 4.0 and 8.7, but, under these conditions, there are larger standard 
deviations in these values due to pronounced variations between runs, Figure 
4.7A & B. 
 
Table 4.1. Kinetic parameters from the sigmoidal fits of the Am-GLP-1 ThT assay 
data shown in Figures 4.5 and 4.6. 
SD is the standard deviation.  
At pH 3.0, the observed variance between triplicate runs for Am-GLP-1 is low, 
however, at higher pH values it increases such that by pH 8.2 the variation is 
significant and at pH 8.7 it is pronounced, Figures 4.5 and 4.6. The possibility 
that the increase in variance is caused by impurities in the peptide preparations 
can be excluded because the same batch of peptide is used for all pH values. 
The large variance is associated with longer lag times,352 conditions which 
favour the population of off-pathway oligomers.  
pH 3.0 pH 4.0 pH 8.2 pH 8.7
Conc. (µM) t 1/2 (h) SD t 1/2 (h) SD t 1/2 (h) SD t 1/2 (h) SD
25 19.0 0.0 9.4 0.2 126.0 0.0 115.3 7.2
50 18.2 0.5 8.3 0.3 82.2 12.6 111.3 32.4
75 13.6 0.4 10.0 0.3 60.3 2.2 91.5 34.6
100 14.2 0.2 11.0 0.3 73.0 1.7 84.8 41.2
125 13.6 0.1 9.8 0.6 100.9 7.7 82.0 17.8
150 11.8 0.5 10.1 0.1 109.6 14.0 70.3 5.5
Conc. (µM) t lag (h) SD t lag (h) SD t lag (h) SD t lag (h) SD
25 14.7 0.1 7.6 0.2 115.7 0.0 108.9 8.5
50 13.9 0.6 6.4 0.3 68.8 15.5 106.2 35.1
75 9.7 0.5 7.7 0.2 51.9 3.5 85.0 35.7
100 10.2 0.2 5.7 0.5 64.1 1.8 78.8 43.2
125 8.2 0.3 6.0 0.9 90.6 8.1 74.4 16.9
150 7.6 0.3 8.3 0.1 100.2 16.8 62.7 6.9
Conc. (µM) k  (h-1) SD k  (h-1) SD k  (h-1) SD k  (h-1) SD
25 0.47 0.01 1.10 0.05 0.19 0.00 0.32 0.07
50 0.47 0.02 1.07 0.07 0.16 0.04 0.46 0.19
75 0.52 0.01 0.88 0.07 0.24 0.05 0.31 0.06
100 0.50 0.01 0.38 0.05 0.24 0.07 0.37 0.15
125 0.37 0.01 0.57 0.24 0.20 0.02 0.27 0.04
150 0.48 0.02 1.15 0.08 0.23 0.06 0.27 0.05
4.6 The Variance Between Triplicate Runs Increases 
with Lag Time 
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An additional analysis of the ThT assay data of Am-GLP-1 and previously 
published data of GLP-15 was performed by normalising the data and fitting it 
to an analytical approximation of a nucleated-polymerisation and elongation 
model with fragmentation (NEF) as a secondary nucleation mechanism, 
Equation 2.6.83,353,354 It is assumed that there is no fibril seeding and the 
complete peptide concentration is monomeric at the beginning of the reaction. 
In Equation 2.6, δ and κ represent the effective rate for nucleated 
polymerisation without secondary pathways (primary nucleation) and the rate 
of multiplication of the filament population (secondary nucleation), 
respectively, Section 2.9.3. Both δ and κ are not individually linked to one 
specific physical process or step in the reaction mechanism but are instead the 
product of several different steps. The primary nucleation rate, δ, is related to 
the size of the nucleus, the primary nucleation and elongation rates, as well as 
dependent upon the total peptide concentration, Equation 2.7. In comparison, 
the secondary nucleation rate, κ, is related to the primary nucleation rate and 
the fragmentation rate constant, in addition to being dependent upon the total 
peptide concentration, Equation 2.8. These relationships are the direct 
consequence of the solution of a Master equation based on physical 
principles.83,353,354 
For Am-GLP-1 and GLP-1, at all four pH values studied, it was not possible to 
fit the data globally using datasets acquired at different peptide concentrations 
using constant primary and secondary nucleation rates. Therefore, the data for 
each peptide concentration were fitted separately to Equation 2.6, Figures 
4.8A-D and 4.9A-D.  
4.7 Additional Analysis of Kinetic Aggregation Data 
Using a Nucleated-Polymerisation Model 
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Figure 4.8. Fits of Am-GLP-1 ThT data to the NEF model.  
All samples were measured at the following peptide concentrations: 25 µM 
(pink), 50 µM (orange), 75 µM (blue), 100 µM (dark blue), 125 µM (green), 
and 150 µM (dark green) and all experiments performed at 37 °C. The data 
were normalised and fitted using Equation 2.6. The model is based on 
nucleation, elongation and fragmentation steps. The best fits are shown by the 
solid lines. All fits showed high R
2
 values with the vast majority showing 
values above 0.97. A) Am-GLP-1 in 25 mM citrate buffer at pH 3.0 B) Am-
GLP-1 in 25 mM citrate buffer at pH 4.0. C) Am-GLP-1 in 25 mM Tris buffer 
at pH 8.2. D) Am-GLP-1 in 25 mM Tris buffer at pH 8.7.  
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Figure 4.9. Fits of GLP-1 ThT data to the NEF model.  
The original data were acquired by Dr Karolina Zapadka. All samples were 
measured at the following peptide concentrations: 25 µM (pink), 50 µM 
(orange), 75 µM (blue), 100 µM (dark blue), 125 µM (green), and 150 µM 
(dark green) and all experiments performed at 37 °C. The data were 
normalised and fitted using Equation 2.6. The model is based on nucleation, 
elongation and fragmentation steps. The best fits are shown by the solid lines. 
All fits showed high R
2
 values with the vast majority showing values above 
0.97. A) Am-GLP-1 in 25 mM citrate buffer at pH 3.0 B) Am-GLP-1 in 25 
mM citrate buffer at pH 4.0. C) Am-GLP-1 in 25 mM Tris buffer at pH 8.2. 
D) Am-GLP-1 in 25 mM Tris buffer at pH 8.7. 
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The primary nucleation rates,	r,	of Am-GLP-1 are shown in Figure 4.10A & B. 
r varies tenfold across pH values for both GLP-1 and Am-GLP-1, but they vary 
differently with pH. For Am-GLP-1, there is a clear difference in the rates 
between the samples at acidic and basic pH values. The longer lag times 
observed under basic conditions are the result of small r values at basic pH 
values in comparison to the acidic samples. Consistent with the decrease in the 
lag time at pH 3.0 with increasing peptide concentration, the primary nucleation 
rate r increases with increasing peptide concentration. In contrast, at pH 4.0 
the values are approximately constant and independent of peptide 
concentration. 
The values of the secondary nucleation rate, k, calculated for Am-GLP-1 at all 
pH values are similar, Figures 4.10C and 4.11B. The values are closely related 
to the steepness of the apparent growth phase in the ThT data. Although some 
trends can be observed between k and peptide concentration, for example, k 
increases with increasing peptide concentration at pH 3.0, in general the errors 
associated with k are large and it can be considered to be generally independent 
of peptide concentration. At pH 8.2, the secondary nucleation rate is lower than 
it is for the acidic samples.  
For Am-GLP-1, particularly large variations in d and k were calculated at pH 
8.7, Figures 4.10C and 4.11A. This may be due to the variance in the maximum 
ThT signal, Figure 4.5D, which the method assumes is equivalent to the amount 
of peptide in a fibrillar form capable of binding ThT. The primary nucleation 
rate even showed negative values at a peptide concentration between 25 and 50 
µM which is theoretically not possible but caused by the slight negative slope 
of the initial baseline in the ThT data, Figure 4.8D. The negative values of the 
primary nucleation rate are the reason why the data points at 25 and 50 µM 
disappear in a log-linear plot, Figure 4.11A. 
As with the Am-GLP-1 data, the data for GLP-15,351 at each pH value and 
peptide concentration were fitted individually to Equation 2.6. Figure 4.9 
shows the best fit of the ThT data to Equation 2.6, whilst the parameters d and 
k from the analysis are shown in Figure 4.10B and D, respectively. The range 
of values of d for GLP-1 are similar to Am-GLP-1 but the pH dependence 
differs. However, some similarities with the Am-GLP-1 data were observed: d 
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increases with peptide concentration at pH 3.0. At other pH values, d is 
relatively independent of peptide concentration.  
 
Figure 4.10. Kinetic parameters from the aggregation kinetics of the NEF model of 
GLP-1 and Am-GLP-1. 
The parameters were determined at six different peptide concentrations 
between 25 – 150 µM. The error bars show the standard deviation of a 
triplicate measurement. A) Linear plot of the primary nucleation rates, the 
effective rate for nucleated polymerisation without secondary pathways of 
Am-GLP-1 at pH 3.0 (red closed triangles), 4.0 (green closed hexagons), 8.2 
(dark blue closed squares) and 8.7 (blue closed diamonds). B) Linear plot of 
the primary nucleation rates, the effective rate for nucleated polymerisation 
without secondary pathways of GLP-1 at pH 3.0 (red open triangles), 3.5 
(orange open circles), 7.5 (green open triangles) and 8.2 (dark blue open 
squares). C) Linear plot of the secondary nucleation rates i.e., the rate of 
multiplication of the filament population of Am-GLP-1. D) Linear plot of the 
secondary nucleation rates i.e., the rate of multiplication of the filament 
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Figure 4.11. Primary and secondary nucleation rates for Am-GLP-1 ThT data fitted 
to the NEF model.  
A) Log-linear plot of the primary nucleation rates, the effective rate for 
nucleated polymerisation without secondary pathways. B) Linear-log plot of 
the secondary nucleation rates i.e., the rate of multiplication of the filament 
population. The data is shown for pH 3.0 (red closed triangles), pH 4.0 (green 
closed hexagons), pH 8.2 (dark blue closed squares) and pH 8.7 (blue closed 
diamonds). The error bars show the standard deviation of a triplicate 
measurement. 
The pH dependence of k is different for GLP-1 and Am-GLP-1. However, the 
values are in the same range. The data for GLP-1 at pH 3.5 and 7.5 does appear 
to show a decrease of k with increasing peptide concentration suggesting that 
off-pathway events are happening, Figure 4.12. Here too, the error bars are 
large, but the trend appears to be real. 
The analysis of the ThT-assay data of GLP-1 and Am-GLP-1 shows that, if the 
aggregation kinetics are following a NEF-model, the primary (d) and secondary 
(k) nucleation rates vary with pH as expected. Similar it shows that some of the 
aggregation parameters like the size of the nucleus, primary nucleation, 
elongation and fragmentation rates are under most conditions peptide 
concentration-independent because, under specific conditions, constant d and 
k values have been observed with increasing peptide concentration.17,274 
However, under some conditions, a decrease of k was detected with increasing 
peptide concentration. 
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Figure 4.12. Primary and secondary nucleation rates for GLP-1 ThT data fitted to 
the NEF model.  
A) Log-linear plot of the primary nucleation rates, the effective rate for 
nucleated polymerisation without secondary pathways. B) Linear-log plot of 
the secondary nucleation rates i.e., the rate of multiplication of the filament 
population. The data are shown for pH 3.0 (red open triangles), pH 4.0 
(orange open circles), pH 8.2 (green open triangles) and pH 8.7 (dark blue 
open squares). GLP-1 data reanalysed from Zapadka et al.5 The error bars 
show the standard deviation of a triplicate measurement. 
It is well-established that the kinetics of aggregation of a system that follows a 
nucleation-propagation mechanism is monomer concentration dependent with 
higher peptide concentrations leading to a decrease in the lag time. That is why 
the measured peptide concentration dependence for Am-GLP-1 at pH 4.0, pH 
8.2 and pH 8.7 (37 °C), where the lag time is constant or even increases with 
peptide concentration, are so unusual. It has been suggested that this behaviour 
is due to the population of off-pathway oligomers.5 Here, a mathematical proof 
that the population of off-pathway oligomers cannot lead to an increase in the 
lag time with increasing peptide concentration is presented.  
 
4.8 General Solution to Predict the Maximum Influence 
of Off-Pathway Species on Monomer Concentration 
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Assuming that the presence of off-pathway oligomers populated during the 
aggregation reaction affects the monomer concentration [M], the degree to 
which the off-pathway species reduce the effective monomer concentration can 
be estimated. It is possible to show that for two different monomer starting 
concentrations [M1]0 and [M2]0, where [M2]0 > [M1]0, it is true that at every 
time point the concentration [M2](t) > [M1](t). This means that the 
concentration of monomers accessible to the on-pathway process is at any time 
always higher in case of [M2] than [M1]. Mathematically, this becomes clear if 
the condition [M2]0 > [M1]0 is inserted into the integrated rate law (Equation 
4.2), which leads to the Inequation 4.3. 




= [u]E (4.1) 










E0* + QS <
1
[u*]#
E0* + QS (4.3) 
Following Inequation 4.3, [M2](t) is always bigger than [M1](t) if the reaction 
follows the same rate equation and [M2]0 > [M1]0. It is also independent of the 
order of the reaction. However, when off-pathway species exist then the 
amount of monomer available is reduced compared to the amount of monomer 
that would be populated in the absence of off-pathway oligomers.  
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Because ThT assays provide indirect evidence of fibrillation, scanning electron 
microscopy (SEM) was used to verify that amyloid-like fibrils of Am-GLP-1 
were formed, as well as to gain information on their morphology.  
4.9.1 SEM Control Measurements of Pure Buffer  
To be able to differentiate between artefacts caused by the buffer or the 
deionised water used for rinsing and peptide aggregates, controls were 
undertaken where a glass sheet with buffer only on it was subsequently dried 
and imaged. Exactly the same method was used as for the protein samples: the 
samples containing buffer were allowed to dry exactly like the peptide samples, 
they were also rinsed with deionised water and subsequently dried with a gentle 
stream of nitrogen.  
For all three buffer samples, white round deposits can be observed at lower 
magnifications, Figures 4.13A, 4.14A and 4.15A. These deposits consist of 
crystal-like species on the glass sheet as seen for phosphate buffer at pH 3.0, 
Figure 4.13B and C, or similar crystal-like, sharp but randomly distributed 
fragments as imaged for phosphate buffer at pH 4.0, Figure 4.14C and D, or 
Tris buffer at pH 8.2 (37 °C), Figure 4.15D. It is most likely that these 
fragments are caused by salt residues from the dried buffers. Images without 
deposits (the uncovered region of the glass microscopy sheet surface) are 
shown at different magnifications in Figures 4.13D, 4.14B and 4.15B and C. 
Typically some thin scratches in the glass sheet can be seen. 
 
4.9 Fibril Morphology and Higher Structures 
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Figure 4.13. SEM images of phosphate buffer at pH 3.0.  
The preparation of the samples was exactly the same as for the peptide 
samples. A) Image at lower magnification shows white deposits and 
uncovered areas. B and C) Typical images of the deposits seen in Figure 
4.13A at different magnifications. D) Images showing the uncovered surface 
of the glass microscopy slide at a higher magnification.  
Chapter 4: The Influence of C-terminal Amidation on the Physical Stability of GLP-1 
  151 
 
Figure 4.14. SEM images of phosphate buffer at pH 4.0.  
A) Image at lower magnification shows the white deposits and uncovered 
areas. B) Image showing the uncovered surface of the glass microscopy sheet 
at higher magnification. C and D) Typical images of the deposits seen in 
Figure 4.14A at different magnifications.  
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Figure 4.15. SEM images of Tris buffer at pH 8.2.  
pH value measured in solution at 37 °C A) Image at lower magnification 
shows the white deposits and uncovered areas. B and C) Images showing the 
uncovered surface of the glass microscopy sheet at different magnifications. 
D) Typical image of the deposits seen in Figure 4.15A at high magnification.  
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4.9.2 Fibril Morphology and Higher-Order Structure Varies with 
pH 
Samples of Am-GLP-1 at four different pH values, at the end of the ThT 
aggregation assay, were imaged in three different ways. First, 5 µL of a sample 
of 150 µM of aggregated Am-GLP-1 was allowed to dry on a microscopy glass 
sheet. The first spot that was imaged was chosen in a region where there was 
dense fibril cover. Further images were then taken directly next to the dense 
fibril cluster where the density of packing was not as high and therefore it was 
easier to observe single fibrils. In addition, a second 5 µL sample was placed 
onto an additional glass sheet where it was left for 2 mins before it was gently 
blown away with nitrogen. This has the advantage that it prevents a high 
concentration of fibrils covering any other aggregates that might be present. It 
can, however, favour aggregated species that adhere faster to the glass surface. 
Typical images of aggregates of Am-GLP-1 formed at pH 3.0, 4.0, 8.2 and 8.7 
at 37 °C using the first two methods are shown in Figures 4.16A-D and 4.17A-
D, whilst images recorded after the samples were blown dry with nitrogen are 
shown in Figure 4.18. The SEM images of Am-GLP-1 aggregates were 
analysed in detail using Fiji (Figures 4.19, 4.20 and 4.21), an image processing 
package based on ImageJ2. It is worth noticing that SEM imaging does not 
enable the measurement of the height of the samples. Therefore, the analysis is 
restricted to distance measurement based on the grey scale of the sample 
images. Additionally, it is essential to keep in mind that SEM samples have 
been coated with a 10 nm thick platinum layer. 
At pH 3.0, in the most densely covered region, most fibrils are parallel to each 
other and longer than 2 µm, Figure 4.16A. A few short fibrils are misaligned 
and spread over the surface in a disordered way. The width of the fibrils is 21 
± 3 nm. In the less densely covered region two different, straight, slightly 
thicker (width: 42 ± 3 and 61 ± 3 nm), 200-900 nm long fibrils are observed, 
Figure 4.16B. There are also some shorter fragments with a length of 50-300 
nm and 26 ± 4 nm width, which are randomly distributed.  
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Figure 4.16. SEM images of aggregated forms of Am-GLP-1 under acidic 
conditions. 
After 144 h of incubation time in the plate reader at 37 °C, 5 µL of 150 µM 
sample were pipetted on to a glass microscopy sheet and subsequently dried. 
All images have the same magnification. A & B) Am-GLP-1 aggregated in 
25 mM citrate buffer at pH 3.0. C & D) Am-GLP-1 aggregated in 25 mM 
citrate buffer at pH 4.0. The images show the most typical of those obtained. 
A & C) show images of regions where there is a high local concentration of 
fibrils (Region 1). B & D) show images of less densely populated regions of 
the surface (Region 2). B) Three different types of fibrils were observed and 
analysed. These are indicated by coloured arrows (I blue, diameter approx. 
26 nm, II orange, diameter approx. 42 nm, and III, green, diameter approx. 
61 nm) D) Typical fibril class I (blue arrow, diameter approx. 22 nm) and 
oligomeric structure O (orange arrow, diameter between 10 - 50 nm). 
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Figure 4.17. SEM images of aggregated forms of Am-GLP-1 under basic conditions. 
After 144 h of incubation time in the plate reader at 37 °C, 5 µL of 150 µM 
sample was pipetted on to a glass microscopy sheet and subsequently dried. 
All images have the same magnification. A & B) Am-GLP-1 aggregated in 
Tris buffer at pH 8.2. C & D) Am-GLP-1 aggregated in Tris buffer at pH 8.7. 
The images show the most typical of those obtained. A & C) show images of 
regions where there is a high local concentration of fibrils (Region 1). B & 
D) show images of less densely populated regions of the surface (Region 2). 
B) Three different types of fibrils are observed and were analysed (I/II/III). 
These are indicated by coloured arrows (I blue, diameter approx. 20 nm, II 
orange, diameter approx. 24 nm, and III, green, diameter approx. 30 nm). D) 
Fibrils type I (blue, diameter approx. 31 nm) and II (orange, diameter approx. 
76 nm). 
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Figure 4.18. SEM images of aggregated forms of Am-GLP-1 samples dried with 
nitrogen. 
After 144 h of incubation time in the plate reader at 37 °C, 5 µL of 150 µM 
sample were pipetted on to a glass microscopy sheet and the drop was blown 
away with a gentle nitrogen stream after 2 min on the surface. Different types 
of analysed aggregates are marked with an arrow. All panels are at the same 
magnification. Different species are labelled and indicated with arrows. A) 
Am-GLP-1 aggregated in 25 mM citrate buffer at pH 3.0. Typical fibril type 
I indicated with a blue arrow (diameter approx. 20 nm). B) Am-GLP-1 
aggregated in 25 mM citrate buffer at pH 4.0. Fibrils type I (blue, diameter 
approx. 22 nm), oligomer-like aggregates are marked O in orange and 
amorphous aggregates marked A in green. C) Am-GLP-1 aggregated in Tris 
buffer at pH 8.2. Amorphous aggregates marked A in green. D) Am-GLP-1 
aggregated in Tris buffer at pH 8.7. Fibril type I (blue, diameter approx. 53 
nm) and circular oligomer O (orange, diameter approx. 70 nm) are marked.  
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Figure 4.19. Width or diameter of Am-GLP-1 fibrils and oligomers determined 
using grey scale profiles. 
The grey scale profiles were analysed using Fiji. A) A typical example of 
grey scale profiles to determine the widths of fibrils. Am-GLP-1 incubated 
at pH 8.2 at 37 °C. B) Grey scale profiles of two circular or ring-like 
oligomers. For each oligomer three profiles at three different angles were 
taken. The profiles of Oligomer A and B are shown in blue and grey, 
respectively. Am-GLP-1 incubated at pH 8.7 at 37 °C. C) Width or diameter 
of eleven different aggregate types as observed in Figures 4.16, 4.17 and 
4.18. 
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Figure 4.20. Measurement of major and minor axis of Am-GLP-1 oligomers formed 
in 25 mM citrate buffer at pH 4.0. 
A) Binary image of Figure 4.16D. B) Histogram of the oligomer major axis 
size distribution. To avoid counting fibril fragments, only aggregates with a 
circularity value higher than 0.5 were considered. The distribution follows a 
Gaussian with a mean value of 18.5, a standard deviation of 9.1 and R
2
 = 
0.93. C) Relation between minor and minor axis of the detected oligomers.  
For the nitrogen-dried samples, thin fibrillar species (approx. diameter 19 ± 2 
nm, within error of that measured for the type I fibrils observed in the earlier 
experiment), can be seen. These are approx. 200-500 nm in length, Figure 
4.18A. Overall, at pH 3.0, it appears as if high concentrations of fibrils of Am-
GLP-1 have a tendency to stick to each other, as shown by the fibrils with 
diameters which are twice and three times the size of the thinnest fibrils 
observed.  
The morphology of Am-GLP-1 fibrils at pH 4.0 shows different patterns. In 
regions of high coverage, the fibrils are dense but form a randomly distributed 
mesh appearing sponge-like, with little holes in between, which consists of 15-
25 nm thick and 30-200 nm long fibrils, Figure 4.16C. Smaller oligomers with 
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a diameter of 10	-	45 nm (Figure 4.20A-C) and some longer thin fibrils (22 ± 
3 nm wide and 500-1000 nm long) were typically found next to the thick patch 
of fibrils, Figure 4.16D.   From the analysis, it becomes clear that the oligomers 
are not perfectly round as the minor and major axis lengths stand in a relation 
of approximately 0.35, Figure 4.20C. For the nitrogen-dried sample, similar 
thin fibrils were observed as well as oligomer-like species and larger 
aggregates, Figure 4.18B. 
At pH 8.2, the image taken in the region with high fibril coverage shows that 
the fibrils appear to organise into bundles (Figure 4.17A). In less densely 
covered regions, the fibrils can be seen more easily and are twisted. 
At least two different species have been measured, which are either 24 ± 1 nm 
or 30 ± 2 nm thick. The total length of one turn of the thinner fibril is slightly 
shorter than 200 nm, whereas the thicker fibril turns with a periodicity of 85 ± 
10 nm, Figure 4.21. Most of these fibrils are longer than 2 μm and, therefore, 
longer than those formed under acidic conditions, Figure 4.17B.  
 
Figure 4.21. Grey scale profiles along Am-GLP-1 fibrils. 
A) Am-GLP-1 fibrils formed in 25 mM Tris buffer at pH 8.2 (37°C). B) Grey 
scale profiles of curly fibrils II (grey) and III (blue) along their longitudinal 
axis. They show a turn length of 85 ± 10 nm (grey) and slightly less than 200 
nm (blue) which has been measured using the distance of the maximum 
amplitudes.  
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There are also some thin (width: 20 ± 1 nm), slightly curved fibrils, which are 
shorter than 100 nm, Figure 4.16B. The image of the sample dried with nitrogen 
shows a high number of oligomer-like species or really short fibril fragments 
which are not thicker than 10 nm and only 20-40 nm long. Some of them appear 
to arrange into larger clusters with a width up to 200 nm, Figure 4.18C. 
Fibrils of Am-GLP-1 formed at pH 8.7 appear to be similar in terms of length 
and width to those obtained at pH 8.2. They appear, however, slightly less rigid 
and allow covered fibrils to trace through the top layer of fibrils especially if 
they cross each other as shown in Figure 4.17C. In the less dense region, Figure 
4.17D, they also form bundle-like structures with a width of 50-200 nm that are 
mostly longer than 500 nm. Donut-like shaped oligomers with a diameter of 70 
± 4 nm can be seen in the nitrogen-dried sample shown in Figures 4.18D and 
4.19B.  
The SEM pictures of Am-GLP-1 show the whole complexity of the aggregation 
reaction and the different higher-order structures that can be formed at different 
pHs. Two other main observations are striking. First, the images taken from 
glass sheets on which the sample drop was blown away after 2 min show 
differences in the ability of different species to stick to the glass surface. Am-
GLP-1 aggregated under acidic conditions shows fibrils sticking to the glass 
sheet within two minutes, Figure 4.18A & B, whereas both glass sheets covered 
with sample aggregated under basic conditions, Figure 4.18C & D, did not 
show fibrils after the two minutes but instead had oligomers covering the 
surface. This is possibly driven by the different net charge on the peptide and 
therefore on the aggregated species formed under acidic and basic conditions. 
Second, only samples with dominant off-pathway species populated during 
aggregation, as shown by the aggregation kinetics, show significant amounts 
of oligomeric species, as is the case of Am-GLP-1 at pH 4.0, 8.2 and 8.7 
(Figures 4.16D and 4.18C, D). 
In our previous study, aggregates of GLP-1 were imaged using atomic force 
microscopy.5,351 Similar results were obtained, with the most common fibrils 
forming structures around 15-25 nm in width or multiples of this. The results 
of the SEM data for Am-GLP-1 reported here and the previously published 
AFM data for GLP-1 are summarised in Table 4.2 and Table 3.2, respectively. 
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pH Region 1 Region 2 Nitrogen dried 
3.0 Fibrils  
width 15-25 nm 
length: > 2000 nm 
Fibrils a)  
width: 26 ± 3 nm 
length: 50-300 nm 
fragmented, straight 
Fibrils b/c)  
width: 42 ± 3 / 61 ± 3 
nm 
length: 200-900 nm 
straight 
Fibrils  
width: 19 ± 2 nm 
 
4.0 Fibrils  
width: 15-25 nm 
length: 30-200 nm 
spongy / cavernous / 
porous 
Oligomers 
diameter: 10-45 nm 
Mean value of major 
axis: 19 ± 9 nm 
Fibrils 
width: 22 ± 3 nm 
length: 500-1000 nm 
Oligomer like dots  
diameter: 8-15 nm 
Fibrils 
width: 22 ± 3 nm 
length: > 500 nm 
8.2 Fibrils  
width: 15-25 nm 
length: >2000 nm 
twisted 
Fibrils a)  
width: 20 ± 1 nm 
length: < 100 nm 
straight 
Fibrils b/c)  
width: 24 ± 1 / 30 ± 2 
nm 




width: 10 nm thick 
length: 20-40 nm 
Bigger clusters 
consisting out of the 
fragments 
diameter: < 200 nm 
8.7 Fibrils  
width: 15-25 nm 
length: > 2000 
twisted, similar to pH 
8.5 but they seem to 
break more easily in 
general or during the 
drying process 
especially if they cross 
other fibrils 
Fibril bundles 
width: 50 - 200 nm 
length: > 500 nm 
slightly twisted 
Oligomers 
diameter: 70 ± 4 nm 
Donut shaped 
Fibrils  
width: 53 ± 4 nm 
Table 4.2. Description of Am-GLP-1 aggregates imaged by SEM 
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The results from SEM imaging showed that Am-GLP-1 forms different high-
order structures at different pH values. For a deeper insight into these 
structures, ANS and tryptophan fluorescence experiments were conducted for 
both peptides to probe whether a) hydrophobic patches are exposed and b) the 
environment around the tryptophan, in the aggregates. 
ANS is known to bind to hydrophobic patches in proteins and peptide 
aggregates and increase its fluorescence.350 Immediately after the peptide was 
dissolved and the sample filtered, the ANS fluorescence signal is low, Figure 
4.22A. The same samples measured after 144 h of incubation at 37 °C are 
shown in Figure 4.22B. All basic and neutral samples show no change after 
aggregation, however, all four acidic samples show a clear increase in 
fluorescence signal indicative of ANS binding. This suggests that under acidic 
conditions species are formed which have hydrophobic patches exposed and 
binding of ANS is favourable. It is possible that the different results obtained 
at acidic versus neutral/basic pH may be due to the difference in the net charge 
of the peptides under these conditions. ANS, which is negatively charged, 
binding is likely to be more favourable to peptide aggregates at low pH values 
where the peptide is positively charged under the conditions. Thus, it is difficult 
to be quantitative about the relative amounts of aggregated species with 
exposed hydrophobic patches present at different pH values. Interpretation of 
these data is also not straightforward as, although it is frequently assumed that 
ANS binds specifically to oligomers, experiments shown in Section 4.11 show 
that it also binds to fibrils under certain conditions.  
 
The tryptophan fluorescence data shows that, before the aggregation assay, the 
signals of all samples are similar with a wavelength of maximum fluorescence 
(lmax) around 350 nm, Figures 4.22C & D and 4.23. At pH 3.0 and 4.0, the 
wavelength of maximum fluorescence changes from 350 to 335 nm over the 
time course of aggregation compared to a much smaller change from 350 to 
345 nm at pH 8.2 and 8.7, Figure 4.23. A shorter wavelength for #max is known 
4.10 Conformational Differences Between Aggregates 
Formed Under Acidic and Basic Conditions 
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to indicate that the tryptophan is more buried and has less contact with the 
aqueous solvent.355 
 
Figure 4.22. ANS and Trp fluorescence of Am-GLP-1 and GLP-1 before and after 
aggregation 
ANS binding and tryptophan (Trp) assay of 150 µM Am-GLP-1 and GLP-1 
samples at room temperature. Am-GLP-1 incubated at 37 °C in citrate buffer 
at pH 3.0, citrate buffer pH 4.0, Tris buffer at pH 8.2 and Tris buffer at pH 
8.7. GLP-1 incubated at 37 °C in citrate buffer at pH 3.0, citrate buffer at pH 
3.5, phosphate buffer at pH 7.5 and Tris buffer at pH 8.2. The pH of the Tris 
buffers used during the fluorescence measurements changed from pH 8.2 to 
8.5 and pH 8.7 to 9.0 because of the temperature change from 37 °C 
(aggregation assay) to room temperature (spectroscopic analysis). The buffer 
concentration was 25 mM. A) ANS fluorescence of Am-GLP-1 and GLP-1 
samples before the aggregation assay. B) ANS fluorescence of Am-GLP-1 
and GLP-1 samples after aggregation. C) Trp fluorescence of Am-GLP-1 and 
GLP-1 samples before the aggregation assay. D) Trp fluorescence of Am-
GLP-1 and GLP-1 samples after aggregation. 
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Figure 4.23. Tryptophan fluorescence: shift in lmax after aggregation 
λmax of tryptophan fluorescence of Am-GLP-1 and GLP-1 before and after 
the aggregation assay, Figure 4.22. 
ANS is known to bind to hydrophobic patches and one common assumption is 
that ANS binds only to oligomeric intermediates and not to monomers or 
fibrils.356–358 If this is true, it would enable the measurement of the relative 
amount of oligomers in different samples at different pH values and times. 
However, there is some evidence that ANS might also bind, albeit more 
weakly, to fibrils. Consequently, it is important to establish whether the 
increase in ANS fluorescence measured at the end of the aggregation assays is 
caused by oligomers in equilibrium with fibrils or due to direct binding of the 
ANS to the fibrils. To test this, an aggregation assay (without ThT which can 
interfere with ANS fluorescence) with GLP-1 and Am-GLP-1 was run.  At the 
end of the incubation period, part of the sample was mixed with ANS or ThT 
and the fluorescence measured, in addition to the tryptophan fluorescence. The 
other half of the sample was centrifuged, and the pellet carefully separated from 
the supernatant, this was washed with buffer and recentrifuged, then the pellet 
was resuspended in the same volume of the buffer used initially.  
4.11 Specificity of ANS Binding to Oligomers/Fibrils  
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Figure 4.24. ANS fluorescence of GLP-1 and Am-GLP-1 aggregates formed after 
aggregation and after separation of insoluble/soluble fractions. 
ANS binding assay of 150 µM Am-GLP-1 and GLP-1 samples. Am-GLP-1 
incubated at 37 °C in citrate buffer at pH 3.0, citrate buffer pH 4.0, Tris buffer 
at pH 8.2 and Tris buffer at pH 8.7 (9.0 at 25 °C). GLP-1 incubated at 37 °C 
in citrate buffer at pH 3.0, citrate buffer at pH 3.5, phosphate buffer at pH 7.5 
and Tris buffer at pH 8.2 (8.5 at 25 °C). The pH of the Tris buffers used 
during the fluorescence measurements changed from pH 8.2 to 8.5 and pH 
8.7 to 9.0 because of the temperature change from 37 °C (aggregation assay) 
to room temperature (spectroscopic analysis). All buffers were used at a 
concentration of 25 mM. A) ANS fluorescence after 140 h of incubation at 
37 °C in plate reader B) ANS fluorescence of supernatant 1. C) ANS 
fluorescence of supernatant 2. D) ANS fluorescence of the samples with 
dissolved pellet.  
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Figure 4.25. ANS fluorescence experiments to determine the specificity of ANS 
binding: maximum fluorescence signal.  
Maximum ANS fluorescence of 150 µM Am-GLP-1 or GLP-1 samples after 
140 h of incubation at 37 °C in a plate reader, as well as of the supernatant 1, 
supernatant 2 and the pellet dispersed in buffer. A) Am-GLP-1 incubated in 
25 mM citrate buffer at pH 3.0, citrate buffer pH 4.0, Tris buffer at pH 8.2 
(8.5 at 25 °C) and Tris buffer at pH 8.7 (9.0 at 25 °C). B) GLP-1 incubated 
in citrate buffer at pH 3.0, citrate buffer at pH 3.5, phosphate buffer at pH 7.5 
and Tris buffer at pH 8.2 (8.5 at 25 °C). 
It was anticipated that the centrifugation steps should effectively separate the 
fibrils from soluble oligomers and monomer. The ANS, ThT and tryptophan 
fluorescence were measured for supernatant 1, supernatant 2 and the final 
resuspended pellet sample. 
4.11.1 ANS Fluorescence: Higher Under Acidic Conditions 
The ANS data, Figure 4.24A, clearly shows that for both GLP-1 and Am-GLP-
1 after aggregation, there are only significant levels of ANS fluorescence at 
acidic pH values. At neutral or basic pHs, the ANS fluorescence is low, Figure 
4.24A. At pH 3.0, the first and second supernatants after centrifugation still 
show 50-70% of the ANS fluorescence in comparison to sample measured 
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before any separation step, Figure 4.24B & C.  This suggests that either the 
centrifugation is insufficient to separate monomers/oligomers from fibrils, or 
that the fibrils also bind to ANS and increase its fluorescence. GLP-1 at pH 3.5 
and Am-GLP-1 at pH 4.0 show no ANS fluorescence in the supernatants but 
fluorescence in the final resuspended pellet sample. This indicates that ANS 
may well bind to fibrils, increasing its fluorescence, Figure 4.24D. 
Alternatively, this could also be caused by any oligomeric aggregates binding 
to species that are pelleted during the centrifugation step. A plot of the 
maximum ANS fluorescence for all samples and measurements is shown in 
Figure 4.25A & B. 
4.11.2 Comparison to Tryptophan Fluorescence and Change of 
lmax 
The strength of the tryptophan fluorescence can be used as an estimate of the 
amount of peptide in solution. Similar to the ANS data, the tryptophan 
fluorescence is stronger at acidic pH values, Figure 4.26A. The peaks at neutral 
or basic conditions are approx. 3-4 times lower than in acidic conditions, Figure 
4.26A. Again, the data shows a high fluorescence signal in supernatant 1 at pH 
3.0, Figure 4.26B, indicating that the centrifugation step either failed to pellet 
all of the aggregated material, or that not all the peptide had formed insoluble 
aggregates. Similarly, there is a clear peak at pH 8.2, Figure 4.26B. This shows 
that for GLP-1 at pH 8.2, large aggregates/fibrillar species were not completely 
separated by the centrifugation step, or that there was still a measurable 
equilibrium between soluble and insoluble species under these conditions.  
In addition, the fluorescence of tryptophan, particularly the lmax value, is 
known to be influenced by its solvent exposure and degree to which it is buried 
within a hydrophobic environment. Therefore, it can be used as a probe of the 
environment of the tryptophan side chain in the different aggregated states. 
Following Vivian and Callis (2001), the wavelength of emission of Trp is 
primarily determined by the electrical potential difference across the long axis 
of the tryptophan's indole ring.  For example, positive charges create a redshift 
when acting on the benzene ring end and a blue shift when acting on the pyrrole 
ring. For negative charges, the reverse is true.  
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Figure 4.26. Tryptophan fluorescence experiments: after aggregation and 
centrifugation steps.  
Tryptophan fluorescence assay of 150 µM Am-GLP-1 and GLP-1 samples. 
Am-GLP-1 incubated at 37 °C in citrate buffer at pH 3.0, citrate buffer pH 
4.0, Tris buffer at pH 8.2 (8.5 at 25 °C) and Tris buffer at pH 8.7 (9.0 at 25 
°C). GLP-1 incubated at 37 °C in citrate buffer at pH 3.0, citrate buffer at pH 
3.5, phosphate buffer at pH 7.5 and Tris buffer at pH 8.2 (8.5 at 25 °C). The 
used buffer concentration was 25 mM. A) Tryptophan fluorescence after 140 
h of incubation at 37°C in plate reader B) Tryptophan fluorescence of 
supernatant 1. C) Tryptophan fluorescence of supernatant 2. D) Tryptophan 
fluorescence of the samples with resuspended pellet.  
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Figure 4.27. Tryptophan fluorescence experiments: (max. 
Tryptophan λmax of 150 µM Am-GLP-1 and GLP-1 samples after 140 h of 
incubation at 37 °C and in 25 mM buffer in a plate reader before and after 
two centrifugation and separation steps. A) Am-GLP-1 in citrate buffer at pH 
3.0, citrate buffer pH 4.0, Tris buffer at pH 8.2 (8.5 at 25 °C) and Tris buffer 
at pH 8.7 (9.0 at 25 °C). B) GLP-1 in citrate buffer at pH 3.0, citrate buffer 
at pH 3.5, phosphate buffer at pH 7.5 and Tris buffer at pH 8.2 (8.5 at 25 °C). 
The influence of water is, in most cases, difficult to anticipate, but if one or 
both faces of the benzene ring are water exposed, the wavelength of the 
fluorescence peak is more likely close to 350 nm and therefore red-shifted as is 
seen for monomeric samples of Am-GLP-1 and GLP-1. The lmax of both 
peptides, GLP-1 and Am-GLP-1, was also determined after the aggregation 
assay, Figure 4.27A. Both peptides show a pH dependence of lmax. After 
aggregation, the maximum wavelength is around 335-340 nm under acidic 
conditions (pH 3.0 to 4.0) and 340-345 nm under neutral or basic conditions. 
The tryptophan fluorescence of the resuspended pellet (Figure 4.27B) shows a 
similar pH dependence of lmax values compared to the measurements of Am-
GLP-1 and GLP-1 directly after the aggregation assay and without the 
centrifugation step, Figure 4.23. Therefore, it is most likely that the structure 
of the samples is conserved during the centrifugation steps. 
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4.11.3 Separated Aggregates Interact with ANS and ThT 
Additional information about the formation of fibrils comes from ex-situ ThT 
experiments. As expected, there is no general difference in the intensity of the 
ThT fluorescence signal between the acidic and basic samples, Figure 4.28A, 
as amyloid-like fibrils are formed under both conditions. Interestingly, Am-
GLP-1 at pH 3.0 and GLP-1 at pH 3.0 and pH 8.2 both show strong ThT 
fluorescence in supernatant 1, Figure 4.28B, indicating that there must be 
species containing extensive b-structure in these samples. This may be short 
fibrils that have not centrifuged down into the pellet or soluble oligomers with 
sufficient b-structure to bind to ThT. 
In contrast, the samples of Am-GLP-1 at pH 4.0, 8.2 and 8.7 as well as GLP-1 
at pH 3.5 and 7.5 show significant levels of ThT fluorescence only in the final 
pellet. From the comparison of ANS with the ex-situ ThT fluorescence, ANS 
shows a low fluorescence gain under acidic conditions. It could be caused by a 
higher fraction of oligomeric aggregates under neutral and basic conditions, or 
ANS binding is influenced more by net charge and therefore pH compared to 
ThT. The behaviour of the ANS fluorescence and its pH dependence is, overall, 
similar to the intrinsic fluorescence of tryptophan. 
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Figure 4.28. Ex-situ ThT fluorescence experiments: after aggregation and 
centrifugation. 
Ex-situ ThT fluorescence assay of 150 µM Am-GLP-1 and GLP-1 samples. 
Am-GLP-1 incubated at 37 °C in citrate buffer at pH 3.0, citrate buffer pH 
4.0, Tris buffer at pH 8.2 (8.5 at 25 °C) and Tris buffer at pH 8.7 (9.0 at 
25°C). GLP-1 incubated at 37 °C in citrate buffer at pH 3.0, citrate buffer at 
pH 3.5, phosphate buffer at pH 7.5 and Tris buffer at pH 8.2 (8.5 at 25 °C). 
All buffers prepared at a concentration of 25 mM. A) Ex-situ ThT 
fluorescence after 140 h of incubation at 37 °C in plate reader B) Ex-situ ThT 
fluorescence of supernatant 1. C) Ex-situ ThT fluorescence of supernatant 2. 
D) Ex-situ ThT fluorescence of the samples with resuspended pellet.  
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The fluorescence data presented in Section 4.10 & 4.11 shows that the 
hydrophobicity of the aggregates as well as the environment around the 
tryptophan side chain in the aggregates, most likely fibrils, changes depending 
on the pH. To assess whether these changes are also accompanied by changes 
in secondary structure, far-UV CD spectroscopy was undertaken on both 
peptides both before and after aggregation over a range of pH values. 
  
In Figures 4.29A, 4.30A and 4.31A, the far-UV CD spectra of GLP-1 and Am-
GLP-1 are shown before aggregation under acidic, close to neutral and basic 
conditions. While the far-UV CD spectra were recorded, the HT voltage was 
always kept below 500 V to guarantee that enough photons are being sampled. 
At pH values between 3 and 4, both peptides have the same secondary structure, 
but this structure differs with pH, Figure 4.29A.  
 
Figure 4.29. Secondary structure of GLP-1 and Am-GLP-1 at acidic pH before and 
after aggregation.  
A) Far-UV CD spectra for GLP-1 and Am-GLP-1 in 25 mM citrate buffer at 
pH 3.0, 3.5 and 4.0 before aggregation. B) Far-UV CD spectra of the same 
samples as in Figure 4.29A after 144 h aggregation in the plate reader under 
the same conditions as the ThT assay.  
4.12 Influence of the C-terminal Amidation on 
Secondary Structure 
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There is a significant increase in α-helical structure and a decrease of all other 
structures on increasing the pH from 3.0 to 4.0. At pH values close to neutral, 
both peptides have the same secondary structure and this does not change 
between pH 5.0 and 7.0, Figure 4.30A. At basic pH values, there is a significant 
difference in the far-UV CD spectra between the two peptides but the secondary 
structure is independent of pH over the range from pH 8.0 to 9.0 (At 37 °C, 
during the incubation, pH values of the Tris buffer samples change to pH 7.7, 
8.2 and 8.7) C), Figure 4.31A. The differences in secondary structure between 
GLP-1 and Am-GLP-1 observed at higher pH values are likely due to the 
difference in net charge under these conditions as a consequence of C-terminal 
amidation. At pH 8.5, the net charge is estimated to be -1.2 for GLP-1 and -0.2 
for Am-GLP-1, Figure 4.3B (a change of 600%). In comparison, it is interesting 
to note that at pH 3.0 the net charge of GLP-1 and Am-GLP-1 are estimated to 
be 3.8 and 4.7, respectively. Here, the net charge of Am-GLP-1 is only 24% 
higher than for GLP-1. This increases to a relative change of 45% at pH 4.0 as 
the net charge of GLP-1 and Am-GLP-1 is calculated to be 2.2 and 3.2, 
respectively, under these conditions. 
 
 
Figure 4.30. Secondary structure of GLP-1 and Am-GLP-1 at acidic and neutral pH 
before and after aggregation. 
A) Far-UV CD spectra for GLP-1 and Am-GLP-1 in 25 mM citrate buffer at 
pH 5.0 and 6.0 as well as in 25 mM phosphate buffer at pH 7.0 before 
aggregation. B) Same samples as in Figure 4.29C after 144 h of aggregation 
in the plate reader.  
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After aggregation, there is a large change in the far-UV CD spectra of both 
peptides at most pH values indicative of β-sheet formation (maxima and 
minima at ~202 and ~218 nm), Figures 4.29B, 4.30B and 4.31B. There are 
different intensities in signal between the samples, with the signal being 
particularly low at pH 4.0-6.0. This is attributed to inaccuracy in determining 
the peptide concentration due to low concentrations resulting from 
precipitation. In these cases, the peptide concentration has probably been 
overestimated because of light scattering in the aggregated sample. 
In the basic regime, differences between the secondary structures of the 
aggregates formed by GLP-1 and Am-GLP-1 are observed, as well as changes 
in maxima/minima with pH, Figure 4.31B. Although overall the aggregates 
look like they have largely β-sheet structure, there is evidence that the 
secondary conformation within the fibrils differs.   
 
 
Figure 4.31. Secondary structure of GLP-1 and Am-GLP-1 at neutral and basic pH 
before and after aggregation. 
A) Far-UV CD spectra for GLP-1 and Am-GLP-1 in 25 mM Tris buffer at 
pH 8.0, 8.5 and 9.0 before aggregation and at 25 °C. B) Far-UV CD of the 
same samples as in Figure 4.29E after 144 h aggregation at pH 7.7, 8.2 or 8.7 
in the plate reader under the same conditions as the ThT assay. The far-UV 
CD spectra were recorded at 25 °C, whilst the aggregation assays were 
performed at 37 °C. Thus, the pH values in the Tris buffers were 0.3 pH units 
higher when the far-UV CD spectra were acquired compared to the pH at 
which aggregation took place in the plate reader. 
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The data were analysed using CDPro, which estimates the different fractions 
of regular α-helix, distorted α-helix, regular β-sheet, distorted β-sheet, turns 
and disordered structures.327,328,359 It is worth noting that the analysis with 
CDPro is based on previously gained structural data from peptides and proteins. 
Therefore, the analysis always has to be taken to a certain degree qualitatively. 
However, CDPro still enables a comparison between different sets of far-UV 
CD data of peptides collected in a systematic manner. For reasons of simplicity, 
the regular and distorted fractions of either α-helix or β-sheet were combined 
into one single value of α-helix and β-sheet, respectively. Figure 4.32A & C 
clearly show how the different elements of secondary structure change with pH 
for the monomeric peptides before aggregation. There is an increase in 
α-helicity and concomitant decrease in β-sheet for both peptides between pH 
3.0 and 4.5. Overall, especially between pH 6.0 and 9.0 (25 °C), Am-GLP-1 
has a slightly higher propensity to form helical structure than GLP-1, Figure 
4.32A. These data also show that at pH 3.0, both, Am-GLP-1 and GLP-1 form 
more β-sheet than α-helical structure within the largely monomeric solution 
(the system is referred to as being in State B). Am-GLP-1 shows the same 
behaviour additionally at pH 8.5 and 9.0 (25 °C). All other monomeric 
solutions show higher fractions of α-helix (the system is referred to as being in 
State A). Figure 4.32B & D show the different amounts of secondary structure 
after aggregation as a function of pH. A clear increase in β-sheet structure can 
be seen for both peptides over most pH values as expected for amyloid-like 
fibril formation. The raw data used for the CDPro analysis were also plotted as 
3D surfaces, Figures 4.33 and 4.34. The main difference between the 
Am-GLP-1 and GLP-1 secondary structure data can be seen as the blue 
embayment around 225 nm and at neutral pH, which is only present for the 
amidated version of the peptide, Figure 4.33A & B. 
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Figure 4.32. Fractions of secondary structure of GLP-1 and Am-GLP-1 before and 
after aggregation as a function of pH. 
The fractions are calculated from the far-UV CD spectra using CDPro. A) 
Fraction of α-helical and β-sheet structure of Am-GLP-1 and GLP-1 after the 
peptides were dissolved, filtered and measured within 15 min. The conditions 
under which either Am-GLP-1 or GLP-1 and Am-GLP-1 show a higher 
fraction of β-sheet are marked with a black arrow (State B). All other 
conditions show higher fractions of α-helical structure (State A) B) Fraction 
of α-helical and β-sheet structure of Am-GLP-1 and GLP-1 after aggregation. 
C) Fraction of turn and disordered structure (D/O) of Am-GLP-1 and GLP-1 
after the peptides were dissolved, filtered and measured within 15 min. D) 
Fraction of turn and disordered structure (D/O) of Am-GLP-1 and GLP-1 
after aggregation. The errors shown are the standard deviation of the results 
using three different algorithms to calculate the secondary structure, Section 
2.10. 
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Figure 4.33. Three-dimensional far-UV CD spectral landscape illustrating the 
differences in secondary structure of GLP-1 and Am-GLP-1 at 
different pH values using freshly prepared samples.  
Far-UV CD spectra recorded directly after the peptides were dissolved in 
aqueous buffer. Each graph shows the far-UV CD spectra at 13 different pH 
values from pH 3.0 to 9.0 at 25 °C. The buffers were citrate (pH 3.0 - 6.0), 
phosphate (pH 6.5 - 7.5) and Tris (pH 8.0 - 9.0, 25 °C) and all the buffer 
concentrations were 25 mM. The far-UV CD spectra were recorded at 25 °C, 
whilst the aggregation assays were performed at 37 °C. Thus, the pH values 
in the Tris buffer were 0.3 °C pH units higher when the far-UV CD spectra 
were acquired compared to the pH values of 7.7, 8.2 and 8.7 at which 
aggregation took place in the plate reader. All measurements were done at a 
peptide concentration of approx. 150 µM or slightly below if the solubility 
was low. A) Secondary structure of GLP-1 B) Secondary structure of Am-
GLP-1. 
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Figure 4.34. Three-dimensional far-UV CD spectral landscape illustrating the 
differences in secondary structure of GLP-1 and Am-GLP-1 at 
different pH values after 144 h of aggregation. 
Far-UV CD spectra recorded after the ThT aggregation assay. Each graph 
shows the far-UV CD spectra of 13 different samples aggregated at pH values 
from pH 3.0 to 8.7 at 37 °C. The buffers were citrate (pH 3.0 - 6.0), phosphate 
(pH 6.5 - 7.5) and Tris (pH 7.7 - 8.7) and all buffer concentrations were 25 
mM. All measurements were done at a peptide concentration of approx. 150 
µM or slightly below if the solubility was low. During the spectroscopic 
analysis the pH of the Tris buffers used during the aggregation assay changed 
from pH 7.7 to 8.0, 8.2 to 8.5 and pH 8.7 to 9.0 because of the temperature 
change from 37 °C (aggregation assay) to room temperature (spectroscopic 
analysis). A) Far-UV CD spectrum of GLP-1 B) Far-UV CD spectrum of 
Am-GLP-1. 
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To assess the effect of amidation of the C-terminus on the aggregation 
behaviour of the therapeutic peptide GLP-1 measurements on the solubility, 
charge and aggregation kinetics of Am-GLP-1 were made over a wide range of 
pH values. In addition, ANS assays, tryptophan assays and far-UV CD 
measurements, characterising the hydrophobicity, burial of tryptophan 
residues, secondary structure both before and after aggregation, were also 
undertaken. Finally, the nature of species present at the end of the aggregation 
was assessed using imaging techniques. A number of systematic differences 
between the behaviour of GLP-1 and Am-GLP-1 were observed and, in some 
cases, these could be linked to changes in charge state. Collectively, the data 
provides more information on the mechanism of self-assembly of GLP-1 based 
peptides, confirms the presence of off-pathway species populated during 
fibrillation and illustrates how sensitive aggregation reactions are to small 
changes in the intrinsic properties of the peptide as well as the environment.  
4.13.1 The Mechanism of Aggregation: The Role of On- versus 
Off-Pathway Oligomers 
In these studies, with GLP-1 and Am-GLP-1, three different types of 
aggregation behaviour in terms of how the kinetic parameters t1/2 and tlag depend 
on peptide concentration have been observed. These are assigned to one of 
three classes. Class I: lag time and t1/2 decrease with increasing peptide 
concentration. This is what has been observed for many other peptides85 and is 
consistent with standard nucleation-elongation models, Figure 1.7A. Class II. 
The lag time and t1/2 do not vary significantly with peptide concentration. This 
is in agreement with either i) a critical micelle concentration (CMC) model in 
which the peptide monomer concentration is kept approximately constant 
above a threshold concentration (the CMC) above which excess peptide 
monomers arrange in off-pathway aggregates, for example micelles, Figure 
1.7C.86,360 Alternatively, it is also consistent with ii) an off-pathway model as 
shown by Powers & Powers89 in which, if aggregation is dominated by 
4.13 Discussion 
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elongation and the release of the monomers from the off-pathway species, t1/2 
does not change with peptide concentration. This is illustrated in Figure 1.7D. 
Class III. The kinetic parameters (lag time and t1/2) increase with increasing 
peptide concentration. This is a particularly interesting case and rather unusual 
behaviour which suggests that not only are off-pathway species formed but that 
the off-pathway species actively interferes with the formation of nuclei or 
fibrils, Figure 1.7E.347 This behaviour was observed at pH 3.5 and 7.5 for GLP-
1 and pH 8.2 for Am-GLP-1, Figure 4.6. It is also known that a lipidated 
analogue of GLP-1 (Liraglutide)91 as well as several other peptides (single-
chain Aβ dimer or lysozyme)347 show this unusual behaviour.  
Fitting of ThT data to an NEF model, generates values for d, a measure of the 
rate of primary nucleation and k, a measure of the rate of secondary nucleation. 
r varies tenfold across pH values for both GLP-1 and Am-GLP-1, but they vary 
differentially. From these data, it is clear that the primary nucleation rate 
increases with increasing peptide concentration under conditions showing 
typical nucleation-polymerisation behaviour, for example, at pH 3.0 for both 
peptides. However, For GLP-1 at pH 3.5 and 7.5 (conditions where off-
pathway oligomers are thought to be populated), it decreases with increasing 
peptide concentration, suggesting that off-pathway events are happening. 
Under the same conditions, x also decreases with increasing peptide 
concentration which is the expected behaviour if off-pathway oligomers not 
only depopulate the monomer concentration but actively suppress secondary 
nucleation. 
Previously, the behaviour of increasing lag time with increasing peptide 
concentration was attributed to the formation of off-pathway species alone 
along with a unimolecular step en route to fibril formation.5 However, if both 
pathways are independent of each other and don`t interfere actively during the 
aggregation process, this model would result in tlag remaining constant and only 
t1/2 would increase with increasing peptide concentration as has been shown by 
Powers & Powers in their work on off-pathway aggregation89, Figure 1.7D. A 
shorter mathematical approach to prove that an off-pathway system as 
described in Figure 1.7D cannot lead to longer lag times with increasing peptide 
concentration is shown in Section 4.8. There, it is mathematically shown that 
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the amount of available monomer concentration available for the on-pathway 
route, if the on-pathway is independent of the off-pathway species, cannot be 
smaller at any time point as the monomer concentration of a sample starting 
with a lower total monomer concentration at the same time point. It always 
results in a more rapid formation of both, on- and off-pathway aggregates, and 
can only approach a constant lag time if the off-pathway acts as a sink for free 
monomer, Section 1.5.2.  
4.13.2 Role of Net Charge on Solubility and Aggregation 
Propensity 
One important factor influencing the interaction of monomers, oligomers, or 
fibrils with the solution or each other is the net charge of the peptide. Therefore, 
net charge on the peptide has the potential to influence the aggregation kinetics 
and even completely change the aggregation pathway.  
Amidation of GLP-1 leads to a change in the net charge over pH values between 
pH 3 and 9 and results in the peptide having a particularly wide-ranging 
minimum in charge around its pI value, Figure 4.3B. This can be explained by 
the distance from the pI to the pKa of the next ionisable group. The pI of Am-
GLP-1 is shifted to a value which is further away from the pKa values of other 
ionisable groups such that the net charge stays close to zero over a wider pH 
range compared to GLP-1. The data shows the expected dependence between 
net charge and solubility, Figure 4.3A & B, but also establishes that there is a 
correlation between net charge and aggregation propensity as measured by t1/2 
and lag time, Figure 4.35A & B. This is discussed further in the next section. 
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Figure 4.35. Correlation of net charge with aggregation propensity and secondary 
structure for GLP-1 and Am-GLP-1. 
The net charge was calculated as described in Section 2.15. The error bars 
shown are the standard deviation of the results of three different algorithms 
used to calculate the secondary structure, Section 2.10. A) t1/2 values of GLP-
1 and Am-GLP-1 aggregated at pH values between pH 3.0 and 8.7 plotted 
versus the net charge. B) tlag values of GLP-1 and Am-GLP-1 aggregated at 
pH values between pH 3.0 and 8.7 plotted versus the net charge. All 
measurements were done at a peptide concentration of approx. 150 µM or 
slightly below if the solubility was low. C) The fraction of α-helical-structure 
in the monomeric peptide as calculated from far-UV CD spectra (Figure 
4.33) is shown versus net charge. D) The fraction of β-sheet structure in the 
monomeric peptide as calculated from the far-UV CD spectra (Figure 4.33) 
versus net charge. 
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4.13.3 Less Electrostatic Repulsion Does Not Lead to Higher 
Aggregation Propensity 
The results on the aggregation of Am-GLP-1 and GLP-1, Figures 4.4A and B 
and 4.5, give a broad overview of the aggregation propensity of both peptides 
at different pH values as well as at different peptide concentrations. It is clear 
that net charge strongly influences aggregation affecting the kinetic parameters 
tlag and t1/2, Figure 4.35. Somewhat surprisingly, the results clearly show that 
both peptides have a lower aggregation propensity at pH values close to their 
pIs. This is in contrast to some models that predict that decreasing the net 
charge on a peptide increases its aggregation propensity as a result of 
decreasing the otherwise unfavourable electrostatic interactions that have to be 
overcome in order to achieve self-assembly.132–136 From earlier studies on GLP-
1, this unusual kinetic behaviour was attributed to the formation of off-pathway 
species during the aggregation of this family of peptides under specific 
conditions.5 The off-pathway oligomers are populated close to the pI of the 
peptide and act as an off-pathway sink of monomer thus reducing aggregation 
rates. 
4.13.4 Specificity of ANS Fluorescence  
One of the methods in this project used to gain more information about peptide 
oligomers and the structure of peptide aggregates in general is ANS 
fluorescence, which is widely used to probe the existence of partially structured 
folding intermediates.356–358 However, the data shown here suggest that ANS 
fluorescence is not always highly specific to such intermediates. The data 
shows either i) that aggregates that interact with ANS cannot be separated from 
ThT-binding fibrils by centrifugation, or ii) the fibrils themselves have some 
affinity for ANS and can increase its fluorescence. Thus, care must be taken in 
interpreting the results of ANS experiments and one should not assume that 
ANS fluorescence is solely due to its binding to intermediate states/oligomers.  
The data also demonstrates that the ANS-assay is strongly affected by pH 
showing a clear difference in behaviour between acidic and basic pH values. 
Such a behaviour could be explained by either i) two different forms of 
aggregates being formed in acidic and basic conditions with different 
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propensities to bind to ANS, or ii) different binding affinities of ANS to similar 
species under acidic and basic conditions due to the influence of net charge. 
Under basic conditions, the ANS binding is so low that the assay is not able to 
prove whether in the case of GLP-1 at pH 8.2, a significant amount of peptide 
was in an oligomeric or fibrillar form in the different samples.  
If the washed pellets consist only of fibrils which bind to ThT and the fibrils 
are not disturbed during the centrifugation or washing step, then the results 
suggest that ANS also binds to fibrils as well as oligomers. However, it cannot 
completely be excluded that some of the larger oligomers also pellet with the 
fibril. If this is the case, then the ANS fluorescence might still be due to 
oligomer binding only. 
There is also some evidence, for example at pH 7.5, that ANS can bind under 
certain conditions specifically to oligomeric intermediates, but such findings 
have to be taken with care due to the previously described caveats. These 
experiments all highlight the limitations of using ANS and the care that needs 
to be taken when interpreting ANS fluorescence data in the context of 
protein/peptide aggregation. 
4.13.5 Structure of the Monomeric Peptides  
It is clear that the net charge on the peptide influences both solubility and 
aggregation propensity. This leads to the question of whether net charge alone 
is responsible for the difference in aggregation behaviour observed for GLP-1 
and Am-GLP-1 or whether the effects are indirect, i.e., the net charge 
influences other properties of the peptide such as secondary structure that is 
responsible for the change in aggregation propensity. A number of experiments 
on freshly prepared samples of GLP-1 and Am-GLP-1 shed light on the 
structure of the monomeric peptides in solution. 
From the ANS and tryptophan fluorescence data, it is likely that the monomer 
of both peptides studied has little fixed tertiary structure in either acidic or basic 
conditions, Figure 4.22A-D. In contrast, the secondary structure of the two 
peptides differs at specific pH values, Figures 4.29, 4.30 and 4.31. The far-UV 
CD data show that the secondary structure of both peptides is similar at acidic 
pH values and also shows that both peptides undergo similar pH-dependent 
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changes in secondary structure in the acidic region. Notably, for both peptides 
there is an increase of α-helical structure on increasing the pH from 3.0 to 4.0 
or 4.5, Figure 4.32A. This is probably caused by protonation of Asp9 or one or 
more of the three glutamic acid residues at positions 3, 15 and 21, which are 
likely to have pKa values around 3.7 and 4.3, respectively.340 Significantly, 
there is a correlation between the secondary structure of the monomeric 
peptides at the start of the aggregation reaction and the net charge, Figure 4.35C 
& D. Higher net charges favour an extended b-conformation over a more 
compact a-helical structure presumably because this minimizes electrostatic 
repulsion between like charges on the same peptide molecule. This, in turn, 
leads to the question if the amount of a-helical versus b-sheet structure in the 
monomeric peptide and the rate of fibril formation, as shown by t1/2 and tlag, is 
correlated, Figure 4.36.  
For both peptides there is no general correlation found between the amount of 
α-helical and β-sheet structure and the rate of fibril formation, Figures 4.36A 
& B and 4.37A & B. What can be seen is a difference for Am-GLP-1 under 
conditions where the peptide is positively charged and negatively charged with 
the exception of pH 6.0, which is close to the pI. Under conditions at which 
Am-GLP-1 has a negative net charge all samples show a high α-helical content 
and longer lag times than for positively charged Am-GLP-1.  
The data also shows a relationship between the difference of α-helical and β-
sheet structure, ∆, and the rate of aggregation observed under conditions where 
the peptide follows a nucleation-polymerisation model. For Am-GLP-1 this is 
at pH 3.0 and for GLP-1, it is at pH 3.0, 8.5 and 8.7, and under most of these 
conditions there are clear negative ∆ values (State B), Figures 4.36C & B and 
4.37C. Other conditions show either values of D close to zero or positive values 
(State A), Figures 4.36C and 4.37C.  
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Figure 4.36. Correlation of aggregation propensity (tlag and t1/2) and secondary 
structure for GLP-1. 
Data of tlag, determined from data shown in Figure 4.5, plotted versus the 
fraction of α-helical and β-sheet structure, Figure 4.32. The data are shown 
for GLP-1 aggregated at pH values between 3.0 and 8.7. The far-UV CD 
spectra used to determine the secondary structure were recorded at 25 °C, 
whilst the aggregation assays were performed at 37 °C. Thus, the pH values 
in the Tris buffer were 0.3 °C pH units higher when the far-UV CD spectra 
were acquired compared to the pH values of 7.7, 8.2 and 8.7 at which 
aggregation took place in the plate reader. Peptides in samples represented 
by a solid symbol have a positive net-charge. The error bars shown are the 
standard deviation of a triplicate measurement of tlag and the results of three 
different algorithms used to calculate the secondary structure, Section 2.10. 
A) tlag of GLP-1 plotted versus its corresponding fraction of α-helical 
structure. B) tlag of GLP-1 plotted versus its corresponding fraction of β-sheet 
structure. C) tlag versus difference of fraction of α-helical and β-sheet 
structure ∆ of GLP-1. Samples under of the conditions in the blue shaded 
area (State B) showed constant or increasing tlag with increasing peptide 
concentration. In the orange shaded region (State A), the samples followed 
typical nucleation-elongation kinetics. 
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Figure 4.37. Correlation of aggregation propensity (tlag and t1/2) and secondary 
structure for Am-GLP-1. 
Data of tlag, determined from data shown in Figure 4.5, plotted versus the 
fraction of α-helical and β-sheet structure, Figure 4.32. The data are shown 
for Am-GLP-1 aggregated at pH values between 3.0 and 8.7. The far-UV CD 
spectra used to determine the secondary structure were recorded at 25 °C, 
whilst the aggregation assays were performed at 37 °C. Thus, the pH values 
in the Tris buffer were 0.3 °C pH units higher when the far-UV CD spectra 
were acquired compared to the pH values of 7.7, 8.2 and 8.7 at which 
aggregation took place in the plate reader. Peptides in samples represented 
by a solid symbol have a positive net-charge. The error bars shown are the 
standard deviation of a triplicate measurement of tlag and the results of three 
different algorithms used to calculate the secondary structure, Section 2.10. 
A) tlag of Am-GLP-1 plotted versus its corresponding fraction of α-helical 
structure. B) tlag of Am-GLP-1 plotted versus its corresponding fraction of β-
sheet structure. C) tlag versus difference of fraction of α-helical and β-sheet 
structure ∆ of Am-GLP-1. Samples under of the conditions in the blue shaded 
area (State B) showed constant or increasing tlag with increasing peptide 
concentration. In the orange shaded region (State A) the samples followed 
typical nucleation-elongation kinetics. 
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4.13.6 The Secondary Structure of the Monomeric Peptides 
Influences Aggregation Propensity and Mechanism 
The far-UV CD spectra show that monomers can be found in at least two 
different conformational states (or ensembles). From CDPro analysis, State A 
is defined by a higher percentage of α-helical than β-sheet structure whilst 
State B has a higher β-sheet content than α-helical structure, Figures 4.32 and 
4.38. The a-helical structure is favoured under conditions where the peptide 
has a low net positive charge whilst higher b-sheet structure is favoured at pH 
values where the peptide has either a high positive or negative charge, Figure 
4.35C & D. In three out of the eight different peptide and pH conditions studied, 
the peptides were observed in State B. In all of these three cases, a decrease of 
the lag time and t1/2 with increasing peptide concentration was observed in the 
ThT assays (Class I).  
 
Figure 4.38. Two different monomer conformations (state MA and MB) and how 
these relate to the pI and their role in in forming on- and off-pathway 
oligomers.  
A) Two different conformational states of the monomeric peptide as shown 
by far-UV CD and their relative predominance at difference pH values. 
Samples with more or the same amount of α-helical than β-sheet structure 
are shown in orange (State A) and samples with more β-sheet than α-helical 
structure are shown in blue (State B). The experimentally determined pI 
values for GLP-1 and Am-GLP-1 are 5.9 and 6.8, respectively and are shown 
in grey. B) Conditions in which peptide monomer is in State B follow a 
predominantly on-pathway mechanism. C) Conditions in which the peptide 
monomer is in State A have more complex kinetics and show the population 
of off-pathway species which may or may not actively interact with on-
pathway species.  
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In all the other conditions studied, the peptides were in State A. Under these 
conditions either a constant (Class II) or even increasing (Class III) lag time 
and t1/2 was observed with increasing peptide concentration. The conditions 
under which State A was observed was always closer to the pI in comparison 
to conditions where the monomeric peptide is in State B, Figures 4.35C & D 
and 4.38. 
4.13.7 Structure/Properties of Off-Pathway Oligomers 
The observation of different aggregation behaviours for two different monomer 
ensembles, states A and B, leads to the proposal that monomers with higher α-
helical content result in the formation of off-pathway aggregates. These more 
helical monomers tend to form under conditions where the peptide has a 
relatively low net charge in comparison to the monomers in state B which have 
a higher percentage of β-sheet structure and which form at pH values where the 
peptide has a higher net charge, Figure 4.35. This leads to the conclusion that 
the net and/or local charge influences the secondary structure of the monomeric 
peptide, which in turn affects the aggregation behaviour. Thus, the charge state 
of the peptide influences the propensity of the peptide to aggregate either 
directly but also likely through induced changes in secondary structure. Based 
on these results and correlations, it is possible to speculate that the off-pathway 
oligomers have more a-helical structure and the on-pathway oligomers more 
b-structure. Although it is not possible to get structural information directly on 
the oligomeric states, it is interesting to note that all samples which start with 
higher α-helical content compared to β-sheet are more likely to populate off-
pathway oligomers. One might therefore speculate that off-pathway species are 
more helical than their on-pathway counterparts. Under some conditions, over 
time α-helical content approaches zero, suggesting that the off-pathway 
oligomers are converted into β-sheet structures and the amount of the off-
pathway oligomers is too small to be distinguished by far-UV CD. 	
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4.13.8 The Structure of Fibrils of GLP-1 and Am-GLP-1 are 
Sensitive to pH 
SEM images at different pH values were recorded to learn more about the 
structure and morphology of fibrils of Am-GLP-1 formed under different 
conditions. These images, and previous AFM images of fibrils of GLP-1 at 
different pH values,351 show that the higher-order structures of the aggregates 
formed by GLP-1 and Am-GLP-1 vary significantly with pH. Am-GLP-1 
showed different fibril morphologies within the densely covered region of the 
dried sample, Figures 4.16A & C and 4.17A & C, suggesting that the fibrils 
formed under different conditions may have distinct surface characteristics 
which may lead to different higher-order structures. Under acidic conditions, 
the fibrils tend to stick faster to the glass surface in comparison to fibrils formed 
under basic conditions. Figure 4.18. This phenomenon could be caused by 
different surface properties, e.g., hydrophobicity, or simply by different net 
charge. 
More evidence that GLP-1 and Am-GLP-1 fibrils have different surface 
properties when formed under acidic or basic conditions comes from the ANS 
and tryptophan fluorescence data. The ANS data shows that fibrils of both 
peptides formed under acidic conditions bind ANS therefore indicating that 
there are hydrophobic patches on the surface of the aggregates formed under 
these conditions. In addition, binding may be facilitated by favourable 
electrostatic interactions between the positive charge on the peptide and the 
negatively charged dye at low pH.361 In contrast, at higher pH no ANS binding 
is observed. This may be due to the lack of exposed hydrophobic patches 
formed in the fibrils under these conditions or may simply be a consequence of 
the lack of favourable electrostatic interactions as the peptide and therefore 
aggregate has a different net charge.  
The results of the tryptophan fluorescence experiments indicate that the Trp 
side chains in GLP-1 and Am-GLP-1 are buried after aggregation under acidic 
and basic conditions, but the observed change in #max is larger under acidic 
conditions, Figure 4.22E. This could be due to differences in the structure of 
the fibril formed or differences in the higher-order structures formed under 
acidic and basic pH. Far-UV CD data supports a model in which the intrinsic 
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structure of the fibrillar species varies with pH, as despite the fact that there is 
strong evidence of β-sheet structure in all cases, the far-UV CD spectra of the 
aggregated species do vary, Figures 4.29B and 4.31B. 
4.13.9 Conclusions  
Here, we have shown that a C-terminally amidated variant of GLP-1 aggregates 
to form amyloid-like fibrils over a wide range of condition similar to previous 
results on GLP-1. The structure, particularly the higher-order structure, of the 
fibrils formed by Am-GLP-1 varies with pH. However, the pH dependence of 
aggregation for Am-GLP-1 differs from that observed for GLP-1, which can be 
attributed to the result of their different pI values and therefore different net 
charge at different pHs. As with GLP-1, there is strong evidence that Am-GLP-
1 also forms off-pathway oligomeric species (as well as on-pathway oligomers 
that lead to fibril formation) under certain conditions. These off-pathway 
species, which act to slow but not prevent fibril formation, are populated near 
to the pI of the peptides, where the net charge on the molecule is close to zero. 
This results in the opposite effect to that has been reported in earlier studies on 
other peptides, where low net charge minimises electrostatic repulsion between 
peptides and thus accelerates the rate of fibril formation. Interestingly, 
correlations between the net charge on the peptide and the secondary structure 
it forms in its monomeric state, low positive net charge favouring more a-
helical conformations, higher positive or negative net charges favouring more 
extended b-structures are observed. The consequence is that there is a 
correlation between the secondary structure in the monomer and its aggregation 
propensity – more helical structures favouring the formation of off-pathway 
oligomers resulting in slower aggregation, whilst more b-structures seem to 
favour the formation of on-pathway oligomers (or disfavour the formation of 
off-pathway species) and enhance aggregation propensity. Collectively, these 
studies show how sensitive aggregation reactions are to even small changes in 
the chemical nature of a peptide as well as to external factors such as pH. In 
addition, these results suggest that all members of the GLP-1 family of peptides 
are likely to populate off-pathway oligomers and show a delicate balance 
between on- and off-pathway processes which can be altered by changing the pH. 
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From the detailed study of GLP-1 and Am-GLP-1, it is clear that C-terminal 
amidation and the consequent change of net charge has a significant influence 
on the aggregation characteristics of GLP-1. In this Chapter, the results of 
studies on the effect of lipidation on the physical stability of GLP-1 are 
described. Two peptides, called IPP4 and IPP5, were studied. They are 
lipidated at different positions, the modification involving attachment of a 
palmitic acid to the amino group of a glutamic acid, which is used as a spacer, 
the g-carboxyl group of which is subsequently covalently linked to the K-amino 
group of a lysine side chain in the peptide, Figure 5.1. 
In the case of IPP5, the lipid-spacer molecule was attached at the first naturally 
occurring lysine (at position 20) in the Am-GLP-1 sequence. Subsequently, the 
positive charge of the lysine is lost and an additional negatively charged 
carboxylate group of the glutamic acid is added. In addition, in IPP5, the lysine 
at position 28 is substituted by an arginine (K28R) to prevent lipidation at this 
position. Arginine is chosen as a substitute as it retains the positive charge and 
shows a similar hydropathicity to lysine. The lipidation and the loss of the 
positive charge on the lysine side chain on conjugation should increase the 
5 THE EFFECT OF LIPIDATION ON 
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overall hydrophobicity of the peptide, however, the hydrophilicity may be 
partly replaced by the negative charge of the glutamic acid spacer. IPP5 has the 
same sequence and modification as Liraglutide but is amidated at the C-
terminus.  
For IPP4, both naturally occurring lysines are substituted by arginines (K20R 
and K28R) to prevent covalent modification. In this case, the hydrophilic 
glutamine at position 17 is replaced with a lysine (Q17K) enabling lipidation 
at this site, Figure 5.1.  
 
Figure 5.1. Amino-acid sequence of GLP-1, Am-GLP-1, IPP4, IPP5 and Liraglutide. 
Possible de-/protonation sites are marked in green or red including the N- and 
C-terminus of the peptides if not amidated. Green sites are positively charged 
if the pH is lower than the pKa of the group (pKa values are shown in green 
next to the site for the parent peptide GLP-1). Red sites are negatively charged 
if the pH is higher than the pKa value (shown in red next to the site for the 
parent peptide GLP-1 and the linker group in IPP4). The fraction of de-
/protonation and therefore the change of charge around the pKa can be 
determined using Equations 2.12 and 2.13. 
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To measure the molecular weight of the lipidated peptides, as well as to 
compare the purity of the samples, LC-MS measurements were conducted. The 
UV absorbance at 210 nm shows a single narrow peak for both peptides, 
Figures 5.2A and 5.3A. The same peak was found in the total ion count (TIC) 
data, Figures 5.2B and 5.3B. This establishes that the peptides have high purity 
and no other molecules with a similar molecular weight which absorb in the 
UV are present. However, both peptides also show additional smaller peaks at 
longer elution times. The species corresponding to these peaks do not absorb 
in the UV and are probably more hydrophobic, causing the longer retention 
times. Between 5.30 and 6 min, both lipidated peptides also show a broad peak 
which was not observed for the non-lipidated peptides. These broad peaks are 
artefacts caused by the LC-MS method used for lipidated peptides and were 
similarly seen in a run with pure water injected (data not shown). 
Figure 5.2C shows the mass spectrum of IPP4 with IPP4 mainly present as a 
+3 molecular ion (1260.27 m/z). Smaller fractions are also observed as +5 
molecular ion (756.85 m/z), +4 molecular ion (945.33 m/z), and +2 molecular 
ion (1890.12 m/z), Figure 5.4C. The determined molecular weight is 3778.2 ± 
0.8 Da, Figure 5.3C. This value is in good agreement with the theoretical value 
of 3778.26 Da as well as the relative molecular mass of 3778.33 Da obtained 
by Bachem using matrix-assisted laser desorption/ionization-mass 
spectrometry (MALDI-MS). 
The mass spectrum of IPP5 shows that it is also mainly present as a +3 
molecular ion (1250.85 m/z). Again, some smaller peaks are seen for the +4 
molecular ion (938.56 m/z), and +2 molecular ion (1875.83 m/z) but not the +5 
molecular ion as the maximum positive charge of IPP5 is +4. The determined 
molecular weight is 3749.8 ± 0.4 Da, Figure 5.3C. This value is in good 
agreement with the theoretical value of 3750.2 Da. 
 
 
5.1 Molecular Weight and Purity of IPP4 and IPP5 
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Figure 5.2. LC-MS of IPP4. 
A) UV absorbance signal at 210 nm. The peak observed at 0.77 min is caused 
by the injection of the sample. It is due to the different percentage of 
acetonitrile in the sample in comparison to the LC gradient as well as the 
presence of salt in the sample. The x-axis is given in minutes. B) Total ion 
chromatogram (TIC). The x-axis is given in minutes. C) Mass spectrum of the 
peptide peak eluting at 2.71 min.  
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Figure 5.3. LC-MS of IPP5. 
A) UV absorbance signal at 210 nm. The peak at 0.78 min is caused by the 
injection of the sample. It is due to the different percentage of acetonitrile in 
the sample in comparison to the LC gradient as well as the presence of salt in 
the sample. The x-axis is given in minutes. B) Total ion chromatogram (TIC). 
The x-axis is given in minutes. C) Mass spectrum of the peptide peak eluting 
at 2.82 min. 
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Initial experiments were used to measure the effect of lipidation on the 
solubility of the peptide. The solubility of IPP4 and IPP5 was determined as in 
the earlier studies on Am-GLP-1 and the results are shown in Figure 5.4A. The 
results establish that lipidation greatly reduces the solubility of the peptide, 
such that IPP4 and IPP5 are only soluble at pH values higher than their pIs, i.e., 
towards the basic pH range, Figure 5.4A. IPP5 is soluble from pH 6.5 upwards 
and IPP4 from pH 7.5. upwards. The net charge was calculated for both 
peptides in a similar way as for Am-GLP-1 and GLP-1 and as described in 
Section 2.15 and results are shown in Figure 5.4B. In addition, the net charge 
of Liraglutide was also calculated and is shown. Theoretically, under basic 
conditions, the net charge on IPP4 parallels the net charge on IPP5 with a net 
charge difference of plus one. The net charge of IPP4 is also similar to the net 
charge on GLP-1 and only shows differences at highly acidic or basic 
conditions. 
The theoretical pI values for IPP4 and IPP5 were calculated using standard 
methods as described in Section 2.15 and are 5.5 for IPP4 and 4.7 for IPP5. The 
values were also determined experimentally and are 6.1 and 5.5 for IPP4 and 
IPP5, respectively, Figure 5.4C. The measured values are similar to, but not the 
same as, the theoretical values, suggesting that there is some structure or local 
charge effects in the lipidated peptides in solution which results in perturbed 
pKa values for some side chains. The peak of IPP5 is broader and less focused 
than for IPP4, which could be caused by the formation of stable oligomers or 
the need for a longer focusing time. The latter was, however, restricted because 
of the pI markers running out of the detectable range of the capillary, 
Section 1.16.  
 
5.2 Solubility, Net Charge and pI are All Influenced by 
Lipidation  
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Figure 5.4. Solubility, net charge and experimentally determined pI of lipidated 
GLP-1 peptides. 
A) Measured peptide concentration after dissolving approx. 0.25 mg of the 
peptide into 0.5 mL buffer at different pHs and after filtration of the sample 
with a 0.2 µm PVDF filter. IPP4 (red closed circles) and IPP5 (blue closed 
diamonds). B) Calculated net charge versus pH based on the peptide amino-
acid sequence and standard pKa values. The data for IPP4 (blue solid line) and 
IPP5 (red solid line) are shown in comparison to the calculated net charge of 
GLP-1 (black dashed line), Am-GLP-1 (grey dashed line) and Liraglutide 
(green dotted line). C) Experimental determination of the pI values for IPP4 
(blue line) and IPP5 (red line). The pI was measured using capillary isoelectric 
focusing (iCIEF). The method used included urea to prevent precipitation.  
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For all pH values at which the peptides showed sufficient solubility, ThT 
aggregation assays were performed to learn more about the aggregation 
propensity of the two lipidated peptides at different pHs. IPP4 shows two 
regions which have different aggregation propensities, Figure 5.5A. At pH 7.5 
and 7.7, the ThT signal shows a strong sigmoidal increase in fluorescence, 
whilst at pH 8.2 and 8.7, there is rather little increase in ThT fluorescence over 
the timeframe studied. Thus, if one assumes that the ThT fluorescence is 
linearly related to the formation of fibrils, IPP4 appears to have a much higher 
propensity to form fibrils at near neutral pH. IPP5 also shows a change in 
aggregation propensity with pH, Figure 5.5B.  
 
Figure 5.5. ThT aggregation assay data for lipidated peptides at different pH 
values.  
Measurements of IPP4 and IPP5 conducted in 25 mM phosphate buffer at pH 
6.5, (red open circles), pH 7.0 (orange open circles) and pH 7.5 (light green 
open circles) and 25 mM Tris buffer at pH 7.7 (dark green open circles), pH 
8.2 (light blue open circles) and pH 8.7 (dark blue open circles). A) ThT assays 
of peptide aggregation for ∼150 µM IPP4 from pH 7.5 to 8.7 at 37 °C. For 
each pH, the average of triplicate runs is shown. B) ThT fluorescence for ∼150 
µM IPP5 from pH 6.5 to 8.7 at 37 °C. For each pH, the average of triplicate 
runs is shown. 
A    IPP4 B        IPP5 
5.3 A pH Induced Switch of Aggregation Propensity 
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Figure 5.6. Three-dimensional aggregation landscapes illustrating the ThT assay 
data for peptide aggregation for lipidated peptides at different pH 
values.  
A) ThT assays of peptide aggregation for 150 µM IPP4 from pH 7.5 to 8.7 at 
37 °C. For each pH, the results of triplicate runs are shown. The x-axis shows 
the pH value, z-axis time (h) and the y-axis ThT fluorescence (arbitrary units) 
with 0-1000 (blue), 1000-2000 (red), 2000-3000 (green) and 3000-4000 
(purple). B) ThT fluorescence for 150 µM IPP5 at pH 6.5 to 8.7 at 37 °C. For 
each pH, the results of triplicate runs are shown. The x-axis shows the pH 
value, z-axis time (h) and the y-axis ThT fluorescence (a.u.) with 0-500 (blue), 
500-1000. 





















































Chapter 5: The Effect of Lipidation on the Physical Stability of Peptides 
  201 
At pH values between 6.5 and 7.5, the samples show no lag phase and nearly 
no growth phase, but rapidly reach a moderately high ThT fluorescence plateau 
which may indicate fibril formation. However, on increasing the pH to 7.7, 
aggregation is significantly slower and by pH 8.2 and 8.7, there is relatively 
little fibril formation over the time course of the experiment as indicated by 
increased ThT fluorescence. Indeed, under these conditions, the ThT signal 
decreases not increases with time. It is worth mentioning that all samples of 
IPP5 from pH 7.5 to 8.7 show an initial ThT signal that does not start at zero, 
in contrast to the data for IPP4. Similarly, at pH 7.0 and 7.5, once the 
moderately high fluorescence signal has been reached, it then decreases slowly 
over time. 3D plots of the ThT data are shown in Figure 5.6A & B, illustrating 
the two different regions of aggregation behaviour for each peptide. 
The peptide concentration dependence of the aggregation of IPP4 and IPP5 at 
different pH values probed by ThT fluorescence measurements are shown in 
Figure 5.7. The ThT signal for IPP4 in phosphate buffer at pH 7.5 at higher 
peptide concentrations are sigmoidal in shape and data were fitted to Equation 
2.4 and 2.5, to obtain values of t1/2 and lag time. At lower peptide 
concentrations, 25 and 50 µM, the fits did not converge and therefore values 
for t1/2 and lag time were not determined for these concentrations. Both kinetic 
parameters, t1/2 and lag time, decrease with increasing peptide concentration, 
Figure 5.8A & C. IPP4 in Tris buffer at pH 8.2 also showed a sigmoidal 
increase in ThT signal; however, the amplitude of the change in signal was 
approximately four times lower than at pH 7.5, Figure 5.7B. These data were 
also fit to Equation 2.4 and 2.5, and values for t1/2 and lag time shown in Figure 
5.8B & D vary rather little with peptide concentration. It is interesting to note 
that there is a higher variance of the data at pH 8.2 compared with pH 7.5, 
Figure 5.7B. 
In contrast to IPP4, the ThT kinetics of IPP5 aggregation at pH 6.5 starts at 
relatively high ThT fluorescence values but the signal does not change 
5.4 Aggregation Kinetics of Lipidated Peptides at 
Different Peptide Concentrations 
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significantly with time, Figure 5.7C. At pH 7.5, there is no lag phase, but a 
short sharp increase in ThT signal to some maximum is observed which is 
followed by a slow decrease in signal over longer times, Figure 5.7D. In both 
cases the maximum ThT signal for each peptide concentration is approximately 
linearly proportional to the peptide concentration, Figure 5.7C & D.  
 
Figure 5.7. ThT aggregation assays of lipidated peptides at different peptide 
concentrations and pH values. 
All samples were measured at the following peptide concentrations: 25 µM 
(pink), 50 µM (orange), 75 µM (blue), 100 µM (dark blue), 125 µM (green), 
and 150 µM (dark green). All experiments performed at 37 °C. A) IPP4 in 25 
mM phosphate buffer at pH 7.5. The solid lines show the best fit of the data to 
Equation 2.4. B) IPP4 in 25 mM Tris buffer at pH 8.2. The solid lines show 
the best fit of the data to Equation 2.4. C) IPP5 in 25 mM phosphate buffer at 
pH 6.5. Data not fitted. D) IPP5 in 25 mM phosphate buffer at pH 7.5. Data 
not fitted.  
A  pH 7.5 
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Figure 5.8. Kinetic parameters from the aggregation kinetics of IPP4. 
ThT kinetic data for six different peptide concentrations between 25 – 150 µM 
were fitted to Equation 2.4. Fits at lower peptide concentrations did not 
converge and therefore values for t1/2, lag time and apparent growth rate are 
not shown for 25 and 50 µM at pH 7.5 or 25 µM at pH 8.2. The error bars 
show the standard deviation between triplicate measurements. A) t1/2 at pH 7.5. 
B) t1/2 at pH 8.2. C) tlag at pH 7.5. D) tlag at pH 8.2. E) Apparent growth rate at 
pH 7.5. F) Apparent growth rate at pH 8.2. 
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The higher-order structures formed during the aggregation of the lipidated 
peptides, and proof of whether amyloid-like fibrils are forming or not, was 
assessed by SEM imaging. SEM imaging does not allow the highest resolution, 
but it gives a valuable overview of the higher-order structures of aggregates 
formed. Differences in the higher-order structure can point towards differences 
in the microstructure of the aggregates. Images of IPP4 aggregated in phosphate 
buffer at pH 7.5 recorded at different levels of magnification are shown in 
Figure 5.9. No fibrillar structures are observed at all at any level of 
magnification. Instead, roundish white dots on the barely covered region of the 
slide are seen, along with a sharp transition from the densely packed surface to 
the barely covered region, Figure 5.9C. The roundish white dots were analysed 
in detail: they were counted and the length of the major and minor axis of the 
dots were determined, Figure 5.10. It showed that the length of the major axis 
is Gaussian distributed with a mean of 14 nm, Figure 5.10C. Similarly, the 
length of the minor axis is distributed around 12 nm. Both values are linearly 
related to each other, Figure 5.10D.   
IPP4 aggregated in Tris at pH 8.2 shows different higher-order structures in 
comparison to samples aggregated at pH 7.5, Figure 5.11. The images at low 
magnification show long (>100 µm) thin species, Figure 5.11A, however, these 
are unlikely to be fibrils as there are many breaks in them. In some cases, 
thicker species can divide into two species with a sharp and well-defined angle 
between them Figure 5.11A. At higher magnifications, the aggregates appear 
curved and even smaller diameter, ∼20 nm, strands are observed, Figure 5.11B 
& C. In the right upper corner of Figure 5.11C a strand splits into two and the 
widths are approximately	20 nm or 10 nm for the thicker and the thinner 
strands, respectively. These structures show numerous cracks, probably caused 
by the drying process.  
 
5.5 Imaging of Higher-Order Structure in Aggregated 
Samples of Lipidated Peptides 
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Figure 5.9. SEM images of aggregated forms of IPP4 in phosphate buffer at pH 7.5. 
After 144 h of incubation time in the plate reader at 37 °C, 5 µL of 150 µM 
sample was dried on to a glass microscopy sheet. The images show the most 
typical of those obtained. A) Low magnification. Overview of regions with 
high and low peptide density. B) Higher magnification. Shows the image of a 
region where there is a high local concentration of aggregated peptide (Region 
1). C) Highest magnification. High local density on the left and less densely 
populated regions of the surface on the right (Region 2). The border is marked 
with a red arrow. The less densely populated region shows white roundish 
species (orange arrow). 
In regions with a high density of the aggregated sample, the surface is highly 
porous and no clear fibrillar structure can be observed, Figure 5.11D.  
SEM images of samples of IPP5 before and after the aggregation process at pH 
7.5 were taken, Figures 5.12 and 5.13. The sample imaged before the 
aggregation assay shows two different regions. One region is covered with 
more dense crystal-like aggregates, Figure 5.12A & C.  
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Figure 5.10. Size of oligomer-like IPP4 species formed in 25 mM phosphate buffer 
at pH 7.5 
A) SEM image of less densely populated region with the white roundish 
species. B) Binary and inverted version of Image A. C) Histogram of the 
number of aggregates distributed by the length of the major axis of the 
aggregates. The data follows a Gaussian distribution. D) Relation between 
the length of the major and minor axis of the aggregates. The average length 
of the major axis value is approximately 14 nm and for the minor axis it is 
12 nm. 
From imaging of pure buffer these aggregates are most likely due to salt in the 
buffer, possibly mixed with sample but it is not possible to differentiate 
between them, Figures 4.14D and 4.15D. The second region shows a typical 
surface without dense peptide coverage, Figure 5.12B & D. The darker marks 
are most likely thin scratches on the glass surface. In general, the resolution of 
SEM is not high enough to say anything about the possible oligomeric structure 
of peptides before the aggregation assay.  
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Figure 5.11. SEM images of aggregated forms of IPP4 in Tris buffer at pH 8.2.  
After 144 h of incubation time in the plate reader at 37 °C, 5 µL of 150 µM 
sample was dried on a glass microscopy sheet. The images show the most 
typical of those obtained. A-C) Show images of regions where there is a low 
density of aggregates, but flow marks are visible. A) Sharp and well-defined 
angle between two splitting flow marks (orange arrow) C) A strand splitting 
into two (red arrow) D) Shows a densely populated region of the surface. 
The same sample after the aggregation assay is shown in Figure 5.13. Two 
different regions were observed. A densely covered region shows a porous 
surface with some little holes in it, Figure 5.13A. The less densely covered 
region shows structures approximately 100 – 200 µm in diameter, seemingly 
consisting of shorter fibrils, as well as several thin short fibrils, Figure 5.13B 
& C. Characterisation of the fibrils showed a width of approximately 15 nm, 
Figure 5.13D. It is in the same range as the major axis of the roundish white 
dots or oligomer-like aggregates seen for IPP4 at pH 7.5, Figure 5.10. 
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Figure 5.12. SEM images of freshly dissolved lipidated peptides of IPP5 in 
phosphate buffer at pH 7.5.  
Before the samples were incubated in the plate reader, 5 µL of freshly 
prepared 150 µM IPP5 was dried on a glass microscopy sheet. The images 
show the most typical of those obtained. A & C) Show images of regions 
where there is a high density of aggregates. B & D) Shows a less densely 
populated region of the surface. C & D are at slightly higher magnifications 
than A & B. 
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Figure 5.13. SEM images of aggregated forms of IPP5 in 25 mM phosphate buffer 
at pH 7.5 and measurement of width of fibrils. 
After 144 h of incubation time in the plate reader at 37 °C, 5 µL of 150 µM 
sample was dried on a glass microscopy sheet. The images show the most 
typical of those obtained. A) Image of region where there is a high density of 
aggregates (Region 1). B) Less densely populated region of the surface 
(Region 2). C) Detail of Figure 5.13B. Arrows point towards measured 
fibrils. D) Normalised grey scale value plotted vs the distance orthogonal to 
the measured fibrils highlighted in Figure 5.13C. Each fibril was measured 
twice. The average width of the fibril is 15 ± 1 nm. 
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To learn more about the aggregates imaged with SEM a detailed study of the 
secondary structure was conducted. In Chapter 4, it was shown that even a 
small modification to GLP-1 (C-terminal amidation) influences the secondary 
structure of the peptide. It is, therefore, likely that a larger modification such as 
lipidation may also have an effect on secondary structure. The far-UV CD 
spectra of IPP4 and IPP5 were measured over a range of pH values in the same 
way as for GLP-1 and Am-GLP-1. However, the measurements on IPP4 and 
IPP5 were restricted to neutral and basic pH values due to the lack of solubility 
at lower pHs, Figure 5.4A. 
The far-UV CD spectra of IPP4 were measured at pH 7.5 (phosphate buffer) 
and 8.0, 8.5 and 9.0 (pH of the Tris buffer at room temperature). At 37 °C, 
under aggregation conditions, the pH of the Tris buffers was 7.7, 8.2 and 8.7, 
respectively. Freshly prepared samples of IPP4 show only minimal differences 
in secondary structure between pH 7.5 and pH 9.0, Figure 5.14A. After the 
aggregation assay, the secondary structure of the samples aggregated at pH 8.2 
and 8.7 show only minor changes in comparison to the freshly prepared 
samples, however, a clear change in the far-UV CD spectra occurs after 
aggregation at pH 7.5 and 7.7, Figure 5.14A. The CDPro analysis shows that 
this change in the far-UV CD spectra at pH 7.5 and pH 7.7 is due to the decrease 
of α-helical and increase of β-sheet structure. The data also show a small 
increase in turns, Figure 5.15A & B. 
Before the aggregation assay, the far-UV CD spectra of IPP5 were measured 
from pH 6.5 to 9.0 at six different pHs, Figure 5.14B. The secondary structure 
directly after the peptide was dissolved in aqueous buffer shows that, under 
basic conditions, a similar α-helical content to IPP4 but decreasing pH from 
8.0 to 6.5 results in a loss of helicity, Figure 5.15B. After the aggregation assay, 
the secondary structure, of samples aggregated between pH 7.7 and 8.7, 
changes only slightly in comparison to the secondary structure before the 
aggregation assay. However, between pH 6.5 and 7.5 there is a complete 
change in the secondary structure after aggregation. The sample at pH 7.7 
shows intermediate behaviour, Figure 5.14B & D.  
5.6 Secondary Structure of Lipidated Peptides 
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Figure 5.14. Far-UV CD spectra of lipidated peptides at different pH values before 
and after aggregation.  
A) Far-UV CD spectra for IPP4 in 25 mM phosphate buffer at pH 7.5 (bright 
green) and 25 mM Tris buffer at pH 7.7 (dark green), 8.2 (bright blue) and 
8.7 (dark blue) before (dashed lines) and after aggregation (solid lines). B) 
Far-UV CD spectra for IPP5 in 25 mM phosphate buffer at pH 6.5 (red), 7.0 
(orange) and 7.5 (bright green) and Tris buffer at pH 7.7 (dark green), 8.2 
(bright blue) and 8.7 (dark blue) before (dashed lines) and after the 
aggregation (solid lines). C) Comparison of the far-UV CD spectra of the 
same samples as shown in (A) and (B) before the aggregation assay. IPP4 
data shown as dashed lines and IPP5 as solid lines. D) Far-UV CD spectra of 
the same samples as shown in (A) and (B) after 144 h aggregation in the plate 
reader under the same conditions as the ThT assay. IPP4 data shown as 
dashed lines and IPP5 as solid lines. *The far-UV CD spectra were recorded 
at 25 °C, while the aggregation assays were performed at 37 °C. Thus, the 
pH values in the Tris buffers were 0.3 pH units higher when the far-UV CD 
spectra were acquired compared to the pH at which aggregation took place 
in the plate reader. 
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Figure 5.15. Secondary structure of the lipidated peptides at different pH values 
before and after the aggregation assay. 
The fractions are calculated from the far-UV CD spectra shown in Figure 
5.14 using CDPro. A) Fractions of α-helical, β-structure, turn and disordered 
structure of IPP4 and IPP5 after the peptides were dissolved, filtered and 
measured within 15 min. B) Fractions of α-helical, β-structure, turn and 
disordered structure of IPP4 and IPP5 after aggregation. The error is given 
as the standard deviation of the three algorithms used to calculate the 
secondary structure, Section 2.10. D/O stands for disordered structure. 
If one compares the far-UV CD spectra before the aggregation assay of IPP4 
and IPP5 directly, it can be seen that IPP5 has a less pronounced minimum at 
208 and 220 nm and its maximum at 190 nm is lower compared to IPP4, Figure 
5.14C. Plotting the far-UV CD spectra of the samples after the aggregation 
assay shows again the similarity in the behaviour of both peptides at basic pH 
values, Figure 5.14D. It is worth mentioning that the sample of IPP4 at pH 7.5 
shows certain similarities with the spectra of IPP5 at pH 7.7.  
The far-UV CD data were further analysed using CDPro. It shows that IPP4 
immediately after it is dissolved has more α-helical structure at pH 7.5, 8.0 and 
8.5 in comparison to IPP5. At pH 9.0, the amounts of α- versus β-structure are 
similar for both peptides. For freshly prepared IPP5, the fraction of α-helical 
structure is higher with increasing pH. After aggregation, the CDPro analysis 
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shows only minor changes of their α-helical content for both peptides incubated 
at pH 8.2 and pH 8.7. In contrast, from pH 7.7 towards more acidic pH values 
the fraction of α-helix decreases and β-structure increases for both peptides 
after 144 h of incubation in the plate reader. After the aggregation assay and at 
pH 7.5, IPP5 has a higher fraction of β-structure in comparison to IPP4, despite 
showing a lower ThT signal, Figures 5.5A & B and 5.15B. 
 
5.6.1 Influence of Lipidation and Amidation on the Secondary 
Structure 
A direct comparison of the secondary structure of all four peptides investigated 
is shown in Figure 5.16. Immediately after the peptides are dissolved Am-GLP-
1, IPP4 and IPP5 show, under all conditions, more α-helical structure than β-
structure. The fractional range of α-helicity spans from 0.3 to 0.5, whereas, the 
fraction of β-structure is always below 0.2, except for IPP5 at pH 6.5. GLP-1, 
the only non-amidated peptide of the four, shows a different behaviour of its 
secondary structure. At pH 6.5, the fractions of α-helical and b-structure for 
GLP-1 are still similar to the values of Am-GLP-1, IPP4 and IPP5. However, 
as the pH increases, the fraction of α-helices for GLP-1 becomes smaller and 
the fraction of β-structure higher, compared with the trend for the other three 
peptides where generally α-helicity increases with pH with a concomitant 
decrease in b. For GLP-1, from pH 8.0 upwards, the fraction of β-structure even 
exceeds the fraction of α-helical structure, Figure 5.16A.  
The main observation after aggregation is that the α-helical fraction for both 
lipidated peptides stays at a high level at basic pH values, consistent with the 
SEM data which indicate that neither lipidated peptide form large amounts of 
fibrils under these conditions. This suggests that the lipidation stabilises the α-
helical structure, especially at basic pH values. The non-lipidated peptides 
GLP-1 and Am-GLP-1 show α-helical fractions approaching zero and 
increased amounts of β-structure, consistent with the fact that these have 
formed amyloid-like fibrils over the 144 h incubation period. 
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Figure 5.16. Secondary structure of GLP-1, Am-GLP-1 and the lipidated peptides 
at different pH values before and after the aggregation assay.  
The fractions are calculated from the far-UV CD spectra shown in Figures 
4.29, 4.30, 4.31 and 5.14 using CDPro. A) Fractions of α-helical and β-
structure of GLP-1, Am-GLP-1, IPP4 and IPP5 after the peptides were 
dissolved, filtered and measured within 15 min. B) Fractions of α-helical, β-
structure, turn and disordered structure of GLP-1, Am-GLP-1, IPP4 and IPP5 
after aggregation. The error bars show the standard deviation of the three 
algorithms used to calculate the secondary structure, Section 2.10. 
Size-exclusion chromatography (SEC) measurements were conducted by Eva 
Brichtová to analyse the oligomer distribution of the lipidated peptides.341 SEC 
is a chromatographic method in which molecules are separated by their 
hydrodynamic radii with larger species eluting earlier from the column than 
smaller ones. IPP4 and IPP5 have been measured at a concentration of 
135 μM in 25 mM phosphate, pH 7.5. Before each run, the samples were 
filtered to remove any larger insoluble aggregates. At the first time point, IPP4 
and IPP5 show two different size distributions, Figure 5.17. IPP4 shows one 
broad peak eluting at 13.1 mL (A) (Figure 5.17), whereas IPP5 shows three 
different peaks eluting at 13.2 mL (A), 14.4 mL (B) and a minor peak at 17.6 
mL (C), Figure 5.17. 
5.7 Size of Lipidated Peptide Oligomers 
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Figure 5.17. IPP4 and IPP5 oligomer distribution analysed by SEC and estimated 
sizes of oligomers. 
The SEC experiments were conducted by Eva Brichtová and are also 
described in her First Year Report. IPP4 and IPP5 samples at a concentration 
of 135 µM and in 25 mM phosphate buffer at pH 7.5 were analysed on a 
Superdex® 200 Increase 10/300 GL column. The samples were filtered prior 
to the SEC analysis. The molecular weight and Stoke’s radius of oligomers 
were estimated using calibration curves. 
The molecular weight and Stoke's radii were determined to get a better insight 
into the species present. However, the values obtained are rough estimates only 
because the commercially-available SEC calibration kits are purely based on 
globular proteins, Section 2.18. The estimated number of peptide subunits in 
the different oligomeric species are 24/25 for peak A, 14 for peak B and 3 for 
peak C. A comparison of these results with the literature shows that Liraglutide 
populates a similar-sized oligomer as IPP5. The studies of Wang et al. and 
Bothe et al. on Liraglutide, a non-amidated analogue of IPP5, identify 
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oligomers consisting of 12/13 peptide molecules at pH values below pH 7 
which is similar in size to those found for IPP5 in peak B, however, under 
different pH conditions.91,227 For Liraglutide, smaller oligomers comprising of 
approx. 7 monomers were found at more basic pH values.91,227  
 
Figure 5.18. IPP4 and IPP5 oligomers distribution at two different time points 
analysed by SEC. 
The SEC experiments were conducted by Eva Brichtová and are also 
described in her First Year Report. IPP4 and IPP5 samples at a concentration 
of 135 µM and in 25 mM phosphate buffer at pH 7.5 were analysed on a 
Superdex® 200 Increase 10/300 GL column. The samples were filtered prior 
to the SEC analysis. A) IPP4 measured at t = 0 h and after 24 h of incubation. 
B) IPP5 measured at t = 0 h and after 24 h of incubation.  
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Additional measurements were conducted on IPP4 and IPP5, to learn more 
about the influence of incubation on oligomer size and stability. After 24 h 
incubation in 25 mM phosphate buffer (pH 7.5) at 37 °C and agitation with 180 
rpm, the oligomer distribution of IPP4 changed only marginally and only a 
minor shift of the maximum of the main peak was observed and a small new 
peak appeared, Figure 5.18A. This small peak elutes at around 8 mL and most 
likely results from the formation of higher molecular weight oligomers which 
elute in the void of the column, Figure 5.18A. 
IPP5 analysed after 24 h of incubation shows an increase in a high molecular 
weight peak eluting at around 7.5 mL. Similar to IPP4 this peak is attributed to 
large Mw oligomers which elute in the void volume of the column. The results 
for IPP5 also showed a decrease in the oligomeric peaks eluting at 13.2 mL (A) 
and 14.4 mL (B), Figure 5.18B. The reduction of peak B is more pronounced 
than that of peak A, Figure 5.18B. It is possible that this oligomer (peak B) is 
on-pathway and crucial for the further self-assembly of IPP5 into larger species.  
The faster self-assembly of larger soluble oligomeric species for IPP5 in 
comparison to IPP4 is in agreement with the ThT assay data which shows a 
steep increase in ThT fluorescence within the first 24 h only for IPP5 and not 
for IPP4 at pH 7.5, Figure 5.5A & B. 
Dynamic light scattering (DLS) data were collected for 150 µM IPP5 in 25 mM 
phosphate buffer at pH 7.0 and 7.5 and in 25 mM Tris buffer at pH 8.5 and 9.0, 
Figure 5.19A-D. Note that the Tris buffer samples change their pH at 37 °C, 
under aggregation conditions, to pH 8.2 and 8.7. In all four samples, 60-80% 
of the intensity of the monomeric peptide is represented by the first peak (Peak 
I), Figure 5.20A. The actual percentage of the species represented by Peak I is 
expected to be even higher than the given percentage of the intensity as smaller 
particles scatter light less and have therefore a lower intensity in comparison to 
larger species. The apparent hydrodynamic diameters of these peaks are 
approximately 7 nm at pH 7.5, 8.5 and 9.0 (pH values at 25 °C) and 14 nm at 
pH 7, Figure 5.20B. The smaller hydrodynamic diameter suggests that the 
peptide at pH 7.5, 8.5 and 9.0 stays in the solution as monomers or assembles 
into small oligomers like dimers. The larger oligomers with a diameter of 
Chapter 5: The Effect of Lipidation on the Physical Stability of Peptides 
218   
approx.14 nm formed at pH 7 likely contain more monomeric units than those 
species formed under more basic conditions. 
 
 
Figure 5.19. Results of DLS measurements to determine the size of IPP5 species in 
solution at time zero and at four different pH values. 
DLS measurements of 150 µM IPP5 at 25 °C shown as intensity vs. 
hydrodynamic diameter. The darker pink areas show the overlap of three 
repeated measurements. A) 25 mM phosphate buffer at pH 7.0, B) 25 mM 
phosphate buffer at pH 7.5, C) 25 mM Tris buffer at pH 8.5 and D) 25 mM 
Tris buffer at pH 9.0. At 37 °C, under aggregation conditions, the Tris buffer 
pH values change to pH 8.2 and 8.7. 
At all pH values studied, a smaller fraction of the total amount of peptide also 
forms oligomeric species with approx. hydrodynamic radii between 200 and 
300 nm (Peak II). Here, a difference can again be seen between pH 7 and the 
IPP5 at more basic pH values, where the former shows a higher size variance 
of the larger aggregates. 
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Figure 5.20. Analysis of DLS results: size and amount of smaller species of IPP5 
formed at four different pH values. 
Percentage of intensity and diameter of aggregates of peak I observed by 
DLS measurements of samples of 150 µM IPP5 at 25 °C. IPP5 was measured 
in 25 mM phosphate buffer at pH 7.0, 25 mM phosphate buffer at pH 7.5, 25 
mM Tris buffer at pH 8.2 (37 °C) and 25 mM Tris buffer at pH 8.7 (37 °C). 
A) Percentage of IPP5 found in peak I at different pH values. B) Apparent 
hydrodynamic diameter of species in peak I vs pH. 
After 144 h of incubation of IPP5 in a ThT plate reader at pH 7.0 and 7.5, the 
main peak observed in the DLS moves and indicates an increased amount of 
species with hydrodynamic diameters of around 200 nm, Figure 5.21A & B. 
These aggregates are likely either short fibrils or oligomers which have β-
structure because at pH 7.0 and 7.5 no distinct lag time was observed in the 
ThT kinetics, Figure 5.5B, and similarly sized aggregates are already present at 
the first time point. Under these conditions, the signal corresponding to the 
smaller species with hydrodynamic diameters of approximately 7 or 14 nm, 
respectively, has nearly entirely vanished. At pH 8.2 and 8.7, the DLS 
measurements were not reproducible and, for unknown reasons, showed single 
spikes with high variance, Figure 5.21C & D. This may be because of the 
concentration of peptide used in these experiments, which was chosen to be 
consistent with other biophysical measurements, but which is rather low for 
DLS. 
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Figure 5.21. Results of DLS measurements to determine the size of IPP5 species in 
solution after 144 h incubation at 37 °C and at four different pH 
values. 
DLS measurements performed at 25 °C of samples of 150 µM IPP5 which 
have been incubated with shaking at 37 °C. Data shown as intensity vs. 
hydrodynamic diameter. The darker pink areas show the overlap of three 
repeated measurements. A) 25 mM phosphate buffer at pH 7.0, B) 25 mM 
phosphate buffer at pH 7.5, C) IPP5 incubated in 25 mM Tris buffer at pH 
8.2 and D) IPP5 incubated in 25 mM Tris buffer at pH 8.7.  
  
pH 8.2 pH 8.7 
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5.8.1 Solubility of Lipidated Peptides is Restricted to Neutral and 
Basic Conditions 
The solubility of IPP4 and IPP5 is dominated by the influence of the lipid, 
which causes very low solubility at acidic pHs. Towards neutral and more basic 
pH values, the solubility increases for both peptides. For IPP4 this starts around 
pH 7.5, in comparison to pH 6.5 for IPP5. This difference is probably due to 
the differences in net charge at these pH values, where IPP4 has a smaller net 
charge than IPP5. The measured pI values of pH 6.1 and 5.6 for IPP4 and IPP5, 
respectively, are in good agreement with the solubility data, a significant 
increase in solubility being observed 1 to 1.5 pH units above the pI. The slightly 
higher difference of 1.4 pH units for IPP4 can be explained by the different 
slope of the net charge versus pH. The relative net charge of IPP5 increases 
faster than for IPP4 with increasing pH in this range.  
5.8.2 Is There Evidence that Lipidated GLP-1 Peptides Form 
Amyloid-Like Fibrils? 
IPP4 
For IPP4, the fact that there is a sigmoidal increase in ThT fluorescence over 
time when it is incubated at 37 ℃ at pH 7.0 and 7.5 and the fact that the final 
ThT fluorescence is higher than that of GLP-1 and Am-GLP-1 under similar 
conditions, indicate that IPP4 might form fibrils under these conditions. In 
support of this, the far-UV CD spectra show clear increases in b-structure at 
pH 7.0 and 7.5. However, the SEM images recorded at the end of the incubation 
at pH 7.5 do not show any evidence of fibril formation. Nevertheless, there are 
regions which show dense peptide coverage possibly due to amorphous 
aggregation, indicating that some aggregation phenomenon has taken place. 
The density of coverage and the amorphous aggregation may well obscure any 
fibrils present in the sample.  
5.8 Discussion  
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In contrast, IPP4 at pH 8.2 after incubation at 37 ℃  for 144 h, shows a 
considerably lower ThT fluorescence either indicative of the formation of a 
smaller quantity of amyloid-like fibrils or a different species of aggregate that 
cannot bind ThT, or can bind only weakly. These results are consistent with the 
observed lack of change in the far-UV CD spectra of IPP4 before and after 
aggregation suggesting that amyloid-like fibrils are not formed at this pH. The 
SEM results are consistent with this: no amyloid-like fibrils are seen, however, 
there is some evidence of aggregated species of unknown type.  
IPP5 
For IPP5, an increase in ThT fluorescence was observed after incubation at 
37 ℃ for 144 h at pH 6.5 and 7.5, albeit to a much smaller degree than IPP4 
under similar conditions. The lower ThT fluorescence is despite the fact that 
IPP5 has a higher negative net charge in comparison to IPP4 under basic 
conditions which should attract the positively charged ThT to a greater extent. 
It has been shown that the }-potential of fibrils, which is strongly correlated to 
the net charge, influences the binding affinity of the positively charged 
Thioflavin T.291 Despite the smaller change in ThT fluorescence, there was a 
noticeable change in the far-UV CD spectra of IPP5 under these conditions, the 
CDPro analysis indicating a pronounced increase of β-structure and a decrease 
in α-helical structure. At pH 7.5, the aggregated form of IPP5 showed some 
evidence of fibrils in the SEM imaging, however, the observed fibril-like 
structures differ from the typical rigid fibrils observed for GLP-1 and 
Am-GLP-1, Figure 5.13C. In this case, the IPP5 aggregates resemble more 
closely the thin curly fibrils observed in the early stages of aggregation of GLP-
1, Figure 3.15B. 
At pH 7.7 and above, there is little change in ThT fluorescence from start to 
end of aggregation, and the difference in the far-UV CD spectra before and 
after aggregation is not as pronounced as for the more acidic pH values. Thus, 
there is little evidence that amyloid-like fibrils have formed under these 
conditions. 
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5.8.3 ThT Fluorescence Caused by Non-Fibrillar Structures 
Although an increase in ThT fluorescence is frequently used as an indicator of 
amyloid-fibril formation, it cannot be excluded that other aggregates, such as 
oligomers, can also interact with and increase the fluorescence of ThT. This is 
because ThT does not recognize fibrils per se, but it is assumed to bind to the 
molecular grooves which are typically found on the surface of amyloid 
fibrils.362 This raises the question of the whether the increase in ThT 
fluorescence observed for both IPP4 and IPP5 at near neutral pH values is due 
to fibril formation or the formation of some other aggregated species.  
The question arises, therefore, what is causing the high fluorescence signal if 
not amyloid-like fibrils? From the SEM imaging, it appears that IPP4 at pH 7.5 
shows two different kinds of aggregated morphologies. The glass sheet was 
mostly covered by a dense rather amorphous cover of peptides, which 
constituted most of the peptide molecules. However, small oligomers could be 
observed in the less densely covered regions, Figures 5.9C and 5.10. It is 
possible that the densely covered region consists out of tightly packed 
oligomers and it is, therefore, not clear if there are two different species present 
or not.  
At pH 8.2 the SEM images again show an extended region with thick peptide 
cover and in a less densely covered region, some extended structures can be 
seen, however, they do not show typical rigid fibril-like structures either.  In 
both cases, ThT may bind to the non-amyloid like aggregates observed 
(amorphous or with more regular structure) and increase in fluorescence giving 
rise to the typical sigmoidal ThT kinetics observed. The same may also be the 
case for IPP5, however, here some short thin fibrils were also observed.  The 
hypothesis that ThT also binds to non-fibrillar species, also explains why the 
maximum ThT fluorescence of IPP5 is lower than for IPP4 despite it forming 
more β-structure during the aggregation process.  
Collectively, the results for both lipidated peptides suggest that during 
aggregation the peptides increase their β-structure but that this structure forms 
inside oligomers or other types of amorphous structures instead of amyloid 
fibrils. 
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5.8.4 Kinetics of the Formation of Aggregates 
The ThT data for IPP4 and IPP5 at different pH values establishes that there 
are three types of behaviour observed. The first, in which the ThT fluorescence 
increases to a high value showing standard sigmoidal kinetics, is observed for 
IPP4 at pH 7.5 and 7.7. In the second class, the ThT shows an immediate or 
rapid increase in fluorescence reaching a final value that is significantly lower 
than in the first case. IPP5 shows such kinetics at pH 6.5 to 7.5. In the third 
case, there is either little or no increase in ThT fluorescence over the time 
course of the experiment, and in some cases, the low starting ThT fluorescence 
decreases even further. This is found for IPP4 and IPP5 at pH 8.2 and 8.7. The 
first behaviour observed suggests an aggregation reaction that follows a classic 
nucleation-propagation mechanism, the second behaviour is also consistent 
with this, but the initial primary nucleation must be rapid. However, in the 
second case, the kinetics are also compatible with a mechanism in which 
oligomerisation does not involve a nucleation step. The third case suggests that 
no aggregation occurs or that the aggregated species is not capable of binding 
to ThT.  
5.8.5 Unusual Decrease of ThT Fluorescence 
At pH 7.5 and higher peptide concentrations, the ThT fluorescence of IPP5 
decreases linearly after reaching a maximum early in the assay, Figure 5.7D. It 
is interesting to note that pH 7.5 is close to the pH value where a change in 
aggregation behaviour is observed (pH 7.7 and higher). It is possible to 
speculate that if two different aggregated species with either different ThT 
affinities or which affect the ThT fluorescence differentially are populated 
under these conditions, that this slow decrease in the ThT signal, could be due 
to the transition from one aggregated species to another, Figure 5.22. 
Alternatively, the decrease could be explained by a structural change of the 
aggregate and therefore, a different ThT affinity or effect on fluorescence, 
Figure 5.22. From the amorphous structures observed with SEM for IPP5 at pH 
7.5, it is likely that these are all non-fibrillar aggregates, Figure 5.13A. 
It may also be possible that hydroxylation of ThT causes the decrease of ThT 
fluorescence observed at the higher pH values.301  
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Figure 5.22. ThT fluorescence caused by non-fibrillar structures. 
The formation of oligomers X and Y is described by the primary nucleation 
rate constants knX and knY as well as the dissociation rate constants knX- and 
knY-. The transition between oligomers X and Y and the structure change 
between oligomer X and X* is defined by the rate constants kXY, kYX, kXX* 
and kX*X, respectively. If smaller non-fibrillar aggregates bind ThT, as 
suggested by the IPP4 and IPP5 data, a change from one species X to another 
species Y can cause a change in ThT fluorescence f. Similarly, a 
conformational change illustrated by the change in structure from X to X* 
can have the same effect.  
5.8.6 Peptide Concentration Dependence of the Aggregation 
Kinetics 
IPP4 
The aggregation kinetics at different peptide concentrations of IPP4 showed 
two distinct characteristics. At pH 7.5, the peptide aggregated faster with 
increasing peptide concentration, consistent with a classic nucleation-
propagation mechanism. Under more basic conditions (pH 8.2), the kinetics 
change and slightly shorter but constant lag times show that the aggregation 
process must be influenced by an additional factor next to the nucleation-
propagation mechanism, for example, off-pathway species. The observed 
decrease of the ThT intensity under basic conditions is most likely influenced 
by a change of the populated species, a structural change of the aggregate or 
the hydroxylation of ThT301 as discussed in Section 5.8.5. 
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IPP5 
The concentration dependence of IPP5 aggregation was measured at pH 6.5 
and 7.5. In both cases, no lag time is visible in the aggregation kinetics which 
may be due to the lag phase being shorter than the time needed to prepare the 
samples before the aggregation assay is started or may be due to seeds in the 
freshly prepared samples. There is an approximately linear relationship 
between the final ThT signal and the peptide concentration, suggesting some 
type of aggregation process has occurred. It is most likely not caused by fibrils 
but ThT binding to oligomers, assuming that oligomers form rapidly after the 
peptide is dissolved in aqueous buffer and can bind to and restrict the rotation 
of the ThT leading to an increase in fluorescence. 
5.8.7 Different Oligomer Sizes Influenced by Sequence and pH  
The SEC measurements of IPP4 and IPP5 at pH 7.5 established that the two 
peptides can form oligomeric species, A, B and C. IPP4 forms only oligomers 
of type A which contain approx. 24 monomers. Oligomers of the same size 
were also found in smaller amounts for IPP5, the majority of which forms 
smaller oligomers containing approx. either 14 or 3 monomers.  
The different-sized oligomers of IPP5 can be compared to oligomers found for 
Liraglutide, a non-amidated analogue of IPP5. Frederiksen et al. showed by 
small-angle X-ray scattering (SAXS) that at pH 8.1, Liraglutide assembles into 
oligomers with a global shape of hollow elliptical cylinders which are either 
hexa-, hepta- or octamers depending upon peptide concentration.363 
Asymmetric flow field flow fractionation-UV-multi-angle light scattering 
(AF4-UV-MALS) measurements confirmed the size of the oligomers as 
hexamers – the solutions being at lower concentrations in this case.363  
Additional simulations predicted heptamers as the most likely size of the 
oligomers.363  
These findings were reproduced by Wang et al., who also described one 
additional larger oligomer using static-light scattering (SLS).227 They described 
a pH-dependent assembly of octamers below pH 7.0 and dodecamers under 
more basic conditions. Measurements were performed in a range between pH 
6.4 and 8.7 at a concentration well over that used in the previous study (over 1 
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mM). Bothe et al. found similar results and reported heptamers below pH 7 and 
oligomers consisting out of 13 monomeric units above pH 7. The size of the 
oligomers was measured using SEC and online DLS and MALS.91  
IPP5 forms a similar-sized oligomer to Liraglutide with approx. 14 monomer 
subunits. However, it forms these oligomers at pH 7.5, a pH at which 
Liraglutide assembles into smaller heptamers. IPP5 oligomers appear to be 
similar in size to the larger oligomers of Liraglutide detected at high 
concentrations using static light scattering227, suggesting that IPP5 and 
Liraglutide may populate similar species, albeit under different conditions.  
Importantly, IPP5, despite having a higher propensity than Liraglutide to form 
larger oligomers, still assembles further into even bigger aggregates at lower 
pH values close to and below pH 7. The differences observed between IPP5 
and Liraglutide are most likely caused by the difference in net charge or 
different concentrations at which the measurements were conducted.  
 
Figure 5.23. Influence of different on-pathway oligomers on the aggregation 
kinetics. 
Different sized on-pathway oligomers at two different pH values associated 
with different lag times in the aggregation kinetics. F and F* may be fibrils 
but they may also be some other form of aggregate, for example amorphous 
aggregate. The process is described by the primary nucleation rate constants 
knA and knB, the dissociation rate constants knA- and knB-, the rate constants 
kAB, kBA, knF and knF*, the concentrations of the oligomers cA and cB and the 
oligomer size nB and nA. 
A comparison of the aggregation propensity of IPP4 and IPP5 using the ThT 
assay data, Figure 5.7, shows that IPP5, which is initially self-assembled into 
smaller oligomers, than IPP4, aggregates faster, in agreement with results on 
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Liraglutide. Bothe et al. showed that samples with smaller oligomers (pH 8.1) 
also aggregate faster.91 Therefore, it seems that the size and concentration of 
oligomers may have a direct effect on the aggregation kinetics, independent of 
lipidation site, C-terminal amidation or pH, Figure 5.23. 
5.8.8 Two Different Aggregation Behaviours That Depend on pH 
The data for both lipidated peptides, IPP4 and IPP5, show an apparent change 
IPP4 and IPP5 both show a change in their aggregation kinetics depending on 
pH, Figure 5.5. A possible explanation for this is that the peptides follow 
different aggregation pathways to each other, and pathways can vary with pH, 
Fig. 5.23. For example, IPP4 and IPP5 may populate different-sized oligomers 
to each other and the size of the oligomers may vary with pH. In support of this 
hypothesis, a difference in the size of smaller oligomers was measured by DLS 
for IPP5 between pH 7.0 and 7.5. A similar pH-induced switch between two 
different oligomeric species was found for Liraglutide by Wang et al. and 
Bothe et al. (N.B. Liraglutide is the same as IPP5 but lacks the C-terminal 
amidation, see Section 5.8.7.91,227 
The fact that IPP4 and IPP5 both change their aggregation behaviour at a 
slightly more basic pH value than that observed with Liraglutide can be 
explained by the lower pI of Liraglutide and subsequent higher negative net 
charge under these conditions in comparison to IPP4 or IPP5. 
5.8.9 Influence of the Amidation and Lipidation on the 
Secondary Structure 
The attachment of a spacer and fatty acid group to Am-GLP-1 affects the 
secondary structure of the peptide and leads to increase in α-helical structure in 
freshly dissolved peptide samples. However, amidation at the C-terminus has a 
similar significant effect on secondary structure than the lipidation itself even 
though this is a much larger modification, Figure 5.16A. This finding 
underlines the potent influence of the C-terminus amidation on the secondary 
structure of GLP-1-like peptides and potentially the role of net and local charge 
on secondary structure.  
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5.8.10 Conclusions 
One of the most significant influences of lipidation is on peptide solubility. The 
lipidation restricts the solubility to neutral and basic conditions. This may be 
due to the change in the net charge of the molecule but is more likely associated 
with the addition of a large hydrophobic fatty acid moiety. The lipidation also 
influences the secondary structure. Most notable is the higher fraction of α-
helical structure in freshly dissolved samples, however, C-terminal amidation 
has also been shown to have a similar effect. 
The fact that IPP4 shows no formation of fibrils despite having a sigmoidal 
shaped increase of its ThT fluorescence and an increase of β-structure with time 
indicates that the ThT signal and change in secondary structure is not always 
correlated to the formation of amyloid-like fibrils. The ThT signal is, in this 
case, most likely caused by ThT binding to oligomeric structures or amorphous 
aggregates or both362 which still form partial β-sheet structure. Lipidated 
peptides often form micelles or micelle-like structures due to their amphiphilic 
nature. For example, for the lipidated analogue of the gut-derived peptide 
hormone PYY3-36, was shown to forms micelles containing lipopeptides with 
an α-helical conformation.34 The amount of β-structure, as measured by far-
UV CD and indirectly by ThT binding, leads to the conclusion that if IPP4 
forms micelles under these conditions, they must have some β-sheet structure. 
It can also be concluded that the observed amount of β-structure is not 
correlated with the intensity of the ThT fluorescence. For example, IPP5 shows 
a lower ThT fluorescence than IPP4, despite the formation of thin fibrils and 
the most substantial observed increase of β-structure. This is even more striking 
due to the fact that IPP5 has a higher negative net charge under basic conditions 
which should lead to a better binding of positively charged ThT.291 It would be 
worth studying the aggregates in more detail by cryo-TEM and SAXS as 
undertaken for PYY by Hutchinson et al. to learn more about these self-
assembly structures. 
Similar to Liraglutide, a pH-dependent change in aggregation behaviour has 
been described here for IPP4 and IPP5. In this study, different types of 
aggregation kinetics were observed dependent upon peptide and pH. A switch 
between behaviours occurred at pH values approx. 2 units above their pI value. 
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The different aggregation behaviour is associated with the formation of 
different sized oligomers or micelle-like structures, these being influenced by 
the sequence of the peptide as well as the pH conditions.  
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6.1.1 Background 
The work presented in this Thesis is focused on the physical stability and 
aggregation kinetics of peptides belonging to the GLP-1 family, which is 
influenced by parameters such as pH, peptide concentration, net charge and 
chemical modifications (lipidation). Protein/peptide aggregation is a very 
widely studied topic and draws its importance on one hand from its connection 
to several human diseases, for example, Alzheimer’s, Parkinson’s or 
Huntington Diseases,37 and on the other hand from issues faced by the 
pharmaceutical industries who use peptides as biopharmaceutics.364–366 GLP-1 
receptor agonists are under development and used to slow digestion and help 
lower blood sugar levels.226,256,262,367 However, the use of therapeutic peptides 
can be challenging because of problems with their physical stability during 
long-term storage because of fibrillation and precipitation or their short half-
life in vivo after injection.368  
Understanding the formation and proliferation of peptide aggregates under a 
wide range of conditions is, therefore, of great interest scientifically as well as 
6 CONCLUSIONS AND FUTURE 
WORK 
6.1 Summary and Conclusions 
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commercially.369 The results of this study have led to a better understanding of 
the mechanism of aggregation and amyloid formation of GLP-1 and three GLP-
1 analogues. GLP-1 is a naturally occurring incretin hormone, and even though 
it is in extensive use for medicinal purposes, our knowledge about its 
aggregation kinetics and understanding of this self-assembly process is limited.  
A specific focus of these studies was to gain further information on, and 
understanding of, the unusual behaviour of the aggregation kinetics with 
respect to its peptide concentration dependence as had been shown previously 
by the Jackson group.5 In particular, the aim of the studies presented in this 
Thesis, was to extend the preliminary studies conducted at pH 7.5-8.2 to acidic 
pH values and to use time-course experiments to gain further insight into the 
different species populated during aggregation under different conditions.  
In addition, it was crucial to compare the results on the lipidated GLP-1 
analogues investigated here with those published for a different lipidated GLP-
1 variant, Liraglutide. It had already been shown by Wang and co-workers that 
changes in pH have significant influence on the aggregation kinetics of 
Liraglutide.227 In this case, two different sized oligomers were shown to be 
populated at different pH values.227 For the same modified peptide, it was later 
shown by Bothe et al. that an increase in the peptide concentration, lead to 
longer lag times in aggregation experiments.91 
6.1.2 Summary of Experimental Chapters  
In this Thesis, the first approach was to undertake a more detailed study of 
GLP-1, Chapter 3, extending the pH range over which the aggregation was 
monitored. Not only was the aggregation of GLP-1 measured over a wide range 
of conditions but also at different timepoints to learn more about the mechanism 
underpinning its aggregation kinetics. In the second study, Chapter 4, the 
aggregation kinetics of a C-terminal amidated analogue Am-GLP-1 were 
established and compared to those obtained for GLP-1. The amidation, a rather 
small perturbation with a predictable influence on the net charge of the peptide, 
was shown to perturb the aggregation kinetics in a pH-dependent manner. The 
results enabled the influence of net charge on the aggregation kinetics of GLP-
1 and Am-GLP-1 to be quantified. In the final study, the aggregation kinetic of 
Chapter 6: Conclusions and Future Work 
  233 
two lipidated analogues of Am-GLP-1 were investigated and compared with 
those already obtained for Am-GLP-1 as well as GLP-1, Chapter 5. In all three 
Chapters, a wide variety of experimental methods were employed. To study the 
secondary structure of the peptides far-UV circular dichroism (CD), and 
Fourier-transform infrared spectroscopy (FT-IR) were used. Both datasets were 
analysed using a singular value decomposition (SVD) method. ANS, 
tryptophan and ex-situ ThT fluorescence were all measured to gain information 
about the changes in tertiary structure during aggregation. ThT-assays were 
used to follow the aggregation kinetics and to determine the lag and t1/2 of the 
aggregation process, using a sigmoidal fit of the data. In addition, the ThT-
assay data was also fitted with a nucleation-elongation model (NEF) to learn 
more about the aggregation kinetics and its rate constants. To probe the 
structure and size of species in solution, dynamic light scattering, atomic force 
microscopy and scanning electron microscopy were all employed. All 
experiments were performed over a wide range of conditions. 
6.1.3 Symmetrical Aggregation Propensity Around the pI  
Results of measurements of the aggregation of GLP-1 under acidic conditions, 
Chapter 3, showed that a relatively small change in pH altered the aggregation 
behaviour, illustrating that the self-assembly of GLP-1 is very sensitive to pH 
not only in basic conditions but also in the acidic pH regime. Results showed 
that at pH 3.5 but not pH 3.0, off-pathway oligomers become populated leading 
to a change in the dependence of the aggregation kinetics on peptide 
concentration. The results demonstrate that the aggregation propensity and the 
population of off-pathway species is strongly related to the pH and the pI of the 
peptides. This was also shown to be true for the C-terminally amidated variant 
of GLP-1, Am-GLP-1. The population of off-pathway oligomers for GLP-1 
and AM-GLP-1 surprisingly results in relatively long lag times close to their 
pIs and therefore also under conditions of relatively low net charge on the 
peptides. This is stark contrast to previous studies on other peptides where they 
were shown to aggregate faster if they carried a lower net charge.131–136 
However, the findings for GLP-1 and its analogues can be explained by the fact 
that they have a significant propensity to form off-pathway species near their 
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pI values, whilst other peptides, such as Ab, do not.85,370 
6.1.4 The Net Charge Influences the Aggregation Propensity 
more than the Secondary Structure of the Monomer 
The motivation to study the aggregation of Am-GLP-1 and to compare it to that 
of GLP-1 came from two ideas: First, it enables the influence of the net charge 
of the peptide on its aggregation propensity to be determined without a 
significant change in the sequence and, secondly, it provides a starting point 
for further studies to assess the impact of chemical modification (lipidation) on 
physical stability. This is because the two lipidated forms of GLP-1 available 
are both amidated at the C-terminus. The results clearly show, for all four 
peptides, several properties of the peptide are correlated with net charge.  
Starting with the protonation sites (and state) of the peptides, these directly 
affect the net charge but were also shown to influence the secondary structure 
of the monomeric peptide as well as the pI and similarly the solubility of the 
peptide at different pH values. Net charge and/or secondary structure both 
affect the aggregation properties. Results described in Chapters 3 and 4, 
strongly suggest that the net charge has a more significant influence on the 
aggregation kinetics compared with secondary structure, Section 4.13.2. 
6.1.5 Changes of Secondary Structure at pH Values near the pKa 
Values of Specific Side Chains Influence Aggregation 
Propensity 
The results of the studies described in Chapters 3 and 4 also suggest that the 
secondary structure also influences the aggregation propensity. However, the 
relationship between the secondary structure and the aggregation propensity is 
more specific to certain conditions. The far-UV CD data suggests that, 
especially in the acidic regime between pH 3.0 and 4.5, the de-/protonation of 
the side chains of aspartic acid and glutamic acid cause a significant increase 
of the α-helical structure of both non-lipidated peptides, Figure 4.32A. The 
observed change in secondary structure most likely affects the aggregation 
propensity of both peptides similarly. While at pH 3.0, both peptides follow 
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nucleation-elongation kinetics with decreasing lag times with increasing 
peptide concentration, leads the increase in alpha-helical structure to a change 
of the aggregation kinetics at less acidic pH values. For example, Am-GLP-1 
shows constant lag time with increasing peptide concentration at pH 4.0 and 
GLP-1 shows even increasing lag time with increasing peptide concentration 
already at pH 3.5. Both behaviours are typical for the formation of off-pathway 
species. The influence of the secondary structure on the aggregation propensity 
under these conditions may also explain why, for example, GLP-1 has similar 
aggregation propensities in the acidic and basic pH regimes despite having very 
different net charges.  
Notable, and against our expectations, a substantial effect of the amidation on 
the secondary structure of the peptide was observed under neutral and basic 
condition: Am-GLP-1 having more α-helical structure than GLP-1, over wide 
range of conditions. It is also of note that, under all the conditions at which the 
aggregation kinetics follow simple nucleation-elongation kinetics where only 
on-pathway oligomers are significantly populated, the peptides show a higher 
fraction of β-sheet in comparison to α-helical structure in the monomeric state. 
In summary, the data suggests the net charge is the main factor influencing the 
aggregation kinetics, however, under specific conditions, there is an additional 
effect and the secondary structure in the monomer also plays a role.  
6.1.6 Lipidation and Amidation Increase α-Helicity of Freshly 
Dissolved Peptides  
The lipidation of peptides is a widely used modification in peptide therapeutics 
which improve half-lives in vivo as well as increasing the physical stability of 
a peptide in vitro. The latter is significant in the improvement of drug 
formulations.3,371  
The study of IPP4 and IPP5 described in Chapter 5 shows that the solubility of 
GLP-1 is greatly affected by lipidation resulting in them only being soluble at 
neutral/basic pH values above their pIs. It was previously reported that 
lipidation increases the α-helical content of freshly dissolved samples in a study 
of Liraglutide, a lipidated GLP-1 analogue.224  The data presented in Chapter 5 
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confirms this finding and extends the conclusion to other lipidated GLP-1 
analogues. However, by comparison of the data on IPP4 and IPP5 with GLP-1 
and Am-GLP-1, it becomes clear that C-terminal amidation itself is responsible 
for the increase in α-helicity observed.  
6.1.7 Lipidated Peptides Self-Assemble to form β-Sheet 
Structures Independent of the Formation of Rigid Fibrils 
SEM imaging of the lipidated peptides which had been incubated under the 
same conditions as those that induced amyloid fibrils in GLP-1 and Am-GLP-
1, showed that they have a much lower tendency to form rigid fibrils. At the 
same time, the ThT fluorescence and the far-UV CD data showed the formation 
of β-sheet during their aggregation. It can therefore be concluded that these two 
lipidated variants of GLP-1 form a β-sheet rich oligomeric structure, which 
does not appear to be able to convert into amyloid-like fibrils over the 
timescales used in this study. 
6.1.8 GLP-1 Forms β-Sheet Rich Intermediate Species   
The time-course measurements of the secondary structure of GLP-1 under basic 
conditions showed that GLP-1 forms intermediate oligomers/aggregates that 
contain considerable β-sheet content during the lag phase. Surprisingly, these 
aggregates cannot bind to ThT. There is some evidence of short fibril-like 
aggregates already present during the lag phase, as shown by AFM in Figures 
3.17D and 3.18D, however, it is likely that these species, which are likely to 
bind to ThT, are not present in significant amounts. This suggests that fibrillar 
the oligomers/aggregates formed which contribute to the increase in b-sheet 
signal are globular in nature.  
6.1.9 pH Switch Observed for Four Different GLP-1 Analogues  
The lipidated variants IPP4 and IPP5 also show pH-dependent self-assembly 
behaviour similar to GLP-1 and Am-GLP-1. GLP-1 changes its aggregation 
behaviour twice, between pH 3.0 and pH 3.5 as well as between pH 7.5 and pH 
8.2. Similarly, Am-GLP-1 changes its aggregation kinetics between pH 3.0 and 
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4.0. Also, in the basic regime, a pH switch can be observed for Am-GLP-1, 
however, the pH value at which this occurs is not as well defined as in the case 
of GLP-1. Measurements on the two lipidated peptides were restricted to the 
basic regime where they are soluble, but they also showed a pH-dependent 
aggregation behaviour. IPP4 changes its aggregation behaviour between pH 7.7 
and 8.2 and IPP5 between pH 7.5 and pH 7.7. These results indicate that the 
pH dependence is a common feature of the aggregation of all GLP-1 analogues. 
The data strongly suggests that the pH value at which the self-assembly 
behaviour changes is related to the pI of the peptides.  
6.1.10 Physical Evidence for Different Aggregates Formed Under 
Different pH Conditions for Individual Peptides 
Even though GLP-1 and Am-GLP-1 form similar fibrillar species over a wide 
range of pH values, there is evidence that the structure and aggregation 
pathways can vary. For example, GLP-1 showed different sized curly fibrils 
during the lag phase under acidic and basic conditions. For Am-GLP-1, 
variations in high-order structures were observed under neutral and basic 
conditions, indicating indirectly that the fibrillar structures formed might be 
different.  Finally, both peptides also show changes in their ANS binding 
affinity between acidic and basic conditions. Similarly, the Trp side chain in 
the fibrils are more buried and has less contact with the aqueous solvent under 
acidic conditions.  
6.1.11 Rate Constants are not Globally Valid Under Different 
Sample Concentrations 
In the last decade, much work has gone into developing methods for the fitting 
of kinetic data from aggregation reactions, simulation of aggregation and 
prediction of peptide aggregation propensity. From the fitting of experimental 
aggregation data for some peptides to different mathematical models, it has 
been possible, in some cases, to identify some of the critical processes 
underpinning the self-assembly reactions on the molecular level. These 
mathematical models have helped to generate information on the relative 
importance of primary nucleation, elongation, fragmentation and surface-
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catalysed secondary nucleation.83,353,354 Recently, the active suppression of 
fibril elongation by off-pathway oligomers was shown for human and salmon 
calcitonin (hCT/sCT).90 
In this study, attempts to fit the experimental data for the aggregation of GLP-
1 and Am-GLP-1 at different peptide concentrations to a NEF model 
(nucleation, elongation and fragmentation) were undertaken. However, it was 
not possible to fit the data for different peptide concentrations globally using 
this model and these methods, which shows that, in this case, the rate constants 
of the NEF model are not independent of the peptide concentration. This is 
almost certainly because there are off-pathways species populated during the 
aggregation of GLP-1 and Am-GLP-1 requiring a more complex model and 
fitting algorithm to be developed. 
6.2.1 Further Characterisation of the Structure of Oligomeric 
Species 
To increase our understanding of the pH dependence of GLP-1/Am-GLP-1 
aggregation, more detailed measurements on the size and structure of the 
oligomeric species populated at different pH values is essential. For some of 
the peptides/conditions studied, DLS and SEC were used to measure the size 
of the oligomers. Additional measurements using both techniques, for all four 
peptides over a wider range of conditions, especially close to and around the 
pH conditions at which all four peptides change their aggregation behaviour, 
would be beneficial. In addition, DLS experiments which were undertaken at 
different time points for GLP-1, showed a high variability, Figure 3.25A-D, 
likely because the concentration of peptide was insufficient. The DLS 
experiments should be repeated at higher peptide concentrations, and ThT 
aggregation assays should be performed under the same conditions to allow a 
true comparison of the different datasets. For a more detailed analysis of the 
molecular weight of the oligomers formed during aggregation, alternative 
techniques such as SAXS363 and SEC-MALS91,372 could be employed.  
6.2 Further Work  
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Another promising approach to investigate the aggregation kinetics of peptides 
and small proteins is the combination of mass spectrometry (MS) and its allied 
technique of ion mobility mass spectrometry (IM-MS). IMS provides 
information on the cross-sectional area of ions in the gas phase as measured by 
their mobility through a buffer gas, as well as providing information on the 
mass of the corresponding species.373 IM-MS can therefore separate complex 
mixtures and ions which are indistinguishable by mass spectrometry alone. For 
excellent reviews on how IM-MS is used to study aggregation and amyloid 
formation, reporting recommendations for IM-MS data and the different IM-
MS techniques used in drift-time ion mobility spectrometry (DTIMS), 
traveling-wave ion mobility spectrometry (TWIMS) and field-asymmetry ion 
mobility spectrometry (FAIMS) see Ashcroft (2010)374,  Gabelica et al. 
(2019)375 and Lanucara et al. (2014)376 
To analyse the aggregation pathway of peptides and proteins using MS, and 
specifically ESI-MS (electrospray ionisation-MS) or nano-ES-MS (nanoflow 
electrospray-MS), it is crucial that non-covalently bound peptide complexes 
retain, at least to a certain extent, their tertiary and quaternary structure during 
ionisation and in the gas-phase. This has been shown to be possible in a number 
of cases, for example, in measurements of insulin aggregation conducted by 
Nettleton et al.377 Their nano-ES-MS data showed that insulin in the presence 
of Zn2+ is present in a mix of dimers, tetramers and hexamers.377 The latter with 
two to four Zn2+ ions bound. The absence of small odd-numbered oligomers in 
the gas phase was in good agreement with previous measurements in solution 
by Lord et al.378 which together with the findings of Nettleton et al. provided 
evidence that no additional oligomers form as an artefact of the electrospray 
ionisation or the fact that the experiment is conducted in the gas phase.377  
Bernstein and co-workers used MS techniques to compare the oligomers 
formed by Aβ1-42 with oligomers formed by Aβ1-40.379,380 Such a comparison is 
of interest because their propensity to aggregate into amyloid fibrils is very 
different. Aβ1-42 showed evidence for the formation of dimeric, tetrameric, 
hexameric and dodecameric oligomers, whereas Aβ1-40 showed only evidence 
of dimer and tetramer.379,380  
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IM-MS was also successfully used in a study of Aβ10-30. This fragment, 
containing the Aβ amyloid core region, showed the presence of monomers, 
dimers, trimers, tetramers, pentamers and hexamers.381 To gain more 
information about the structure, Jablonowska et al. also combined their IM-MS 
experiments with HDX.381 The results indicated no difference in the rate of 
exchange for different oligomers suggesting that the oligomers lack a defined 
or stable structure or that the exchange of monomeric subunits is fast. A 
comparison with 15N-labeled peptides confirmed the latter and showed 
evidence of an exchange of monomers with subunits in the oligomers on a sub-
second time scale.381 
Together, these results show that IM-MS can be a powerful method to study 
the aggregation kinetics and the formation of oligomers arising from 
monomers. However, IM-MS results have to be considered carefully. It is, for 
example, not immediately given that every detected species in the gas phase is 
also naturally occurring in solution and not merely an artefact of the ionisation 
technique. It is also possible that different species are suppressed. This question 
is closely related to the general challenge of proving that fibril formation in 
vivo can be reproduced in vitro. Both can only be solved by carefully comparing 
the results of many different biophysical techniques. 
6.2.2 Further Characterisation of the Atomic Structure of Fibrils 
under Different pH Conditions  
The studies presented in this Thesis showed some evidence that GLP-1 and 
Am-GLP-1 form different aggregates under different pH conditions, Section 
6.1.10. Additional, solid-state NMR measurements could resolve if the 
differences observed in the aggregates are caused by altered atomic structures 
and conformations of the β-strands forming the β-sheets. This would also 
enable a comparison to published results on the fibrils of glucagon formed 
under acidic conditions, in which the entire peptide length is involved in cross-
β bonding.65 
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6.2.3 Is the Aggregation of GLP-1 and GLP-1 Analogues 
Influenced by Liquid-Liquid Phase Transition or Gelation?  
IM-MS methods discussed in Section 6.2.1 can be described as bottom-up 
approaches measuring the initial steps in aggregation, which consequently 
influence the aggregation behaviour. Alternatively, a detailed study of the bulk 
behaviour of dissolved peptides and therefore, a top-down approach could also 
lead to valuable insights. A broader comparison between the ThT fluorescence 
and the change of the turbidity or viscosity of the samples could provide 
information on whether the system undergoes a liquid-liquid phase transition 
or gelation is happening. A change of these parameters would raise the question 
of whether they influence the aggregation kinetics or not. 
Wang et al. described a liquid-liquid phase transition (LLPS) for six 
palmitoylated as well as one unconjugated incretin peptides.382 For the 
lipopeptide, IP5 which has a pI of 4.0 and molecular weight of 4500 Da, quasi-
elastic light-scattering was measured at several pH values between pH 5.5 and 
7.42. The peptide solution appeared either in a clear or cloudy phase depending 
on the temperature, which could be changed reversibly by lowering or 
increasing the temperature. The data showed that the temperature at which 
phase separation occurred decreased with increasing pH and therefore 
increasing net charge on the peptide. The peptide concentrations used were very 
high, starting at 2250 µM, and were at least a magnitude higher in comparison 
to the concentrations used in the studies undertaken and reported in this Thesis.    
Gelation caused by peptides and especially peptide amphiphiles has been 
previously reported.34,72,383–386 The preferred secondary structure of peptides 
forming hydrogels is the β-sheet structure,386 however, hydrogels can also form 
from peptides rich in α-helical structure.387 A detailed study of the potential 
gelation of GLP-1 and GLP-1 analogues samples could clarify if gelation 
occurs under the conditions used in these studies. 
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6.2.4 Complementary Experiments for a Deeper Understanding 
of the Effect of Lipidation  
One primary aim of this study was to learn more about the influence of 
lipidation on the physical stability of GLP-1. Am-GLP-1 was studied in detail 
to be able to compare its aggregation kinetics with the kinetics of the lipidated 
peptides which are both analogues of Am-GLP-1. However, both lipidated 
peptides had additional modifications of their sequence to remove lysine side 
chains to avoid additional covalent attachment of the spacer and fatty acid. In 
these cases, a lysine was mutated to arginine which retains the positive charge. 
It is assumed that these mutations have a rather small effect on the aggregation 
behaviour. However, it was shown in a separate study that substitution of lysine 
with arginine can influence a peptide’s aggregation kinetics.388 Therefore, it 
would be valuable to also measure the sequences of Am-GLP-1 which 
correspond directly to the non-lipidated form of both IPP4 and IPP5. This 
would exclude any misinterpretation of characteristics observed for the 
lipidated peptides that were due to the lysing-arginine substitution. 
In addition, a detailed study of the effect of different linker types as well as 
different fatty acids, could lead to valuable information regarding how the exact 
nature of the lipidation modifications affect physical stability. This would 
enable an assessment of the contribution of different parts of the lipidated GLP-
1 variants to physical stability and whether the properties of the different 
regions of the lipidated peptides acted in an additive fashion or if the product 
of peptide, linker and fatty acid show independent characteristics. 
6.2.5 Role of Zeta Potential in the Aggregation of GLP-1 and 
GLP-1 Analogues  
The results in Chapter 4 show the influence of the net charge on the aggregate 
kinetics. A detailed study of the zeta potential, especially at the pH values 
summarised in Section 6.1.9 could help to understand the influence of the net 
charge on off-pathway oligomers or aggregates. It might also help to 
understand why under certain conditions samples with lower net charge are 
more likely to form off-pathway species and show longer aggregation lag times. 
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Learning more about the zeta potential is also valuable for the understanding 
of the binding affinity of fluorescent molecules such as ANS or ThT. It was 
recently shown that the zeta potential is related to the binding and fluorescence 
of thioflavin T.291 In this study, it was shown that the zeta potential rather than 
pH-dependent assembly of the fibrils is the primary factor affecting ThT 
binding and fluorescence. Interestingly, the ThT fluorescence measurements of 
GLP-1 and GLP-1 analogues under acidic and basic condition show similar 
maximum fluorescence intensities. This means that either the assumption of a 
significant influence of the zeta potential is not correct for GLP-1 or the fibrils 
formed under acidic conditions are structurally different in comparison to 
fibrils formed under basic conditions and the influence of the different 
structures on the ThT fluorescence is more dominant than the influence of the 
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not for drug use
Catalog number H-9560
Product number 4043014
Product GLP- 1 (7- 37) (human, bovine, guinea pig, mouse,
rat) acetate salt
H- His- Ala- Glu- Gly- Thr- Phe- Thr- Ser- Asp- Val- Ser-
Ser- Tyr- Leu- Glu- Gly- Gln- Ala- Ala- Lys- Glu- Phe-
Ile- Ala- Trp- Leu- Val- Lys- Gly- Arg- Gly- OH acetate
salt  
Molecular formula C151H228N40O47
Relative molecular mass 3355.71  
Tests Results
Appearance white lyophilisate
Appearance of solution clear, colorless solution (1 mg/mL in 50% acetic acid)
Identification (ESI-MS) m = 3355.7u (average mass)
Purity (HPLC) 99.2% (TFA)
96.6% (TEAP)
Assay (elemental analysis) 91.4% (Nth 16.70%, Nfd 15.27%)
Latest update: October 19, 2015 Analytical Data Sheet
Lot number 1061673
This Analytical Data Sheet is automatically generated based on reviewed analytical data and is therefore unsigned. 1/1
Chapter 8: Appendices 






not for drug use
Product number 4094597
Product H- His- Ala- Glu- Gly- Thr- Phe- Thr- Ser- Asp- Val-
Ser- Ser- Tyr- Leu- Glu- Gly- Gln- Ala- Ala- Lys- Glu-
Phe- Ile- Ala- Trp- Leu- Val- Lys- Gly- Arg- Gly- NH2
acetate salt
Molecular formula C151H229N41O46




Amino acid analysis Asx 1.04 (1) Ala 3.99 (4) Phe 1.87 (2)
Thr 1.99 (2) Val 1.91 (2) His 1.03 (1)
Ser 2.84 (3) Ile 0.97 (1) Lys 2.04 (2)
Glx 4.16 (4) Leu 1.91 (2) Trp* 0.69 (1)
Gly 4.07 (4) Tyr 0.99 (1) Arg 1.02 (1)
*Partially destroyed during acid hydrolysis 
Solubility soluble in water at 1mg/mL
Purity (HPLC) 96.7%
Assay (AAA) 97.3%
Date of manufacture February 19, 2016 
Latest update: February 25, 2016 Analytical Data Sheet
Lot number 3014701
This Analytical Data Sheet is automatically generated based on reviewed analytical data and is therefore unsigned. 1/1
Chapter 8: Appendices 





not for drug use
Product number 4094484
Product H- His- Ala- Glu- Gly- Thr- Phe- Thr- Ser- Asp- Val-
Ser- Ser- Tyr- Leu- Glu- Gly- Lys(g- Glu- palmitoyl) -
Ala- Ala- Arg- Glu- Phe- Ile- Ala- Trp- Leu- Val- Arg-
Gly- Arg- Gly- NH2 acetate salt
Molecular formula C173H270N46O49




Solubility insoluble in water at 1mg/mL
insoluble in DMF at 1mg/mL
soluble in 50% Acetic acid at 1mg/mL
Purity (HPLC) 96.3%
Date of manufacture March 04, 2016 
Latest update: March 04, 2016 Analytical Data Sheet
Lot number 3014726
This Analytical Data Sheet is automatically generated based on reviewed analytical data and is therefore unsigned. 1/1
